UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended ~~June 30, 2022~~March 31, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 000-55775

AMERICAN HEALTHCARE REIT, INC.

(Exact name of registrant as specified in its charter)


Maryland						47-2887436
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

18191 Von Karman Avenue, Suite 300 Irvine, California						92612
(Address of principal executive offices)						(Zip Code)

(949) 270-9200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of ~~August~~May 12, ~~2022,~~2023, there were ~~77,888,698~~19,540,742 shares of Class T common stock and ~~186,275,536~~46,673,686 shares of Class I common stock of American Healthcare REIT, Inc. outstanding.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

(A Maryland Corporation)

TABLE OF CONTENTS


			Page
PART I — FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)			3
Condensed Consolidated Balance Sheets as of ~~June~~ 3 0 ~~, 2022~~March 31, 2023 and December 31, ~~2021~~2022			3
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three ~~and Si~~x Months Ended ~~June~~March 3 0 ,31, 2023 and 2022 ~~and 2021~~			5
Condensed Consolidated Statements of Equity for the Three ~~and S~~ix Months Ended ~~June~~March 3 0 ,31, 2023 and 2022 ~~and 2021~~			6
Condensed Consolidated Statements of Cash Flows for the ~~Six~~Three Months Ended ~~June~~March 3 0 ,31, 2023 and 2022 ~~and 2021~~			98
Notes to Condensed Consolidated Financial Statements			1110
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			4334
Item 3. Quantitative and Qualitative Disclosures About Market Risk			6048
Item 4. Controls and Procedures			6250

PART II — OTHER INFORMATION

Item 1. Legal Proceedings			6351
Item 1A. Risk Factors			6351
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			6351
Item 3. Defaults Upon Senior Securities			6351
Item 4. Mine Safety Disclosures			6452
Item 5. Other Information			6452
Item 6. Exhibits			6452
Signatures			6553

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022

(Unaudited)


		June 30, 2022		December 31, 2021			March 31, 2023		December 31, 2022
ASSETS	ASSETS					ASSETS
Real estate investments, net	Real estate investments, net	$	3,491,845,000	$	3,514,686,000	Real estate investments, net	$	3,568,117,000	$	3,581,609,000
Debt security investment, net	Debt security investment, net	81,167,000		79,315,000		Debt security investment, net	83,955,000		83,000,000
Cash and cash equivalents	Cash and cash equivalents	59,101,000		81,597,000		Cash and cash equivalents	41,346,000		65,052,000
Restricted cash	Restricted cash	45,075,000		43,889,000		Restricted cash	46,883,000		46,854,000
Accounts and other receivables, net	Accounts and other receivables, net	136,843,000		122,778,000		Accounts and other receivables, net	143,740,000		137,501,000

Identified intangible assets, net	Identified intangible assets, net	234,914,000		248,871,000		Identified intangible assets, net	219,279,000		236,283,000
Goodwill	Goodwill	212,714,000		209,898,000		Goodwill	234,942,000		231,611,000

Operating lease right-of-use assets, net	Operating lease right-of-use assets, net	114,489,000		158,157,000		Operating lease right-of-use assets, net	270,939,000		276,342,000
Other assets, net	Other assets, net	147,752,000		121,148,000		Other assets, net	138,480,000		128,446,000
Total assets	Total assets	$	4,523,900,000	$	4,580,339,000	Total assets	$	4,747,681,000	$	4,786,698,000

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY	LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY					LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY
Liabilities:	Liabilities:					Liabilities:
Mortgage loans payable, net(1)	Mortgage loans payable, net(1)	$	1,134,059,000	$	1,095,594,000	Mortgage loans payable, net(1)	$	1,233,745,000	$	1,229,847,000
Lines of credit and term loans, net(1)		1,266,691,000		1,226,634,000
Lines of credit and term loan, net(1)						Lines of credit and term loan, net(1)	1,313,222,000		1,281,794,000
Accounts payable and accrued liabilities(1)	Accounts payable and accrued liabilities(1)	174,179,000		187,254,000		Accounts payable and accrued liabilities(1)	231,469,000		243,831,000
Accounts payable due to affiliates(1)		—		866,000

Identified intangible liabilities, net	Identified intangible liabilities, net	11,663,000		12,715,000		Identified intangible liabilities, net	10,429,000		10,837,000
Financing obligations(1)	Financing obligations(1)	21,568,000		33,653,000		Financing obligations(1)	47,684,000		48,406,000
Operating lease liabilities(1)	Operating lease liabilities(1)	104,193,000		145,485,000		Operating lease liabilities(1)	268,587,000		273,075,000
Security deposits, prepaid rent and other liabilities(1)	Security deposits, prepaid rent and other liabilities(1)	46,450,000		48,567,000		Security deposits, prepaid rent and other liabilities(1)	55,672,000		49,545,000
Total liabilities	Total liabilities	2,758,803,000		2,750,768,000		Total liabilities	3,160,808,000		3,137,335,000

Commitments and contingencies (Note 12)		0		0
Commitments and contingencies (Note 11)						Commitments and contingencies (Note 11)

Redeemable noncontrolling interests (Note 13)		75,337,000		72,725,000
Redeemable noncontrolling interests (Note 12)						Redeemable noncontrolling interests (Note 12)	59,884,000		81,598,000

Equity:	Equity:					Equity:
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; none issued and outstanding	Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; none issued and outstanding	—		—		Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; none issued and outstanding	—		—
Class T common stock, $0.01 par value per share; 200,000,000 shares authorized; 77,864,724 and 77,176,406 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		770,000		763,000
Class I common stock, $0.01 par value per share; 800,000,000 shares authorized; 186,499,872 and 185,855,625 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		1,865,000		1,859,000
Class T common stock, $0.01 par value per share; 200,000,000 shares authorized; 19,536,622 and 19,535,095 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively						Class T common stock, $0.01 par value per share; 200,000,000 shares authorized; 19,536,622 and 19,535,095 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	194,000		194,000
Class I common stock, $0.01 par value per share; 800,000,000 shares authorized; 46,673,686 and 46,675,367 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively						Class I common stock, $0.01 par value per share; 800,000,000 shares authorized; 46,673,686 and 46,675,367 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	467,000		467,000
Additional paid-in capital	Additional paid-in capital	2,541,504,000		2,531,940,000		Additional paid-in capital	2,546,299,000		2,540,424,000
Accumulated deficit	Accumulated deficit	(1,024,328,000)		(951,303,000)		Accumulated deficit	(1,180,741,000)		(1,138,304,000)
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(2,653,000)		(1,966,000)		Accumulated other comprehensive loss	(2,568,000)		(2,690,000)
Total stockholders’ equity	Total stockholders’ equity	1,517,158,000		1,581,293,000		Total stockholders’ equity	1,363,651,000		1,400,091,000
Noncontrolling interests (Note 14)		172,602,000		175,553,000
Noncontrolling interests (Note 13)						Noncontrolling interests (Note 13)	163,338,000		167,674,000
Total equity	Total equity	1,689,760,000		1,756,846,000		Total equity	1,526,989,000		1,567,765,000
Total liabilities, redeemable noncontrolling interests and equity	Total liabilities, redeemable noncontrolling interests and equity	$	4,523,900,000	$	4,580,339,000	Total liabilities, redeemable noncontrolling interests and equity	$	4,747,681,000	$	4,786,698,000

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022

(Unaudited)

___________

(1)Such liabilities of American Healthcare REIT, Inc. represented liabilities of American Healthcare REIT Holdings, LP or its consolidated subsidiaries as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021.~~2022. American Healthcare REIT Holdings, LP is a variable interest entity, or VIE, and a consolidated subsidiary of American Healthcare REIT, Inc. The creditors of American Healthcare REIT Holdings, LP or its consolidated subsidiaries do not have recourse against American Healthcare REIT, Inc., except for the 2022 Credit Facility, as defined in Note 9,8, held by American Healthcare REIT Holdings, LP in the amount of ~~$962,900,000~~$977,900,000 and $965,900,000 as of ~~June 30, 2022~~March 31, 2023 and ~~the 2018 Credit Facility and 2019 Credit Facility, each as defined in Note 9, held by American Healthcare REIT Holdings, LP in the amount of $441,900,000 and $480,000,000, respectively, as of~~ December 31, ~~2021,~~2022, respectively, which ~~were~~was guaranteed by American Healthcare REIT, Inc.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021		2022		2021			2023		2022
Revenues and grant income:	Revenues and grant income:									Revenues and grant income:
Resident fees and services	Resident fees and services	$	326,225,000	$	276,352,000	$	645,199,000	$	529,378,000	Resident fees and services	$	408,630,000	$	318,974,000
Real estate revenue	Real estate revenue	51,105,000		30,642,000		103,048,000		60,665,000		Real estate revenue	43,596,000		51,943,000
Grant income	Grant income	10,969,000		1,099,000		16,183,000		9,328,000		Grant income	—		5,214,000
Total revenues and grant income	Total revenues and grant income	388,299,000		308,093,000		764,430,000		599,371,000		Total revenues and grant income	452,226,000		376,131,000
Expenses:	Expenses:									Expenses:
Property operating expenses	Property operating expenses	296,059,000		250,426,000		583,219,000		495,568,000		Property operating expenses	370,146,000		287,160,000
Rental expenses	Rental expenses	14,663,000		8,119,000		29,950,000		16,174,000		Rental expenses	15,195,000		15,287,000
General and administrative	General and administrative	10,928,000		7,343,000		22,047,000		14,600,000		General and administrative	13,053,000		11,119,000
Business acquisition expenses	Business acquisition expenses	1,757,000		2,750,000		1,930,000		3,998,000		Business acquisition expenses	332,000		173,000
Depreciation and amortization	Depreciation and amortization	39,971,000		26,357,000		82,282,000		52,080,000		Depreciation and amortization	44,670,000		42,311,000
Total expenses	Total expenses	363,378,000		294,995,000		719,428,000		582,420,000		Total expenses	443,396,000		356,050,000

Other income (expense):	Other income (expense):									Other income (expense):
Interest expense:	Interest expense:									Interest expense:
Interest expense (including amortization of deferred financing costs, debt discount/premium and gain/loss on debt extinguishments)		(20,345,000)		(18,490,000)		(43,670,000)		(38,855,000)
Gain in fair value of derivative financial instruments		—		1,775,000		500,000		3,596,000
Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishments)										Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishments)	(39,011,000)		(23,325,000)
(Loss) gain in fair value of derivative financial instruments										(Loss) gain in fair value of derivative financial instruments	(195,000)		500,000
(Loss) gain on dispositions of real estate investments	(Loss) gain on dispositions of real estate investments	(73,000)		(42,000)		683,000		(377,000)		(Loss) gain on dispositions of real estate investments	(132,000)		756,000
Impairment of real estate investments		(17,340,000)		(3,335,000)		(17,340,000)		(3,335,000)
Income (loss) from unconsolidated entities		638,000		(901,000)		2,024,000		(2,672,000)
Foreign currency (loss) gain		(3,607,000)		238,000		(4,994,000)		653,000

(Loss) income from unconsolidated entities										(Loss) income from unconsolidated entities	(306,000)		1,386,000
Gain on re-measurement of previously held equity interest										Gain on re-measurement of previously held equity interest	726,000		—
Foreign currency gain (loss)										Foreign currency gain (loss)	1,008,000		(1,387,000)
Other income	Other income	469,000		191,000		1,729,000		463,000		Other income	1,608,000		1,260,000
Total net other expense	Total net other expense	(40,258,000)		(20,564,000)		(61,068,000)		(40,527,000)		Total net other expense	(36,302,000)		(20,810,000)
Loss before income taxes	Loss before income taxes	(15,337,000)		(7,466,000)		(16,066,000)		(23,576,000)		Loss before income taxes	(27,472,000)		(729,000)
Income tax expense	Income tax expense	(205,000)		(495,000)		(373,000)		(658,000)		Income tax expense	(143,000)		(168,000)
Net loss	Net loss	(15,542,000)		(7,961,000)		(16,439,000)		(24,234,000)		Net loss	(27,615,000)		(897,000)
Net (income) loss attributable to noncontrolling interests		(1,768,000)		283,000		(3,827,000)		4,709,000
Net loss (income) attributable to noncontrolling interests										Net loss (income) attributable to noncontrolling interests	1,743,000		(2,059,000)
Net loss attributable to controlling interest	Net loss attributable to controlling interest	$	(17,310,000)	$	(7,678,000)	$	(20,266,000)	$	(19,525,000)	Net loss attributable to controlling interest	$	(25,872,000)	$	(2,956,000)
Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	$	(0.07)	$	(0.04)	$	(0.08)	$	(0.11)	Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	$	(0.39)	$	(0.05)
Weighted average number of Class T and Class I common shares outstanding — basic and diluted	Weighted average number of Class T and Class I common shares outstanding — basic and diluted	263,017,692		179,628,847		262,768,637		179,628,315		Weighted average number of Class T and Class I common shares outstanding — basic and diluted	66,026,173		65,629,204

Net loss	Net loss	$	(15,542,000)	$	(7,961,000)	$	(16,439,000)	$	(24,234,000)	Net loss	$	(27,615,000)	$	(897,000)
Other comprehensive (loss) income:
Other comprehensive income (loss):										Other comprehensive income (loss):
Foreign currency translation adjustments	Foreign currency translation adjustments	(493,000)		42,000		(687,000)		111,000		Foreign currency translation adjustments	122,000		(194,000)
Total other comprehensive (loss) income		(493,000)		42,000		(687,000)		111,000
Total other comprehensive income (loss)										Total other comprehensive income (loss)	122,000		(194,000)
Comprehensive loss	Comprehensive loss	(16,035,000)		(7,919,000)		(17,126,000)		(24,123,000)		Comprehensive loss	(27,493,000)		(1,091,000)
Comprehensive (income) loss attributable to noncontrolling interests		(1,768,000)		283,000		(3,827,000)		4,709,000
Comprehensive loss (income) attributable to noncontrolling interests										Comprehensive loss (income) attributable to noncontrolling interests	1,743,000		(2,059,000)
Comprehensive loss attributable to controlling interest	Comprehensive loss attributable to controlling interest	$	(17,803,000)	$	(7,636,000)	$	(20,953,000)	$	(19,414,000)	Comprehensive loss attributable to controlling interest	$	(25,750,000)	$	(3,150,000)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

For the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)

Three Months Ended June 30, 2022
Stockholders’ Equity
Common Stock
Number
of
Shares Amount Additional
Paid-In
Capital Accumulated
Deficit Accumulated
Other
Comprehensive
Loss Total
Stockholders’
Equity Noncontrolling
Interests Total Equity
BALANCE — March 31, 2022 263,809,729 $ 2,629,000 $ 2,536,811,000 $ (980,613,000) $ (2,160,000) $ 1,556,667,000 $ 174,154,000 $ 1,730,821,000
Offering costs — common stock — — 1,000 — — 1,000 — 1,000
Issuance of common stock under the DRIP 1,199,427 12,000 11,131,000 — — 11,143,000 — 11,143,000
Issuance of nonvested restricted common stock 54,900 1,000 (1,000) — — — — —
Amortization of nonvested restricted common stock and stock units — — 980,000 — — 980,000 — 980,000
Stock based compensation — — — — — — 21,000 21,000
Repurchase of common stock (699,460) (7,000) (6,442,000) — — (6,449,000) — (6,449,000)
Distributions to noncontrolling interests — — — — — — (3,537,000) (3,537,000)
Reclassification of noncontrolling interests to mezzanine equity — — — — — — (21,000) (21,000)
Adjustment to value of redeemable noncontrolling interests — — (976,000) — — (976,000) (1,000) (977,000)
Distributions declared ($0.10 per share) — — — (26,405,000) — (26,405,000) — (26,405,000)
Net (loss) income — — — (17,310,000) — (17,310,000) 1,986,000 (15,324,000) (1)
Other comprehensive loss — — — — (493,000) (493,000) — (493,000)
BALANCE — June 30, 2022 264,364,596 $ 2,635,000 $ 2,541,504,000 $ (1,024,328,000) $ (2,653,000) $ 1,517,158,000 $ 172,602,000 $ 1,689,760,000

Three Months Ended June 30, 2021
Stockholders’ Equity
Common Stock
Number
of
Shares Amount Additional
Paid-In
Capital Accumulated
Deficit Accumulated
Other
Comprehensive
Loss Total
Stockholders’
Equity Noncontrolling
Interests Total Equity
BALANCE — March 31, 2021 179,658,367 $ 1,798,000 $ 1,730,237,000 $ (876,118,000) $ (1,939,000) $ 853,978,000 $ 164,095,000 $ 1,018,073,000
Amortization of nonvested restricted common stock — — 26,000 — — 26,000 — 26,000
Distributions to noncontrolling interests — — — — — — (179,000) (179,000)
Adjustment to value of redeemable noncontrolling interests — — (261,000) — — (261,000) (112,000) (373,000)
Distributions declared ($0.02 per share) — — — (3,187,000) — (3,187,000) — (3,187,000)
Net loss — — — (7,678,000) — (7,678,000) (253,000) (7,931,000) (1)
Other comprehensive income — — — — 42,000 42,000 — 42,000
BALANCE — June 30, 2021 179,658,367 $ 1,798,000 $ 1,730,002,000 $ (886,983,000) $ (1,897,000) $ 842,920,000 $ 163,551,000 $ 1,006,471,000


	Three Months Ended March 31, 2023
	Stockholders’ Equity
	Class T and Class I Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — December 31, 2022	66,210,462	$	661,000	$	2,540,424,000	$	(1,138,304,000)	$	(2,690,000)	$	1,400,091,000	$	167,674,000	$	1,567,765,000



Issuance of nonvested restricted common stock	1,956	—		—		—		—		—		—		—
Amortization of nonvested restricted common stock and stock units	—	—		1,051,000		—		—		1,051,000		—		1,051,000


Stock based compensation	—	—		—		—		—		—		21,000		21,000
Repurchase of common stock	(2,110)	—		(78,000)		—		—		(78,000)		—		(78,000)

Distributions to noncontrolling interests	—	—		—		—		—		—		(3,102,000)		(3,102,000)


Reclassification of noncontrolling interests to mezzanine equity	—	—		—		—		—		—		(21,000)		(21,000)
Adjustment to value of redeemable noncontrolling interests	—	—		4,902,000		—		—		4,902,000		141,000		5,043,000
Distributions declared ($0.25 per share)	—	—		—		(16,565,000)		—		(16,565,000)		—		(16,565,000)
Net loss	—	—		—		(25,872,000)		—		(25,872,000)		(1,375,000)		(27,247,000)		(1)
Other comprehensive income	—	—		—		—		122,000		122,000		—		122,000
BALANCE — March 31, 2023	66,210,308	$	661,000	$	2,546,299,000	$	(1,180,741,000)	$	(2,568,000)	$	1,363,651,000	$	163,338,000	$	1,526,989,000

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY — (Continued)

For the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)

Six Months Ended June 30, 2022
Stockholders’ Equity
Common Stock
Number
of
Shares Amount Additional
Paid-In
Capital Accumulated
Deficit Accumulated
Other
Comprehensive
Loss Total
Stockholders’
Equity Noncontrolling
Interests Total Equity
BALANCE — December 31, 2021 263,032,031 $ 2,622,000 $ 2,531,940,000 $ (951,303,000) $ (1,966,000) $ 1,581,293,000 $ 175,553,000 $ 1,756,846,000
Offering costs — common stock — — (2,000) — — (2,000) — (2,000)
Issuance of common stock under the DRIP 2,425,500 24,000 22,423,000 — — 22,447,000 — 22,447,000
Issuance of nonvested restricted common stock 54,900 1,000 (1,000) — — — — —
Amortization of nonvested restricted common stock and stock units — — 1,791,000 — — 1,791,000 — 1,791,000
Stock based compensation — — — — — — 42,000 42,000
Repurchase of common stock (1,147,835) (12,000) (10,571,000) — — (10,583,000) — (10,583,000)
Distributions to noncontrolling interests — — — — — — (7,052,000) (7,052,000)
Adjustment to noncontrolling interest in connection with the Merger — — (1,173,000) — — (1,173,000) 1,173,000 —
Reclassification of noncontrolling interests to mezzanine equity — — — — — — (42,000) (42,000)
Adjustment to value of redeemable noncontrolling interests — — (2,903,000) — — (2,903,000) (930,000) (3,833,000)
Distributions declared ($0.20 per share) — — — (52,759,000) — (52,759,000) — (52,759,000)
Net (loss) income — — — (20,266,000) — (20,266,000) 3,858,000 (16,408,000) (1)
Other comprehensive loss — — — — (687,000) (687,000) — (687,000)
BALANCE — June 30, 2022 264,364,596 $ 2,635,000 $ 2,541,504,000 $ (1,024,328,000) $ (2,653,000) $ 1,517,158,000 $ 172,602,000 $ 1,689,760,000

Six Months Ended June 30, 2021
Stockholders’ Equity
Common Stock
Number
of
Shares Amount Additional
Paid-In
Capital Accumulated
Deficit Accumulated
Other
Comprehensive
Loss Total
Stockholders’
Equity Noncontrolling
Interests Total Equity
BALANCE — December 31, 2020 179,658,367 $ 1,798,000 $ 1,730,589,000 $ (864,271,000) $ (2,008,000) $ 866,108,000 $ 168,375,000 $ 1,034,483,000
Offering costs — common stock — — (1,000) — — (1,000) — (1,000)
Amortization of nonvested restricted common stock — — 53,000 — — 53,000 — 53,000
Stock based compensation — — — — — — (14,000) (14,000)
Distributions to noncontrolling interests — — — — — — (355,000) (355,000)
Adjustment to value of redeemable noncontrolling interests — — (639,000) — — (639,000) (260,000) (899,000)
Distributions declared ($0.02 per share) — — — (3,187,000) — (3,187,000) — (3,187,000)
Net loss — — — (19,525,000) — (19,525,000) (4,195,000) (23,720,000) (1)
Other comprehensive income — — — — 111,000 111,000 — 111,000
BALANCE — June 30, 2021 179,658,367 $ 1,798,000 $ 1,730,002,000 $ (886,983,000) $ (1,897,000) $ 842,920,000 $ 163,551,000 $ 1,006,471,000

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~CONDENSED CONSOLIDATED STATEMENTS OF EQUITY — (Continued)~~

~~For the Three and Six Months Ended June 30, 2022 and 2021~~

~~(Unaudited)~~


	Three Months Ended March 31, 2022
	Stockholders’ Equity
	Class T and Class I Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — December 31, 2021	65,758,004	$	658,000	$	2,533,904,000	$	(951,303,000)	$	(1,966,000)	1,581,293,000		$	175,553,000	$	1,756,846,000

Offering costs — common stock	—	—		(3,000)		—		—		(3,000)		—		(3,000)
Issuance of common stock under the DRIP	306,518	3,000		11,301,000		—		—		11,304,000		—		11,304,000

Amortization of nonvested restricted common stock	—	—		811,000		—		—		811,000		—		811,000
Stock based compensation	—	—		—		—		—		—		21,000		21,000
Repurchase of common stock	(112,094)	(1,000)		(4,133,000)		—		—		(4,134,000)		—		(4,134,000)



Distributions to noncontrolling interests	—	—		—		—		—		—		(3,515,000)		(3,515,000)
Adjustment to noncontrolling interest in connection with the Merger	—	—		(1,173,000)		—		—		(1,173,000)		1,173,000		—

Reclassification of noncontrolling interests to mezzanine equity	—	—		—		—		—		—		(21,000)		(21,000)
Adjustment to value of redeemable noncontrolling interests	—	—		(1,927,000)		—		—		(1,927,000)		(929,000)		(2,856,000)
Distributions declared ($0.40 per share)	—	—		—		(26,354,000)		—		(26,354,000)		—		(26,354,000)
Net (loss) income	—	—		—		(2,956,000)		—		(2,956,000)		1,872,000		(1,084,000)		(1)
Other comprehensive loss	—	—		—		—		(194,000)		(194,000)		—		(194,000)
BALANCE — March 31, 2022	65,952,428	$	660,000	$	2,538,780,000	$	(980,613,000)	$	(2,160,000)	$	1,556,667,000	$	174,154,000	$	1,730,821,000

___________

(1)For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ amounts exclude ~~$(218,000)~~$(368,000) and ~~$(30,000),~~$187,000, respectively, of net ~~loss attributable to redeemable noncontrolling interests. For the six months ended June 30, 2022 and 2021, amounts exclude $(31,000) and $(514,000), respectively, of net loss~~(loss) income attributable to redeemable noncontrolling interests. See Note ~~13,~~12, Redeemable Noncontrolling Interests, for a further discussion.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the ~~Six~~Three Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)


		Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021			2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES	CASH FLOWS FROM OPERATING ACTIVITIES					CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	Net loss	$	(16,439,000)	$	(24,234,000)	Net loss	$	(27,615,000)	$	(897,000)
Adjustments to reconcile net loss to net cash provided by operating activities:	Adjustments to reconcile net loss to net cash provided by operating activities:					Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	Depreciation and amortization	82,293,000		52,080,000		Depreciation and amortization	44,670,000		42,311,000
Other amortization	Other amortization	12,178,000		11,622,000		Other amortization	20,370,000		6,166,000
Deferred rent	Deferred rent	(3,542,000)		(1,771,000)		Deferred rent	(1,090,000)		(1,695,000)

Stock based compensation	Stock based compensation	1,779,000		39,000		Stock based compensation	1,072,000		779,000

(Income) loss from unconsolidated entities		(2,024,000)		2,672,000

Impairment of real estate investments		17,340,000		3,335,000
(Gain) loss on dispositions of real estate investments		(683,000)		377,000
Foreign currency loss (gain)		4,848,000		(622,000)

Loss (gain) on dispositions of real estate investments						Loss (gain) on dispositions of real estate investments	132,000		(756,000)
Loss (income) from unconsolidated entities						Loss (income) from unconsolidated entities	306,000		(1,386,000)
Gain on re-measurement of previously held equity interest						Gain on re-measurement of previously held equity interest	(726,000)		—
Foreign currency (gain) loss						Foreign currency (gain) loss	(1,063,000)		1,335,000

Loss on extinguishments of debt	Loss on extinguishments of debt	4,410,000		2,293,000		Loss on extinguishments of debt	—		4,591,000

Change in fair value of derivative financial instruments	Change in fair value of derivative financial instruments	(500,000)		(3,596,000)		Change in fair value of derivative financial instruments	195,000		(500,000)
Other adjustments		—		850,000

Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts and other receivables	Accounts and other receivables	(14,474,000)		(2,835,000)		Accounts and other receivables	(7,119,000)		(8,300,000)
Other assets	Other assets	(5,277,000)		(1,869,000)		Other assets	(3,489,000)		(1,432,000)
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities	(5,231,000)		(8,679,000)		Accounts payable and accrued liabilities	1,790,000		(7,878,000)
Accounts payable due to affiliates	Accounts payable due to affiliates	(184,000)		(5,158,000)		Accounts payable due to affiliates	—		(184,000)
Operating lease liabilities	Operating lease liabilities	(8,617,000)		(8,326,000)		Operating lease liabilities	(9,328,000)		(4,602,000)
Security deposits, prepaid rent and other liabilities	Security deposits, prepaid rent and other liabilities	(9,739,000)		(12,599,000)		Security deposits, prepaid rent and other liabilities	5,757,000		(5,192,000)
Net cash provided by operating activities	Net cash provided by operating activities	56,138,000		3,579,000		Net cash provided by operating activities	23,862,000		22,360,000
CASH FLOWS FROM INVESTING ACTIVITIES	CASH FLOWS FROM INVESTING ACTIVITIES					CASH FLOWS FROM INVESTING ACTIVITIES
Developments and capital expenditures						Developments and capital expenditures	(21,500,000)		(20,856,000)
Acquisitions of real estate investments	Acquisitions of real estate investments	(75,125,000)		(78,546,000)		Acquisitions of real estate investments	(11,680,000)		(19,878,000)
Developments and capital expenditures		(35,508,000)		(46,177,000)
Acquisition of previously held equity interest						Acquisition of previously held equity interest	(335,000)		—
Proceeds from dispositions of real estate investments	Proceeds from dispositions of real estate investments	14,002,000		1,400,000		Proceeds from dispositions of real estate investments	6,901,000		14,074,000

Investments in unconsolidated entities	Investments in unconsolidated entities	(200,000)		(650,000)		Investments in unconsolidated entities	(6,000,000)		(200,000)

Real estate and other deposits	Real estate and other deposits	(533,000)		(192,000)		Real estate and other deposits	(705,000)		(507,000)

Net cash used in investing activities	Net cash used in investing activities	(97,364,000)		(124,165,000)		Net cash used in investing activities	(33,319,000)		(27,367,000)
CASH FLOWS FROM FINANCING ACTIVITIES	CASH FLOWS FROM FINANCING ACTIVITIES					CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under mortgage loans payable	Borrowings under mortgage loans payable	89,712,000		111,442,000		Borrowings under mortgage loans payable	7,700,000		22,489,000
Payments on mortgage loans payable	Payments on mortgage loans payable	(40,662,000)		(7,215,000)		Payments on mortgage loans payable	(5,122,000)		(4,538,000)

Borrowings under the lines of credit and term loan	Borrowings under the lines of credit and term loan	1,009,900,000		16,600,000		Borrowings under the lines of credit and term loan	113,600,000		941,400,000
Payments on the lines of credit and term loan	Payments on the lines of credit and term loan	(968,900,000)		(23,000,000)		Payments on the lines of credit and term loan	(82,100,000)		(928,900,000)
Deferred financing costs	Deferred financing costs	(5,617,000)		(833,000)		Deferred financing costs	(1,048,000)		(4,796,000)
Debt extinguishment costs	Debt extinguishment costs	(2,790,000)		(125,000)		Debt extinguishment costs	—		(2,790,000)

Payments on financing obligations	Payments on financing obligations	(12,141,000)		(9,609,000)		Payments on financing obligations	(733,000)		(787,000)

Distributions paid to common stockholders	Distributions paid to common stockholders	(30,247,000)		—		Distributions paid to common stockholders	(26,492,000)		(15,010,000)
Repurchase of common stock	Repurchase of common stock	(10,583,000)		—		Repurchase of common stock	(78,000)		(4,134,000)

Distributions to noncontrolling interests in total equity	Distributions to noncontrolling interests in total equity	(7,052,000)		(355,000)		Distributions to noncontrolling interests in total equity	(3,516,000)		(3,511,000)
Contribution from redeemable noncontrolling interest		173,000		—
Distributions to redeemable noncontrolling interests		(1,405,000)		(551,000)

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For the Three Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)


		Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021			2023		2022
Security deposits and other		$	(464,000)	$	117,000
Net cash provided by financing activities		19,924,000		86,471,000
Contribution from redeemable noncontrolling interest						Contribution from redeemable noncontrolling interest	$	—	$	173,000
Distributions to redeemable noncontrolling interests						Distributions to redeemable noncontrolling interests	(560,000)		(695,000)
Repurchase of redeemable noncontrolling interest						Repurchase of redeemable noncontrolling interest	(15,803,000)		—
Payment of offering costs						Payment of offering costs	(3,000)		(9,000)
Security deposits						Security deposits	(145,000)		(199,000)
Net cash used in financing activities						Net cash used in financing activities	(14,300,000)		(1,307,000)
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	$	(21,302,000)	$	(34,115,000)	NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	$	(23,757,000)	$	(6,314,000)
EFFECT OF FOREIGN CURRENCY TRANSLATION ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH	EFFECT OF FOREIGN CURRENCY TRANSLATION ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(8,000)		(27,000)		EFFECT OF FOREIGN CURRENCY TRANSLATION ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH	80,000		(2,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	125,486,000		152,190,000		CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	111,906,000		125,486,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$	104,176,000	$	118,048,000	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$	88,229,000	$	119,170,000

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH	RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH					RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Beginning of period:	Beginning of period:					Beginning of period:
Cash and cash equivalents	Cash and cash equivalents	$	81,597,000	$	113,212,000	Cash and cash equivalents	$	65,052,000	$	81,597,000
Restricted cash	Restricted cash	43,889,000		38,978,000		Restricted cash	46,854,000		43,889,000
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash	$	125,486,000	$	152,190,000	Cash, cash equivalents and restricted cash	$	111,906,000	$	125,486,000

End of period:	End of period:					End of period:
Cash and cash equivalents	Cash and cash equivalents	$	59,101,000	$	76,659,000	Cash and cash equivalents	$	41,346,000	$	75,115,000
Restricted cash	Restricted cash	45,075,000		41,389,000		Restricted cash	46,883,000		44,055,000
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash	$	104,176,000	$	118,048,000	Cash, cash equivalents and restricted cash	$	88,229,000	$	119,170,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION					SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for:	Cash paid for:					Cash paid for:
Interest	Interest	$	36,348,000	$	32,984,000	Interest	$	37,424,000	$	18,916,000
Income taxes	Income taxes	$	382,000	$	861,000	Income taxes	$	383,000	$	191,000
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES	SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES					SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Accrued developments and capital expenditures	Accrued developments and capital expenditures	$	14,055,000	$	18,074,000	Accrued developments and capital expenditures	$	26,102,000	$	14,750,000

Tenant improvement overage	Tenant improvement overage	$	568,000	$	177,000	Tenant improvement overage	$	—	$	223,000

Issuance of common stock under the DRIP	Issuance of common stock under the DRIP	$	22,447,000	$	—	Issuance of common stock under the DRIP	$	—	$	11,304,000
Distributions declared but not paid — common stockholders	Distributions declared but not paid — common stockholders	$	8,812,000	$	3,187,000	Distributions declared but not paid — common stockholders	$	16,554,000	$	8,794,000
Distributions declared but not paid — limited partnership units	Distributions declared but not paid — limited partnership units	$	467,000	$	—	Distributions declared but not paid — limited partnership units	$	875,000	$	467,000
Distributions declared but not paid — restricted stock units	Distributions declared but not paid — restricted stock units	$	37,000	$	—	Distributions declared but not paid — restricted stock units	$	68,000	$	—
Accrued offering costs						Accrued offering costs	$	1,255,000	$	—

Capital expenditures from financing obligations		$	—	$	136,000

The following represents the net (decrease) increase in certain assets and liabilities in connection with our acquisitions and dispositions of investments:
The following represents the net increase (decrease) in certain assets and liabilities in connection with our acquisitions and dispositions of investments:						The following represents the net increase (decrease) in certain assets and liabilities in connection with our acquisitions and dispositions of investments:
Accounts and other receivables	Accounts and other receivables	$	(262,000)	$	4,000	Accounts and other receivables	$	(952,000)	$	(173,000)
Other assets, net		$	5,480,000	$	(748,000)
Other assets						Other assets	$	162,000	$	5,023,000
Mortgage loan payable, net	Mortgage loan payable, net	$	(12,059,000)	$	—	Mortgage loan payable, net	$	—	$	(12,059,000)

Accounts payable and accrued liabilities	Accounts payable and accrued liabilities	$	1,672,000	$	(22,000)	Accounts payable and accrued liabilities	$	548,000	$	(21,000)

Financing obligations	Financing obligations	$	56,000	$	—	Financing obligations	$	12,000	$	56,000
Security deposits		$	8,129,000	$	—
Security deposits and other liabilities						Security deposits and other liabilities	$	312,000	$	7,746,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

109

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

The use of the words “we,” “us” or “our” refers to ~~Griffin-American Healthcare REIT III, Inc., or GAHR III, and its subsidiaries, including Griffin-American Healthcare REIT III Holdings, LP, for periods prior to the Merger, as defined below, and~~ American Healthcare REIT, Inc. ~~(formerly known as Griffin-American Healthcare REIT IV, Inc., or GAHR IV)~~ and its subsidiaries, including American Healthcare REIT Holdings, LP, ~~(formerly known as Griffin-American Healthcare REIT III Holdings, LP), for periods following the Merger,~~ except where otherwise noted. ~~Certain historical information of GAHR IV is included for background purposes.~~

1. Organization and Description of Business

Overview and Background

American Healthcare REIT, Inc., a Maryland corporation, is a self-managed real estate investment trust, or REIT, that owns a diversified portfolio of clinical healthcare real estate properties, focusing primarily on medical office buildings, or MOBs, senior housing facilities, skilled nursing facilities, ~~senior housing,~~or SNFs, hospitals and other healthcare-related facilities. We also operate healthcare-related facilities utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007, which is commonly referred to as a “RIDEA” structure (the provisions of the Internal Revenue Code of 1986, as amended, or the Code, authorizing the RIDEA structure were enacted as part of the Housing and Economic Recovery Act of 2008). Our healthcare facilities operated under a RIDEA structure include our senior housing operating properties, or SHOP, ~~(formerly known as senior housing — RIDEA),~~ and our integrated senior health campuses. We have originated and acquired secured loans and may also originate and acquire other real estate-related investments on an infrequent and opportunistic basis. We generally seek investments that produce current income; however, we have selectively developed, and may continue to selectively develop, healthcare real estate properties. We ~~qualified~~have elected to be taxed as a ~~real estate investment trust, or~~ REIT ~~under the Code~~ for U.S. federal income tax ~~purposes,~~purposes. We believe that we have been organized and operated, and we intend to continue to ~~qualify to be taxed~~operate, in conformity with the requirements for qualification and taxation as a ~~REIT.~~REIT under the Code.

~~Merger of~~On October 1, 2021, Griffin-American Healthcare REIT III, Inc. ~~and Griffin-American Healthcare REIT IV, Inc.~~

~~On October 1, 2021, pursuant to an Agreement and Plan of Merger dated June 23, 2021,~~, or ~~the Merger Agreement,~~ GAHR III, merged with and into ~~Continental Merger Sub, LLC,~~ a ~~Maryland limited liability company and newly formed~~ wholly owned subsidiary, ~~of GAHR IV,~~ or Merger Sub, of Griffin-American Healthcare REIT IV, Inc., or GAHR IV, with Merger Sub being the surviving company, orwhich we refer to as the REIT ~~Merger. On October 1, 2021, also pursuant to the~~ Merger, ~~Agreement,~~and our operating partnership, Griffin-American Healthcare REIT IV Holdings, LP, ~~a Delaware limited partnership and subsidiary and operating partnership of GAHR IV, or GAHR IV Operating Partnership,~~ merged with and into Griffin-American Healthcare REIT III Holdings, LP, ~~a Delaware limited partnership,~~ or ~~our operating partnership,~~the Surviving Partnership, with ~~our operating partnership~~the Surviving Partnership being the surviving entity, ~~or the Partnership Merger. We collectively~~which we refer to ~~the REIT Merger and~~as the Partnership Merger asand, together with the REIT Merger, the Merger. Following the Merger on October 1, 2021, our company, or the Combined Company, was renamed American Healthcare REIT, Inc. and ~~our operating partnership, also referred to as~~ the ~~surviving partnership,~~Surviving Partnership was renamed American Healthcare REIT Holdings, LP. The REIT Merger qualified as a reorganization under, and within the meaning of, Section 368(a) of the Code. As a result of and at the effective time of the Merger, the separate corporate existence of GAHR III and GAHR IV Operating Partnership ceased.

At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, converted into the right to receive 0.9266 shares of GAHR IV’s Class I common stock, $0.01 par value per share. At the effective time of the Partnership Merger, (i) each unit of limited partnership interest inLP, or our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership, as amended, of the surviving partnership and (ii) each unit of limited partnership interest in GAHR IV Operating Partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class.

~~AHI Acquisition~~partnership.

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

current Executive Vice President, or collectively, the AHI Principals. NewCo owned substantially all of the business and operations of AHI, as well as all of the equity interests in (i) Griffin-American Healthcare REIT IV Advisor, LLC, or GAHR IV Advisor, a subsidiary of AHI that served as the external advisor of GAHR IV, and (ii) Griffin-American Healthcare REIT III Advisor, LLC, or GAHR III Advisor, also referred to as our former advisor, a subsidiary of AHI that served as the external advisor of GAHR III. See “Operating Partnership and Former Advisor” below for a further discussion.

Pursuant to the Contribution Agreement, AHI contributed substantially all of its business and operations to the surviving partnership, including its interest in GAHR III Advisor and GAHR IV Advisor, and Griffin Capital contributed its then-current ownership interest in GAHR III Advisor and GAHR IV Advisor to the surviving partnership. In exchange for these contributions, the surviving partnership issued limited partnership units, or surviving partnership OP units. Subject to working capital and other customary adjustments, the total approximate value of these surviving partnership OP units at the time of consummation of the transactions contemplated by the Contribution Agreement was approximately $131,674,000, with a reference value for purposes thereof of $8.71 per unit, such that the surviving partnership issued 15,117,529 surviving partnership OP units as consideration, or the Closing Date Consideration.Acquisition. Following ~~the consummation of~~ the Merger and the AHI Acquisition, ~~the Combined Company~~our company became self-managed. Such surviving partnership OP units are owned by AHI Group Holdings, LLC, or AHI Group Holdings, which is owned and controlled by the AHI Principals, Platform Healthcare Investor T-II, LLC, Flaherty Trust and a wholly owned subsidiary of Griffin Capital, or collectively, the NewCo Sellers.

The AHI Acquisition was treated as a business combination for accounting purposes, with GAHR III as both the legal and accounting acquiror of NewCo. While GAHR IV was the legal acquiror of GAHR III in the REIT Merger, GAHR III was determined to be the accounting acquiror in the REIT Merger in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 805, ~~Business Combinations~~, after considering the relative share ownership and the composition of the governing body of the Combined Company. Thus, the financial information set forth herein subsequent to the consummation of the Merger and the AHI Acquisition reflects results of the Combined Company, and the financial information set forth herein prior to the Merger and the AHI Acquisition reflects GAHR III’s results. For this reason, period to period comparisons may not be meaningful.

Operating Partnership ~~and Former Advisor~~

We conduct substantially all of our operations through our operating partnership and we are the sole general partner of our operating partnership. ~~Through September 30, 2021,~~ As of both March 31, 2023 and December 31, 2022, we owned 95.0% of the partnership units, or OP units, in our operating partnership, and the remaining 5.0% limited OP units, were ~~externally advised~~owned by ~~our former advisor pursuant to an advisory agreement, as amended, or~~AHI Group Holdings, LLC, which is owned and controlled by Jeffrey T. Hanson, the ~~Advisory Agreement, between us and our former advisor. Our former advisor used its best efforts, subject to the oversight and review~~non-executive Chairman of our board of directors, or our board, ~~to, among other things, provide asset management, property management, acquisition, disposition~~Danny Prosky, our Chief Executive Officer and ~~other advisory services on~~President, and Mathieu B. Streiff, one of our ~~behalf consistent with our investment policies and objectives.Following the Merger and~~directors, or collectively, the AHI ~~Acquisition, we became self-managed~~Principals; Platform Healthcare Investor TII, LLC; Flaherty Trust; and are no longer externally advised. As a result, any fees that would have otherwise been payable to our former advisor are no longer being paid. Also, on October 1, 2021 and in connection with the AHI Acquisition, we redeemed all 22,222 shares of our common stock owned by our former advisor and the 20,833 shares of our Class T common stock owned by GAHR IV Advisor in GAHR IV.

~~Prior to the Merger and the AHI Acquisition, our former advisor was 75.0% owned and managed by wholly owned subsidiaries of AHI, and 25.0% owned by~~ a wholly owned subsidiary of Griffin Capital Company, LLC, or collectively, ~~our former co-sponsors. Prior to~~ the AHI Acquisition, AHI was 47.1% owned by AHI Group Holdings, 45.1% indirectly owned by Digital Bridge Group, Inc. (NYSE: DBRG), or Digital Bridge, and 7.8% owned by James F. Flaherty III. We were not affiliated with Griffin Capital, Digital Bridge or Mr. Flaherty; however, we were affiliated with our former advisor, AHI and AHI Group Holdings. Please see the “Merger of Griffin-American Healthcare REIT III, Inc. and Griffin-American Healthcare REIT IV, Inc.” and “AHI Acquisition” sections above for a further discussion of our operations effective October 1, 2021.NewCo Sellers. See Note ~~13,~~12, Redeemable Noncontrolling Interests, and Note ~~14,~~13, Equity — Noncontrolling Interests in Total Equity, for a further discussion of the ownership in our operating partnership.

Public ~~Offering~~Offerings

~~Prior to~~As of March 31, 2023, after taking into consideration the impact of the Merger and the reverse stock split as discussed in Note 2, Summary of Significant Accounting Policies, we ~~raised $1,842,618,000 through~~had issued 65,445,557 shares for a ~~best efforts initial public offering that commenced on~~total of $2,737,716,000 of common stock since February 26, 2014 in our initial public offerings and our distribution reinvestment plan, or DRIP, offerings (includes historical offering amounts sold by GAHR III and GAHR IV prior to the Merger).

On September 16, 2022, we filed with the United States Securities and Exchange Commission, or the ~~GAHR III initial~~SEC, a Registration Statement on Form S-11 (File No. 333-267464), with respect to a proposed public offering ~~and issued 184,930,598~~by us of our shares of ~~our~~ common ~~stock. In addition, during the GAHR III initial offering, we issued 1,948,563 shares~~stock in conjunction with a contemplated listing of our common stock ~~pursuant to our initial distribution reinvestment plan,~~on the New York Stock Exchange, or the Initial DRIP, for a total of $18,511,000 in distributions reinvested. Following the deregistration of the GAHR III initial offering on April 22, 2015, we continued issuing shares of our common stock pursuant to subsequent distribution reinvestment plan offerings.Proposed Listing. Such registration statement and contemplated listing are not yet effective.

1210

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

See Note ~~14,~~13, Equity — Common Stock, and Note ~~14,~~13, Equity — Distribution Reinvestment Plan, for a further discussion of our public offerings.

Our Real Estate Investments Portfolio

We currently operate through 6six reportable business segments: integrated senior health campuses, ~~medical office buildings, skilled nursing facilities,~~MOBs, SHOP, SNFs, senior housing — leased and hospitals. As of ~~June 30, 2022,~~March 31, 2023, we owned and/or operated ~~313~~314 buildings and integrated senior health campuses, including completed development and expansion projects, or approximately ~~19,461,000~~19,956,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of ~~$4,370,459,000, including the fair value of the properties acquired in the Merger.~~$4,626,119,000. In addition, as of ~~June 30, 2022,~~March 31, 2023, we also owned a real estate-related debt investment purchased for $60,429,000.

COVID-19

Our residents, tenants, operating partners and managers, our industry and the U.S. economy ~~continue to be~~have been adversely affected by the impact of the COVID-19 pandemic. While the COVID-19 pandemic ~~and related supply chain disruptions and labor shortages. The~~has subsided from its peaks, the timing and extent of the economic recovery from the COVID-19 pandemic is dependent upon many factors, including the emergence and severity of new COVID-19 variants, the ~~continued~~ effectiveness ~~and frequency~~ of ~~booster vaccinations~~vaccines, the actions taken to contain the pandemic or mitigate its impact and the ~~duration~~direct and ~~implications~~indirect economic effects of ~~continued restrictions~~the pandemic and ~~safety measures.~~containment measures, the overall pace of recovery, among others. As the lasting economic effects of the responses to the COVID-19 pandemic, issuch as inflation and labor market challenges, are still impacting the healthcare system to a certain extent, ~~it continues~~such effects continue to present challenges for us as an owner and operator of healthcare facilities, making it difficult to ascertain the long-term impact the COVID-19 pandemic will have on real estate markets in which we own and/or operate properties and our portfolio of investments.

We have evaluated ~~the~~such economic impacts of the COVID-19 pandemic on our business thus far and incorporated information concerning such impacts into our assessments of liquidity, impairment and collectability from tenants and residents as of ~~June 30, 2022.~~March 31, 2023. We will continue to monitor such impacts and will adjust our estimates and assumptions based on the best available information.

2. Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our accompanying condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes thereto are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, or GAAP, in all material respects, and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our operating partnership, the wholly owned subsidiaries of our operating partnership and all non-wholly owned subsidiaries in which we have control, as well as any VIEs, in which we are the primary beneficiary. The portion of equity in any subsidiary that is not wholly owned by us is presented in our accompanying condensed consolidated financial statements as a noncontrolling interest. We evaluate our ability to control an entity, and whether the entity is a VIE and we are the primary beneficiary, by considering substantive terms of the arrangement and identifying which enterprise has the power to direct the activities of the entity that most significantly impacts the entity’s economic performance.

We operate and intend to continue to operate in an umbrella partnership REIT structure in which our operating partnership, or wholly owned subsidiaries of our operating partnership and all non-wholly owned subsidiaries of which we have control, will own substantially all of the interests in properties acquired on our behalf. We are the sole general partner of our operating partnership and as of ~~June 30, 2022~~both March 31, 2023 and December 31, ~~2021,~~2022, we owned ~~an approximately~~a 95.0% ~~and 94.9%~~ general partnership interest therein, ~~respectively,~~ and the remaining 5.0% ~~and 5.1%, respectively,~~ was owned by the NewCo Sellers. Prior to the Merger on October 1, 2021, we owned greater than a 99.99% general partnership interest in our operating partnership and our former advisor was a limited partner that owned less than a 0.01% noncontrolling limited partnership interest in our operating partnership. On October 1, 2021, in connection with the AHI Acquisition, our operating partnership redeemed our former advisor’s 222 limited partnership units in our operating partnership and the 208 limited partnership units owned by GAHR IV Advisor in GAHR IV Operating Partnership.

1311

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The accounts of our operating partnership are consolidated in our accompanying condensed consolidated financial statements because we are the sole general partner of our operating partnership and have unilateral control over its management and major operating decisions (even if additional limited partners are admitted to our operating partnership). All intercompany accounts and transactions are eliminated in consolidation.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the ~~United States Securities and Exchange Commission, or~~ SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to the SEC’s rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments which are, in our view, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim period. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such full year results may be less favorable.

In preparing our accompanying condensed consolidated financial statements, management has evaluated subsequent events through the financial statement issuance date. We believe that although the disclosures contained herein are adequate to prevent the information presented from being misleading, our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022.~~17, 2023.

Use of Estimates

The preparation of our accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include, but are not limited to, the initial and recurring valuation of certain assets acquired and liabilities assumed through property acquisitions, including through business combinations, goodwill and its impairment, revenues and grant income, allowance for credit losses, impairment of long-lived and intangible assets and contingencies. These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions.

Revenue Recognition — Resident Fees and Services Revenue

Disaggregation of Resident Fees and Services Revenue

The following tables disaggregate our resident fees and services revenue by line of business, according to whether such revenue is recognized at a point in time or over time:


		Three Months Ended June 30,													Three Months Ended March 31,
		2022						2021							2023						2022
		Integrated Senior Health Campuses		SHOP(1)		Total		Integrated Senior Health Campuses		SHOP(1)		Total			Integrated Senior Health Campuses		SHOP(1)		Total		Integrated Senior Health Campuses		SHOP(1)		Total
Over time	Over time	$	232,839,000	$	37,891,000	$	270,730,000	$	204,729,000	$	20,039,000	$	224,768,000	Over time	$	298,850,000	$	45,613,000	$	344,463,000	$	230,534,000	$	37,216,000	$	267,750,000
Point in time	Point in time	54,743,000		752,000		55,495,000		51,086,000		498,000		51,584,000		Point in time	62,920,000		1,247,000		64,167,000		50,478,000		746,000		51,224,000
Total resident fees and services	Total resident fees and services	$	287,582,000	$	38,643,000	$	326,225,000	$	255,815,000	$	20,537,000	$	276,352,000	Total resident fees and services	$	361,770,000	$	46,860,000	$	408,630,000	$	281,012,000	$	37,962,000	$	318,974,000

1412

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Six Months Ended June 30,
2022 2021
Integrated
Senior Health
Campuses SHOP(1) Total Integrated
Senior Health
Campuses SHOP(1) Total
Over time $ 463,373,000 $ 75,107,000 $ 538,480,000 $ 392,987,000 $ 39,498,000 $ 432,485,000
Point in time 105,221,000 1,498,000 106,719,000 96,054,000 839,000 96,893,000
Total resident fees and services $ 568,594,000 $ 76,605,000 $ 645,199,000 $ 489,041,000 $ 40,337,000 $ 529,378,000

The following tables disaggregate our resident fees and services revenue by payor class:

Three Months Ended June 30,
2022 2021
Integrated
Senior Health
Campuses SHOP(1) Total Integrated
Senior Health
Campuses SHOP(1) Total
Private and other payors $ 137,419,000 $ 35,632,000 $ 173,051,000 $ 112,747,000 $ 20,257,000 $ 133,004,000
Medicare 93,680,000 — 93,680,000 87,885,000 — 87,885,000
Medicaid 56,483,000 3,011,000 59,494,000 55,183,000 280,000 55,463,000
Total resident fees and services $ 287,582,000 $ 38,643,000 $ 326,225,000 $ 255,815,000 $ 20,537,000 $ 276,352,000


		Six Months Ended June 30,													Three Months Ended March 31,
		2022						2021							2023						2022
		Integrated Senior Health Campuses		SHOP(1)		Total		Integrated Senior Health Campuses		SHOP(1)		Total			Integrated Senior Health Campuses		SHOP(1)		Total		Integrated Senior Health Campuses		SHOP(1)		Total
Private and other payors	Private and other payors	$	269,222,000	$	70,669,000	$	339,891,000	$	218,857,000	$	39,676,000	$	258,533,000	Private and other payors	$	169,678,000	$	43,850,000	$	213,528,000	$	131,803,000	$	35,037,000	$	166,840,000
Medicare	Medicare	188,197,000		—		188,197,000		172,168,000		—		172,168,000		Medicare	126,466,000		311,000		126,777,000		94,517,000		—		94,517,000
Medicaid	Medicaid	111,175,000		5,936,000		117,111,000		98,016,000		661,000		98,677,000		Medicaid	65,626,000		2,699,000		68,325,000		54,692,000		2,925,000		57,617,000
Total resident fees and services	Total resident fees and services	$	568,594,000	$	76,605,000	$	645,199,000	$	489,041,000	$	40,337,000	$	529,378,000	Total resident fees and services	$	361,770,000	$	46,860,000	$	408,630,000	$	281,012,000	$	37,962,000	$	318,974,000

___________

(1)Includes fees for basic housing and assisted living care. We record revenue when services are rendered at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.

Accounts Receivable, Net — Resident Fees and Services Revenue

The beginning and ending balances of accounts receivable, net — resident fees and services are as follows:
Private
and
Other Payors Medicare Medicaid Total
Beginning balance — January 1, 2022
$ 42,056,000 $ 35,953,000 $ 16,922,000 $ 94,931,000
Ending balance — June 30, 2022
45,514,000 35,844,000 19,678,000 101,036,000
Increase/(decrease) $ 3,458,000 $ (109,000) $ 2,756,000 $ 6,105,000

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~


	Private and Other Payors		Medicare		Medicaid		Total
Beginning balance — January 1, 2023	$	55,484,000	$	45,669,000	$	20,832,000	$	121,985,000
Ending balance — March 31, 2023	60,233,000		43,155,000		18,824,000		122,212,000
Increase (decrease)	$	4,749,000	$	(2,514,000)	$	(2,008,000)	$	227,000

Deferred Revenue — Resident Fees and Services Revenue

Deferred revenue is included in security deposits, prepaid rent and other liabilities in our accompanying condensed consolidated balance sheets. The beginning and ending balances of deferred revenue — resident fees and services, almost all of which relates to private and other payors, are as follows:


	Total
Beginning balance — January 1, ~~2022~~2023	$	~~14,673,000~~17,901,000
Ending balance — ~~June 30, 2022~~March 31, 2023	~~16,405,000~~22,214,000
Increase	$	~~1,732,000~~4,313,000

In addition to the deferred revenue above, as of December 31, 2021, we had approximately $12,969,000 remaining in Medicare advance payments that were received during 2020 through an expanded program of the Centers for Medicare & Medicaid Services. Such amounts were included in security deposits, prepaid rentResident and other liabilities in our accompanying condensed consolidated balance sheet as of December 31, 2021, and were fully applied to Medicare claims and recognized as resident fees and services revenue for the six months ended June 30, 2022.

Tenant ~~and Resident~~ Receivables and Allowances

Resident receivables, which are related to resident fees and services revenue, are carried net of an allowance for credit losses. An allowance is maintained for estimated losses resulting from the inability of residents and payors to meet the contractual obligations under their lease or service agreements. Substantially all of such allowances are recorded as direct reductions of resident fees and services revenue as contractual adjustments provided to third-party payors or implicit price concessions in our accompanying condensed consolidated statements of operations and comprehensive loss. Our determination of the adequacy of these allowances is based primarily upon evaluations of historical loss experience, the residents’ financial condition, security deposits, cash collection patterns by payor and by state, current economic conditions, future expectations in estimating credit losses and other relevant factors. Tenant receivables, which are related to real estate revenue, and unbilled deferred rent receivables are reduced for ~~uncollectible~~ amounts where collectability is not probable, which are recognized as direct reductions of real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss.

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we had ~~$14,798,000~~$14,391,000 and ~~$12,378,000,~~$14,071,000, respectively, in allowances, which were determined necessary to reduce receivables by our expected future credit losses. For the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we increased allowances by ~~$9,581,000~~$4,037,000 and ~~$5,121,000,~~$5,223,000, respectively, and reduced allowances for collections or adjustments by ~~$3,643,000~~$1,827,000 and ~~$2,960,000,~~$2,099,000, respectively. For the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022, $1,890,000 and ~~2021, $3,518,000 and $3,740,000,~~$1,630,000, respectively, of our receivables were written off against the related allowances.

~~Accounts Payable and Accrued Liabilities~~

As of June 30, 2022 and December 31, 2021, accounts payable and accrued liabilities primarily include insurance reserves of $35,606,000 and $36,440,000, respectively, reimbursement of payroll-related costs to the managers of our SHOP and integrated senior health campuses of $30,622,000 and $31,101,000, respectively, accrued property taxes of $21,979,000 and $22,102,000, respectively, accrued developments and capital expenditures to unaffiliated third parties of $14,055,000 and $22,852,000, respectively, and accrued distributions to common stockholders of $8,812,000 and $8,768,000, respectively.

~~Statement of Cash Flows~~

For the six months ended June 30, 2021, amounts totaling $101,734,000 have been removed from borrowings under mortgage loans payable and early payoff of mortgage loans payable to properly reflect only actual cash flows resulting from borrowings and payments of mortgage loans compared to amounts previously presented. There was no net change in previously disclosed net cash provided by financing activities.

~~Recently Issued Accounting Pronouncements~~

~~In July 2021, the FASB issued Accounting Standard Update, or ASU, 2021-05,~~ ~~Leases (Topic 842): Lessors — Certain Leases with Variable Lease Payments, or ASU 2021-05, which amends the lease classification requirements for lessors to align them with practice under the previous lease accounting standard, ASC Topic 840,~~ ~~Leases~~. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: (1) the lease would have been classified as a sales-type lease or a direct financing lease; and (2) the lessor would have otherwise recognized a day-one loss. ASU 2021-05 was effective for fiscal years beginning after December 15, 2021. Early adoption was permitted. We adopted such accounting pronouncement on January 1, 2022, which did not have a

1613

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

~~material impact~~Accounts Payable and Accrued Liabilities

As of March 31, 2023 and December 31, 2022, accounts payable and accrued liabilities primarily include insurance reserves of $41,602,000 and $39,893,000, respectively, reimbursement of payroll-related costs to the managers of our ~~consolidated financial statements~~SHOP and ~~disclosures as we have no material sales-type or direct financing leases.~~integrated senior health campuses of $39,718,000 and $38,624,000, respectively, accrued property taxes of $26,168,000 and $24,926,000, respectively, accrued developments and capital expenditures to unaffiliated third parties of $26,102,000 and $30,211,000, respectively, and accrued distributions to common stockholders of $16,554,000 and $26,484,000, respectively.

3. Real Estate Investments, Net and Business Combinations

Our real estate investments, net consisted of the following as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021:~~2022:


		June 30, 2022		December 31, 2021			March 31, 2023		December 31, 2022
Building, improvements and construction in process	Building, improvements and construction in process	$	3,536,965,000	$	3,505,786,000	Building, improvements and construction in process	$	3,682,324,000	$	3,670,361,000
Land and improvements	Land and improvements	335,330,000		334,562,000		Land and improvements	346,005,000		344,359,000
Furniture, fixtures and equipment	Furniture, fixtures and equipment	208,194,000		198,224,000		Furniture, fixtures and equipment	229,477,000		221,727,000
		4,080,489,000		4,038,572,000			4,257,806,000		4,236,447,000
Less: accumulated depreciation	Less: accumulated depreciation	(588,644,000)		(523,886,000)		Less: accumulated depreciation	(689,689,000)		(654,838,000)
		$	3,491,845,000	$	3,514,686,000		$	3,568,117,000	$	3,581,609,000

Depreciation expense for the three months ended ~~June 30,~~March 31, 2023 and 2022 was $35,899,000 and ~~2021 was $34,328,000 and $24,663,000, respectively, and for the six months ended June 30, 2022 and 2021 was $68,750,000 and $48,853,000,~~$34,422,000, respectively. For the three months ended ~~June 30, 2022,~~March 31, 2023, we incurred capital expenditures of ~~$8,530,000~~$10,201,000 for our integrated senior health campuses, ~~$4,144,000~~$3,574,000 for our ~~medical office buildings~~MOBs and ~~$1,597,000~~$1,750,000 for our SHOP. We did not incur any capital expenditures for our properties within our ~~skilled nursing facilities,~~hospitals, SNFs and senior housing — leased ~~or hospitals~~ segments for the three months ended ~~June 30, 2022. For the six months ended June 30, 2022, we incurred capital expenditures~~March 31, 2023.

Acquisition of $16,778,000 for our integrated senior health campuses, $6,578,000 for our medical office buildings and $3,051,000 for our SHOP. We did not incur any capital expenditures for our properties within our skilled nursing facilities, senior housing — leased or hospitals segments for the six months ended June 30, 2022.Real Estate Investment

~~During both the three and~~six months ended June 30, 2022, we determined that 4 of our SHOP were impaired and recognized an aggregate impairment charge of $17,340,000, which reduced the total carrying value of such assets to $19,325,000. The fair value of 1 SHOP was determined by the sales price from an executed purchase and sale agreement with a third-party buyer, which was considered a Level 2 measurement within the fair value hierarchy. The fair value of the remaining 3 SHOP were based on their projected sales prices, which were considered Level 2 measurements within the fair value hierarchy.

~~During both the three and~~six months ended June 30, 2021, we determined that 1 medical office building was impaired and recognized an impairment charge of $3,335,000, which reduced the carrying value of such asset to $2,880,000. The fair value of such property was determined by the sales price from an executed purchase and sale agreement with a third-party buyer, and adjusted for anticipated selling costs, which was considered a Level 2 measurement within the fair value hierarchy. We disposed of such impaired medical office building in July 2021 for a contract sales price of $3,000,000 and recognized a net gain on sale of $346,000.

Included in the capital expenditure amounts above are costs for the development and expansion of our integrated senior health campuses. For the six months ended June 30, 2022, we exercised our right to purchase a leased property that cost $15,462,000 to develop. During the six months ended June 30, 2022,On February 15, 2023, we, through a majority-owned subsidiary of Trilogy Investors, LLC, or Trilogy, acquired ~~a land parcel~~an integrated senior health campus located in ~~Indiana~~Kentucky for a contract purchase price of ~~$320,000,~~$11,000,000, plus immaterial closing costs.

In April and May 2022, we, through a majority-owned subsidiary of Trilogy, of which we owned 72.9% at the time of acquisition, exercised the purchase options to acquire 4 previously leased real estate investments located in Indiana and Kentucky for an aggregate contract purchase price of $54,805,000, which investments are included in our integrated senior health campuses segment. We financed such ~~acquisitions~~acquisition with cash on hand and a mortgage loan payable placed on the property at the time of acquisition with a principal balance of ~~$52,725,000.~~

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

$7,700,000.

We accounted for our ~~acquisitions~~acquisition of ~~land and previously leased~~a real estate ~~investments~~investment completed during the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 as an asset ~~acquisitions. We incurred and capitalized direct acquisition related expenses of $292,000.~~acquisition. The following table summarizes the purchase price of such ~~assets acquired, adjusted for $37,464,000 operating lease right-of-use assets and $36,326,000 operating lease liabilities, and~~acquisition based on ~~their~~ relative fair values:


	~~2022~~2023 ~~Acquisitions~~Acquisition
Building and improvements	$	~~49,645,000~~10,139,000
Land and improvements	~~8,173,000~~912,000




Total assets acquired	$	~~57,818,000~~11,051,000

~~Sale~~Disposition of ~~Controlling Interests in~~ Real Estate ~~Investments~~Investment

On February ~~8, 2022,~~1, 2023, we ~~sold approximately 77.0% ownership interests~~disposed of one facility within our Central Florida Senior Housing Portfolio within our SHOP segment, for a contract sales price of $7,730,000 and recognized a gain on sale of $11,000.

Business Combinations

On February 15, 2023, we, through a majority-owned subsidiary of Trilogy, acquired from an unaffiliated third party, a 60.0% controlling interest in ~~several real estate assets for development within our~~a privately held company, Memory Care Partners, LLC, or MCP, that operated integrated senior health campuses ~~segment for an aggregate sales~~located in Kentucky. The contract purchase price ~~of $19,622,000 and we recognized an aggregate gain on sale of $683,000~~ for the ~~six months ended June 30, 2022. We retained approximately 23.0% ownership interests~~acquisition of MCP was $900,000, which was acquired using cash on hand. Prior to such acquisition, we owned a 40.0% interest in ~~such real estate development assets,~~MCP, which ~~interests are~~was accounted for as an equity method investment and was included in investments in unconsolidated entities within other assets, net in our accompanying condensed consolidated balance sheet as of ~~June 30,~~December 31, 2022. ~~From February 8, 2022 through June 30, 2022, approximately 23.0%~~In connection with the acquisition of the remaining interest in MCP, we now own a 100% controlling interest in MCP. As a result, we re-measured the ~~net earnings or losses~~fair value of ~~such unconsolidated entities were included~~our previously held equity interest in ~~income (loss) from unconsolidated entities~~MCP and recognized a gain on re-measurement of $726,000 in our accompanying condensed consolidated statements of operations and comprehensive loss.

Table of Contents

~~4. Business Combinations~~

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

On January 3, 2022, we, through a majority-owned subsidiary of Trilogy, acquired an integrated senior health campus in Kentucky from an unaffiliated third party. The contract purchase price for such property acquisition was $27,790,000 plus immaterial ~~closing~~transaction costs. We acquired such property using cash on hand and placed a mortgage loan payable of $20,800,000 on the property at the time of acquisition. ~~Further, on April 1, 2022, we, through a majority-owned subsidiary~~

The table below summarizes the acquisition date fair values of ~~Trilogy,~~the assets acquired ~~a 50.0% interest in a pharmaceutical~~and liabilities assumed of our business ~~in Florida from an unaffiliated third party and incurred transaction costs of $938,000. Prior to such pharmaceutical business acquisition, we, through a majority-owned subsidiary of Trilogy, owned~~combinations during the other 50.0% interest in such business, which investment was included in investments in unconsolidated entities within other assets, net in our accompanying condensed consolidated balance sheet as of December 31, 2021. Therefore, throughthree months ended March 31, 2022, our 50.0% interest in the net earnings or losses of such unconsolidated entity was included in income (loss) from unconsolidated entities in our accompanying condensed consolidated statements of operations2023 and ~~comprehensive loss.~~

~~We accounted for the 2 acquisitions for the six months ended June 30, 2022 above as business combinations, which are included within our integrated senior health campuses segment.~~2022. Based on quantitative and qualitative considerations, such business combinations were not material to us individually or in the aggregate and therefore, pro forma financial information is not provided. ~~We did not complete any acquisitions accounted for as business combinations for the six months ended June 30, 2021.~~

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

The table below summarizes the acquisition date fair values of the assets acquired and liabilities assumed of our 2022 property acquisitions accounted for as business combinations. The fair values of the assets acquired and liabilities assumed during 2022 were preliminary estimates. Any necessary adjustments ~~will be~~are finalized within one year from the date of acquisition.


	2022 Acquisitions
~~Building and improvements~~	$	~~17,273,000~~
~~Land~~	~~3,060,000~~
~~In-place leases~~	~~3,420,000~~
~~Goodwill~~	~~2,816,000~~
~~Furniture, fixtures and equipment~~	~~1,936,000~~
~~Cash~~	~~971,000~~
~~Certificates of need~~	~~690,000~~
~~Operating lease right-of-use assets~~	~~646,000~~
~~Other assets~~	~~457,000~~
~~Accounts receivable~~	~~427,000~~
~~Total assets acquired~~	~~31,696,000~~
~~Security deposits~~	~~(8,129,000)~~
~~Accounts payable and accrued liabilities~~	~~(1,802,000)~~
~~Operating lease liabilities~~	~~(646,000)~~
~~Financing obligations~~	~~(56,000)~~
~~Total liabilities assumed~~	~~(10,633,000)~~
~~Net assets acquired~~	$	~~21,063,000~~


	2023 Acquisition		2022 Acquisition

Building and improvements	$	—	$	17,235,000
Goodwill	3,331,000		1,827,000

In-place leases	—		3,420,000
Land	—		3,060,000
Cash and restricted cash	565,000		588,000
Certificates of need	—		690,000
Furniture, fixtures and equipment	39,000		1,558,000
Other assets	66,000		—
Total assets acquired	4,001,000		28,378,000


Security deposits and other liabilities	(812,000)		(7,747,000)
Accounts payable and accrued liabilities	(1,676,000)		(109,000)
Financing obligations	(12,000)		(56,000)
Total liabilities assumed	(2,500,000)		(7,912,000)
Net assets acquired	$	1,501,000	$	20,466,000

5.4. Debt Security Investment, Net

~~On October 15, 2015, we acquired~~Our investment in a commercial mortgage-backed debt security, or ~~debt security, from an unaffiliated third party. The~~ debt security, bears an interest rate on the stated principal amount thereof equal to 4.24% per annum, the terms of which security provide for monthly interest-only payments. The debt security matures on August 25, 2025 at a stated amount of $93,433,000, resulting in an anticipated yield-to-maturity of 10.0% per annum. The debt security was issued by an unaffiliated mortgage trust and represents a 10.0% beneficial ownership interest in such mortgage trust. The debt security is subordinate to all other interests in the mortgage trust and is not guaranteed by a government-sponsored entity.

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, the carrying amount of the debt security investment was ~~$81,167,000~~$83,955,000 and ~~$79,315,000,~~$83,000,000, respectively, net of unamortized closing costs of ~~$890,000~~$701,000 and ~~$1,004,000,~~$767,000, respectively. Accretion on the debt security for the three months ended ~~June 30,~~March 31, 2023 and 2022 was $1,020,000 and ~~2021 was $986,000 and $907,000, respectively, and for the six months ended June 30, 2022 and 2021 was $1,966,000 and $1,788,000,~~$980,000, respectively, which is recorded as an increase to real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss. Amortization expense of closing costs for the three months ended ~~June 30,~~March 31, 2023 and 2022 was $65,000 and ~~2021 was $58,000 and $49,000, respectively, and for the six months ended June 30, 2022 and 2021 was $114,000 and $96,000,~~$56,000, respectively, which is recorded as a decrease to real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss. We evaluated credit quality indicators such as the agency ratings and the underlying collateral of such investment in order to determine expected future credit loss. NoWe did not record a credit loss ~~was recorded~~ for the three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 and ~~2021.~~2022.

1915

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

5. Identified Intangible Assets, Net

Identified intangible assets, net consisted of the following as of March 31, 2023 and December 31, 2022:


	March 31, 2023		December 31, 2022
Amortized intangible assets:
In-place leases, net of accumulated amortization of $43,513,000 and $38,930,000 as of March 31, 2023 and December 31, 2022, respectively (with a weighted average remaining life of 7.1 years and 7.0 years as of March 31, 2023 and December 31, 2022, respectively)	$	67,684,000	$	75,580,000
Above-market leases, net of accumulated amortization of $6,094,000 and $6,360,000 as of March 31, 2023 and December 31, 2022, respectively (with a weighted average remaining life of 8.3 years and 9.0 years as of March 31, 2023 and December 31, 2022, respectively)	21,111,000		30,194,000
Customer relationships, net of accumulated amortization of $822,000 and $785,000 as of March 31, 2023 and December 31, 2022, respectively (with a weighted average remaining life of 13.4 years and 13.7 years as of March 31, 2023 and December 31, 2022, respectively)	2,018,000		2,055,000

Unamortized intangible assets:
Certificates of need	97,679,000		97,667,000
Trade names	30,787,000		30,787,000
	$	219,279,000	$	236,283,000

Amortization expense on identified intangible assets for the three months ended March 31, 2023 and 2022 was $17,071,000 and $8,239,000, respectively, which included $9,083,000 and $1,114,000, respectively, of amortization recorded as a decrease to real estate revenue for above-market leases in our accompanying condensed consolidated statements of operations and comprehensive loss. On March 1, 2023, we transitioned our SNFs within Central Wisconsin Senior Care Portfolio to a RIDEA structure, which resulted in a full amortization of $8,073,000 of above-market leases and $885,000 of in-place leases.

The aggregate weighted average remaining life of the identified intangible assets was 7.5 years and 7.7 years as of March 31, 2023 and December 31, 2022, respectively. As of March 31, 2023, estimated amortization expense on the identified intangible assets for the nine months ending December 31, 2023 and for each of the next four years ending December 31 and thereafter was as follows:


Year	Amount
2023	$	20,289,000
2024	12,861,000
2025	10,037,000
2026	8,867,000
2027	8,230,000
Thereafter	30,529,000
Total	$	90,813,000

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

6. ~~Identified Intangible Assets, Net~~

~~Identified intangible assets, net consisted of the following as of June 30, 2022 and December 31, 2021:~~

June 30,
2022
December 31,
2021
Intangible assets subject to amortization:
In-place leases, net of accumulated amortization of $31,132,000 and $28,120,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 8.1 years and 8.2 years as of June 30, 2022 and December 31, 2021, respectively) $ 72,431,000 $ 81,538,000
Above-market leases, net of accumulated amortization of $4,306,000 and $2,082,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 9.4 years and 9.7 years as of June 30, 2022 and December 31, 2021, respectively) 32,849,000 35,106,000
Customer relationships, net of accumulated amortization of $710,000 and $635,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 14.2 years and 14.7 years as of June 30, 2022 and December 31, 2021, respectively) 2,130,000 2,205,000
Internally developed technology and software, net of accumulated amortization of $446,000 and $399,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 0.2 years and 0.7 years as of June 30, 2022 and December 31, 2021, respectively) 24,000 70,000
Intangible assets not subject to amortization:
Certificates of need 96,693,000 99,165,000
Trade names 30,787,000 30,787,000
$ 234,914,000 $ 248,871,000

Amortization expense on identified intangible assets for the three months ended June 30, 2022 and 2021 was $6,121,000 and $1,501,000, respectively, which included $1,113,000 and $257,000, respectively, of amortization recorded as a decrease to real estate revenue for above-market leases in our accompanying condensed consolidated statements of operations and comprehensive loss. Amortization expense on identified intangible assets for the six months ended June 30, 2022 and 2021 was $14,360,000 and $2,697,000, respectively, which included $2,227,000 and $340,000, respectively, of amortization recorded as a decrease to real estate revenue for above-market leases in our accompanying condensed consolidated statements of operations and comprehensive loss.

The aggregate weighted average remaining life of the identified intangible assets was 8.6 years and 8.8 years as of June 30, 2022 and December 31, 2021, respectively. As of June 30, 2022, estimated amortization expense on the identified intangible assets for the six months ending December 31, 2022 and for each of the next four years ending December 31 and thereafter was as follows:

Year Amount
2022 $ 10,892,000
2023 17,148,000
2024 13,657,000
2025 11,018,000
2026 9,848,000
Thereafter 44,871,000
$ 107,434,000

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

7. Other Assets, Net

Other assets, net consisted of the following as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021:~~2022:


		June 30, 2022		December 31, 2021			March 31, 2023		December 31, 2022
Deferred rent receivables	Deferred rent receivables	$	44,290,000	$	41,061,000	Deferred rent receivables	$	47,911,000	$	46,867,000
Prepaid expenses, deposits, other assets and deferred tax assets, net	Prepaid expenses, deposits, other assets and deferred tax assets, net	36,281,000		22,484,000		Prepaid expenses, deposits, other assets and deferred tax assets, net	31,219,000		25,866,000
Inventory						Inventory	19,053,000		19,775,000
Lease commissions, net of accumulated amortization of $6,636,000 and $6,260,000 as of March 31, 2023 and December 31, 2022, respectively						Lease commissions, net of accumulated amortization of $6,636,000 and $6,260,000 as of March 31, 2023 and December 31, 2022, respectively	18,384,000		19,217,000

Investments in unconsolidated entities	Investments in unconsolidated entities	23,326,000		15,615,000		Investments in unconsolidated entities	15,399,000		9,580,000
Inventory		18,649,000		18,929,000
Lease commissions, net of accumulated amortization of $5,460,000 and $4,911,000 as of June 30, 2022 and December 31, 2021, respectively		16,758,000		16,120,000
Deferred financing costs, net of accumulated amortization of $6,503,000 and $5,704,000 as of March 31, 2023 and December 31, 2022, respectively						Deferred financing costs, net of accumulated amortization of $6,503,000 and $5,704,000 as of March 31, 2023 and December 31, 2022, respectively	3,795,000		4,334,000
Lease inducement, net of accumulated amortization of $2,281,000 and $2,193,000 as of March 31, 2023 and December 31, 2022, respectively (with a weighted average remaining life of 7.7 years and 7.9 years as of March 31, 2023 and December 31, 2022, respectively)						Lease inducement, net of accumulated amortization of $2,281,000 and $2,193,000 as of March 31, 2023 and December 31, 2022, respectively (with a weighted average remaining life of 7.7 years and 7.9 years as of March 31, 2023 and December 31, 2022, respectively)	2,719,000		2,807,000
							$	138,480,000	$	128,446,000
Deferred financing costs, net of accumulated amortization of $4,340,000 and $8,469,000 as of June 30, 2022 and December 31, 2021, respectively		5,466,000		3,781,000
Lease inducement, net of accumulated amortization of $2,018,000 and $1,842,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 8.4 years and 8.9 years as of June 30, 2022 and December 31, 2021, respectively)		2,982,000		3,158,000
		$	147,752,000	$	121,148,000

Deferred financing costs included in other assets, net were related to the ~~2018 Credit Facility, 2019 Credit Facility,~~ 2019 Trilogy Credit Facility and the senior unsecured revolving credit facility portion of the 2022 Credit Facility. See Note 9,8, Lines of Credit and Term ~~Loans,~~Loan, for a further discussion. Amortization expense on lease inducement for both the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ was $88,000, ~~and $176,000, respectively, and~~which is recorded as a decrease to real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss.

8.7. Mortgage Loans Payable, Net

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, mortgage loans payable were ~~$1,152,998,000~~$1,257,057,000 ($~~1,134,059,000,~~1,233,745,000, net of discount/premium and deferred financing costs) and ~~$1,116,216,000~~$1,254,479,000 ($~~1,095,594,000,~~1,229,847,000, net of discount/premium and deferred financing costs), respectively. As of ~~June 30, 2022,~~March 31, 2023, we had 6668 fixed-rate mortgage loans payable and 12 variable-rate mortgage loans payable with effective interest rates ranging from 2.21% to ~~5.25%~~7.76% per annum based on interest rates in effect as of ~~June 30, 2022~~March 31, 2023 and a weighted average effective interest rate of ~~3.35%~~4.46%. As of December 31, ~~2021,~~2022, we had 6668 fixed-rate mortgage loans payable and 1211 variable-rate mortgage loans payable with effective interest rates ranging from 2.21% to ~~5.25%~~7.26% per annum based on interest rates in effect as of December 31, ~~2021~~2022 and a weighted average effective interest rate of ~~3.21%~~4.29%. We are required by the terms of certain loan documents to meet certain reporting requirements and covenants, such as net worth ratios, fixed charge coverage ratios and leverage ratios.

Mortgage loans payable, net consisted of the following as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021:~~2022:


		June 30, 2022		December 31, 2021			March 31, 2023		December 31, 2022
Total fixed-rate debt	Total fixed-rate debt	$	826,465,000	$	845,504,000	Total fixed-rate debt	$	880,770,000	$	885,892,000
Total variable-rate debt	Total variable-rate debt	326,533,000		270,712,000		Total variable-rate debt	376,287,000		368,587,000
Total fixed- and variable-rate debt	Total fixed- and variable-rate debt	1,152,998,000		1,116,216,000		Total fixed- and variable-rate debt	1,257,057,000		1,254,479,000
Less: deferred financing costs, net	Less: deferred financing costs, net	(8,525,000)		(8,680,000)		Less: deferred financing costs, net	(8,410,000)		(8,845,000)
Add: premium	Add: premium	314,000		397,000		Add: premium	215,000		237,000
Less: discount	Less: discount	(10,728,000)		(12,339,000)		Less: discount	(15,117,000)		(16,024,000)
Mortgage loans payable, net	Mortgage loans payable, net	$	1,134,059,000	$	1,095,594,000	Mortgage loans payable, net	$	1,233,745,000	$	1,229,847,000

2117

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The following table reflects the changes in the carrying amount of mortgage loans payable, net for the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:


		Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021			2023		2022
Beginning balance	Beginning balance	$	1,095,594,000	$	810,478,000	Beginning balance	$	1,229,847,000	$	1,095,594,000
Additions:	Additions:					Additions:
Borrowings under mortgage loans payable	Borrowings under mortgage loans payable	155,882,000		213,176,000		Borrowings under mortgage loans payable	7,700,000		88,659,000

Amortization of deferred financing costs	Amortization of deferred financing costs	1,191,000		3,012,000		Amortization of deferred financing costs	577,000		2,078,000
Amortization of discount/premium on mortgage loans payable, net	Amortization of discount/premium on mortgage loans payable, net	1,528,000		405,000		Amortization of discount/premium on mortgage loans payable, net	885,000		(17,000)
Deductions:	Deductions:					Deductions:
Scheduled principal payments on mortgage loans payable	Scheduled principal payments on mortgage loans payable	(40,662,000)		(7,215,000)		Scheduled principal payments on mortgage loans payable	(5,122,000)		(4,538,000)
Early payoff of mortgage loans payable	Early payoff of mortgage loans payable	(78,437,000)		(101,734,000)		Early payoff of mortgage loans payable	—		(78,437,000)

Deferred financing costs	Deferred financing costs	(1,037,000)		(1,001,000)		Deferred financing costs	(142,000)		(333,000)
Ending balance	Ending balance	$	1,134,059,000	$	917,121,000	Ending balance	$	1,233,745,000	$	1,103,006,000

For the three ~~and six~~ months ended ~~June 30, 2022,~~March 31, 2023, we ~~incurred an aggregate~~did not incur any gain ~~(loss)~~or loss on the extinguishment of mortgage loans payable of $181,000 and $(1,249,000), respectively, which is recorded as a decrease (increase), respectively, to interest expense in our accompanying condensed consolidated statements of operations and comprehensive loss. Such aggregate net loss on debt extinguishment was primarily related to the write-off of unamortized loan discount related to 8 mortgage loans payable that we refinanced on January 1, 2022 that were due to mature in 2044 through 2052.

payable. For the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, we incurred an aggregate loss on the extinguishment of mortgage loans payable of ~~$5,000 and $2,293,000, respectively,~~$1,430,000, which is recorded as an increase to interest expense in our accompanying condensed consolidated statements of operations and comprehensive loss. Such loss was primarily related to the write-off of unamortized ~~deferred financing costs of 10~~loan discount related to eight mortgage loans payable that we refinanced on January ~~29, 2021~~1, 2022 that were due to mature in ~~2053.~~2044 through 2052.

As of ~~June 30, 2022,~~March 31, 2023, the principal payments due on our mortgage loans payable for the ~~six~~nine months ending December 31, ~~2022~~2023 and for each of the next four years ending December 31 and thereafter were as follows:


Year	Year	Amount		Year	Amount
2022		$	25,728,000
2023	2023	182,678,000		2023	$	128,240,000
2024	2024	229,721,000		2024	278,056,000
2025	2025	29,463,000		2025	165,544,000
2026	2026	155,297,000		2026	155,159,000
2027				2027	34,413,000
Thereafter	Thereafter	530,111,000		Thereafter	495,645,000
		$	1,152,998,000
Total				Total	$	1,257,057,000

9.8. Lines of Credit and Term ~~Loans~~

~~2018 Credit Facility~~

In order to accommodate the Merger, we amended GAHR IV and its operating partnership's credit agreement, as amended, or the 2018 Credit Agreement, with Bank of America, N.A., or Bank of America; KeyBank, National Association, or KeyBank; Citizens Bank, National Association, or Citizens Bank; Merrill Lynch, Pierce, Fenner & Smith Incorporated; KeyBanc Capital Markets, Inc., or KeyBanc Capital Markets; and the lenders named therein, for a credit facility with an aggregate maximum principal amount of $530,000,000, or the 2018 Credit Facility. The 2018 Credit Facility, which was further amended on October 1, 2021 to provide for updates regarding the Combined Company subsequent to the Merger, consisted of a senior unsecured revolving credit facility in the amount of $235,000,000 and senior unsecured term loan facilities in the aggregate amount of $295,000,000. At our option, the 2018 Credit Facility bore interest at per annum rates equal to (a)(i) the Eurodollar Rate, as defined in the 2018 Credit Agreement, plus (ii) a margin ranging from 1.70% to 2.20% based on our Consolidated Leverage Ratio, as defined in the 2018 Credit Agreement, or (b)(i) the greater of: (1) the prime rate publicly

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

announced by Bank of America, (2) the Federal Funds Rate, as defined in the 2018 Credit Agreement, plus 0.50%, (3) the one-month Eurodollar Rate plus 1.00%, and (4) 0.00%, plus (ii) a margin ranging from 0.70% to 1.20% based on our Consolidated Leverage Ratio.

The 2018 Credit Facility was due to mature on November 19, 2021; however, pursuant to the terms of the 2018 Credit Agreement, at such time we extended the maturity date for an additional 12 months and paid an extension fee of $795,000. As of December 31, 2021, borrowings outstanding totaled $441,900,000 and the weighted average interest rate on such borrowings outstanding was 2.27% per annum. On January 19, 2022, we terminated the 2018 Credit Agreement and entered into the 2022 Credit Agreement, as defined and discussed below.

~~2019 Credit Facility~~

On October 1, 2021, upon consummation of the Merger, we, through the surviving partnership, were subject to GAHR III’s credit agreement, as amended, or the 2019 Corporate Credit Agreement, with Bank of America; KeyBank; Citizens Bank; and a syndicate of other banks, as lenders, for a credit facility with an aggregate maximum principal amount of $630,000,000, or the 2019 Credit Facility. The 2019 Credit Facility consisted of a senior unsecured revolving credit facility in an aggregate amount of $150,000,000 and a senior unsecured term loan facility in an aggregate amount of $480,000,000. On October 1, 2021, upon consummation of the Merger, the previously available $150,000,000 senior unsecured revolving credit facility was cancelled and a ratable amendment to certain financial covenants was made to account for the Combined Company.

At our option, the 2019 Credit Facility bore interest at per annum rates equal to (a) (i) the Eurodollar Rate, as defined in the 2019 Corporate Credit Agreement, plus (ii) a margin ranging from 1.85% to 2.80% based on our Consolidated Leverage Ratio, as defined in the 2019 Corporate Credit Agreement, or (b) (i) the greater of: (1) the prime rate publicly announced by Bank of America, (2) the Federal Funds Rate, as defined in the 2019 Corporate Credit Agreement, plus 0.50%, (3) the one-month Eurodollar Rate plus 1.00%, and (4) 0.00%, plus (ii) a margin ranging from 0.85% to 1.80% based on our Consolidated Leverage Ratio.

As of December 31, 2021, borrowings outstanding under the 2019 Credit Facility totaled $480,000,000 and the weighted average interest rate on such borrowings outstanding was 2.60% per annum. The 2019 Corporate Credit Agreement was due to mature on January 25, 2022. On January 19, 2022, we, through our operating partnership, entered into an agreement that amended and restated the 2019 Corporate Credit Agreement in its entirety, or the 2022 Credit Agreement. See below for a further discussion.Loan

2022 Credit Facility

On January 19, 2022, we, through our operating partnership, as borrower, and certain of our subsidiaries, or the subsidiary guarantors, collectively as guarantors, entered into an agreement, or the 2022 Credit Agreement, ~~that amended, restated, superseded~~to amend and ~~replaced~~restate the ~~2019 Corporate~~credit agreement for our existing credit facility with Bank of America, N.A., or Bank of America, KeyBank National Association, Citizens Bank, National Association, and the lenders named therein. The 2022 Credit Agreement ~~and the 2018 Credit Agreement~~provides for a credit facility with an aggregate maximum principal amount up to $1,050,000,000~~$1,050,000,000,~~, or the 2022 Credit ~~Facility. The 2022 Credit~~ Facility, which consists of a senior unsecured revolving credit facility in the initial aggregate amount of $500,000,000 and a senior unsecured term loan facility in the initial aggregate amount of $550,000,000. The proceeds of loans made under the 2022 Credit Facility may be used for refinancing existing indebtedness and for general corporate purposes including for working capital, capital expenditures and other corporate purposes not inconsistent with obligations under the 2022 Credit Agreement. We may also obtain up to $25,000,000 in the form of standby letters of credit pursuant to the 2022 Credit Facility. Unless defined herein, all capitalized terms under this “2022 Credit Facility” subsection are defined in the 2022 Credit Agreement.

Under the terms of the 2022 Credit Agreement, the revolving loans mature on January 19, 2026, and may be extended for 1one 12-month period, subject to the satisfaction of certain conditions, including payment of an extension fee. The term loan matures on January 19, 2027, and may not be extended. The maximum principal amount of the 2022 Credit Facility may be

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

increased by an aggregate incremental amount of $700,000,000, subject to: (i) the terms of the 2022 Credit Agreement; and (ii) at least five business days’ prior written notice to Bank of America.

The 2022 Credit Facility bears interest at varying rates based upon, at our option, (i) ~~the Daily Simple Secured Overnight Financing Rate, or~~ Daily SOFR, plus the Applicable Rate for Daily SOFR Rate Loans or (ii) ~~the Term Secured Overnight Financing Rate, or~~ the Term SOFR, plus the Applicable Rate for Term SOFR Rate Loans. If, under the terms of the 2022 Credit Agreement, there is an inability to determine the Daily SOFR or the Term SOFR then the 2022 Credit Facility will bear interest at a rate per annum equal to the Base Rate plus the Applicable Rate for Base Rate Loans. The loans may be repaid in whole or in part without prepayment premium or penalty, subject to certain conditions.

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

The 2022 Credit Agreement requires us to add additional subsidiaries as guarantors in the event the value of the assets owned by the subsidiary guarantors falls below a certain threshold as set forth in the 2022 Credit Agreement. In the event of default, Bank of America has the right to terminate the commitment of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions under the 2022 Credit Agreement, and to accelerate the payment on any unpaid principal amount of all outstanding loans and interest thereon. On March 1, 2023, we entered into an amendment to the 2022 Credit Agreement, or the First Amendment. The material terms of the First Amendment provided for revisions to certain financial covenants for a limited period of time. Except as modified by the terms of the First Amendment, the material terms of the 2022 Credit Agreement remain in full force and effect.

As of ~~June 30,~~both March 31, 2023 and December 31, 2022, our aggregate borrowing capacity under the 2022 Credit Facility was $1,050,000,000, excluding the $25,000,000 in standby letters of credit described above. As of ~~June 30,~~March 31, 2023 and December 31, 2022, borrowings outstanding under the 2022 Credit Facility totaled ~~$962,900,000~~$977,900,000 ($~~961,957,000,~~976,988,000, net of deferred financing costs related to the senior unsecured term loan facility portion of the 2022 Credit Facility) and $965,900,000 ($965,060,000, net of deferred financing costs related to the senior unsecured term loan facility portion of the 2022 Credit Facility), respectively, and the weighted average interest rate on such borrowings outstanding was ~~3.22%~~6.57% and 6.07% per ~~annum.~~annum, respectively.

In January 2022, in connection with the 2022 Credit Agreement, we incurred an aggregate $3,161,000 loss on the extinguishment of a portion of senior unsecured term ~~loans which formed part of the 2018 Credit Facility and the 2019 Credit Facility.~~loan related to former credit facilities. Such loss on extinguishment of debt is recorded as an increase to interest expense in our accompanying condensed consolidated statements of operations and comprehensive loss, and primarily consisted of lender fees we paid to obtain the 2022 Credit Facility.

2019 Trilogy Credit Facility

~~On October 1, 2021, upon consummation of the Merger,~~We, through Trilogy RER, LLC, ~~we became subject~~are party to an amended and restated loan agreement, or the 2019 Trilogy Credit Agreement, among certain subsidiaries of Trilogy OpCo, LLC, Trilogy RER, LLC, and Trilogy Pro Services, LLC; KeyBank; CIT Bank, N.A.; Regions Bank; KeyBanc Capital Markets, Inc.; Regions Capital Markets; Bank of America; The Huntington National Bank; and a syndicate of other banks, as lenders named therein, with respect to a senior secured revolving credit facility ~~with~~that had an aggregate maximum principal amount of $360,000,000, consisting of: (i) a $325,000,000 secured revolver supported by real estate assets and ancillary business cash flow and (ii) a $35,000,000 accounts receivable revolving credit facility supported by eligible accounts receivable, or the 2019 Trilogy Credit Facility. The proceeds of the 2019 Trilogy Credit Facility may be used for acquisitions, debt repayment and general corporate purposes. The maximum principal amount of the 2019 Trilogy Credit Facility ~~may be~~could have been increased by up to $140,000,000, for a total principal amount of $500,000,000, subject to certain conditions.

On December 20, 2022, we entered into an amendment to the 2019 Trilogy Credit Agreement, or the 2019 Trilogy Credit Amendment. The material terms of the 2019 Trilogy Credit Amendment provided for an increase to the secured revolver amount from $325,000,000 to $365,000,000, thereby increasing our aggregate maximum principal amount under the credit facility from $360,000,000 to $400,000,000. In addition, all references to the London Inter-bank Offered Rate, or LIBOR, were replaced with the Secured Overnight Financing Rate, or SOFR. On March 30, 2023, we further amended the 2019 Trilogy Credit Agreement to update the definition of Implied Debt Service, which is used to calculate the Real Estate Borrowing Base Availability, for interest rate changes and to add an annual interest-only payment calculation option. Except as modified by the terms of the amendments, the material terms of the 2019 Trilogy Credit Agreement remain in full force and effect. Unless defined herein, all capitalized terms under this “2019 Trilogy Credit Facility” subsection are defined in the 2019 Trilogy Credit Amendment.

The 2019 Trilogy Credit Facility matures on September 5, 2023 and may be extended for 1one 12-month period during the term of the 2019 Trilogy Credit ~~Agreement,~~Amendment, subject to the satisfaction of certain conditions, including payment of an extension fee.

At our option, the 2019 Trilogy Credit Facility bears interest at per annum rates equal to (a) ~~the London Inter-bank Offered Rate, or LIBOR,~~SOFR, plus 2.75%

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

for ~~LIBOR~~SOFR Rate Loans, as defined in the 2019 Trilogy Credit ~~Agreement,~~Amendment, and (b) for Base Rate Loans, as defined in the 2019 Trilogy Credit ~~Agreement,~~Amendment, 1.75% plus the ~~greater~~highest of: (i) the fluctuating ~~annual~~ rate per annum of interest ~~announced~~in effect for such day as established from time to time by KeyBank as its prime rate, (ii) 0.50% above the Federal Funds Effective Rate, as defined in the 2019 Trilogy Credit ~~Agreement,~~Amendment, and (iii) 1.00% above ~~the~~ one-month ~~LIBOR.~~Adjusted Term SOFR.

As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, our aggregate borrowing capacity under the 2019 Trilogy Credit Facility was ~~$360,000,000.~~$400,000,000. As of ~~both June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, borrowings outstanding under the 2019 Trilogy Credit Facility totaled ~~$304,734,000,~~$336,234,000 and $316,734,000, respectively, and the weighted average interest rate on such borrowings outstanding was ~~4.39%~~7.61% and ~~2.85%~~7.17% per annum, respectively.

~~10.~~9. Derivative Financial ~~Instruments~~Instrument

We ~~have used~~use a derivative financial ~~instruments~~instrument to manage interest rate risk associated with our variable-rate ~~debt. We recorded~~term loan pursuant to our 2022 Credit Facility and we record such derivative financial ~~instruments~~instrument in our accompanying condensed consolidated balance sheets as either an asset or a liability measured at fair value. We did not have any derivative financial instruments as of ~~June 30,~~December 31, 2022. The following table lists the derivative financial ~~instruments~~instrument held by us as of ~~December~~March 31, ~~2021,~~2023, which ~~were~~was included in security deposits, prepaid rent and other liabilities in our accompanying condensed consolidated balance ~~sheets:~~sheet:

Instrument Notional Amount Index Interest Rate Maturity Date Fair Value
December 31, 2021
Swap $ 250,000,000 one month LIBOR 2.10% 01/25/22 $ 332,000
Swap $ 130,000,000 one month LIBOR 1.98% 01/25/22 162,000
Swap $ 100,000,000 one month LIBOR 0.20% 01/25/22 6,000
$ 500,000

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

Instrument

Notional Amount

Index

Interest Rate

Maturity Date

Fair Value
March 31, 2023

Swap

275,000,000

one month
Term SOFR

3.74%

01/19/26

(195,000)

As of ~~December~~March 31, ~~2021, none of~~2023, our derivative financial ~~instruments were designated as hedges. Derivative financial instruments~~instrument was not designated as ~~hedges are~~a hedge. The derivative financial instrument not designated as a hedge is not speculative and ~~are~~is used to manage our exposure to interest rate movements, but dodoes not meet the strict hedge accounting requirements. ~~On January 25, 2022, our interest rate swap contracts matured.~~ For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recorded $0$195,000 and ~~$1,775,000, respectively, and for the six months ended June 30, 2022 and 2021, we recorded $500,000 and $3,596,000,~~($500,000), respectively, as ~~a decrease~~an increase (decrease) to interest expense in our accompanying condensed consolidated statements of operations and comprehensive loss related to the change in the fair value of our derivative financial ~~instruments.~~instrument.

See Note ~~16,~~14, Fair Value Measurements, for a further discussion of the fair value of our derivative financial instruments.

~~11.~~10. Identified Intangible Liabilities, Net

As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, identified intangible liabilities, net consisted of below-market leases of ~~$11,663,000~~$10,429,000 and ~~$12,715,000,~~$10,837,000, respectively, net of accumulated amortization of ~~$1,699,000~~$2,898,000 and ~~$1,047,000,~~$2,508,000, respectively. Amortization expense on below-market leases for the three months ended ~~June 30,~~March 31, 2023 and 2022 was $408,000 and ~~2021 was $414,000 and $45,000, respectively, and for the six months ended June 30, 2022 and 2021 was $1,023,000 and $92,000,~~$609,000, respectively, which is recorded as an increase to real estate revenue in our accompanying condensed consolidated statements of operations and comprehensive loss.

The weighted average remaining life of below-market leases was ~~8.8~~8.2 years and ~~9.1~~8.4 years as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. As of ~~June 30, 2022,~~March 31, 2023, estimated amortization expense on below-market leases for the ~~six~~nine months ending December 31, ~~2022~~2023 and for each of the next four years ending December 31 and thereafter was as follows:


Year	Year	Amount		Year	Amount
2022		$	825,000
2023	2023	1,596,000		2023	$	1,188,000
2024	2024	1,475,000		2024	1,475,000
2025	2025	1,347,000		2025	1,347,000
2026	2026	1,198,000		2026	1,198,000
2027				2027	1,162,000
Thereafter	Thereafter	5,222,000		Thereafter	4,059,000
		$	11,663,000
Total				Total	$	10,429,000

~~12.~~

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

11. Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow a policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business, which include calls/puts to sell/acquire properties. In our view, these matters are not expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows.

~~13.~~12. Redeemable Noncontrolling Interests

As ~~a result~~ of ~~the Merger and the AHI Acquisition, as of June 30, 2022~~both March 31, 2023 and December 31, ~~2021,~~2022, we, through our direct and indirect subsidiaries, ~~own an approximately~~owned a 95.0% ~~and 94.9%~~ general partnership interest ~~respectively,~~ in our operating

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

partnership and the remaining ~~approximate~~ 5.0% ~~and 5.1%~~ limited partnership interest ~~respectively,~~ in our operating partnership iswas owned by the NewCo Sellers. Some of the limited partnership units outstanding, which account for approximately 1.0% of our total operating partnership units outstanding, have redemption features outside of our control and are accounted for as redeemable noncontrolling interests presented outside of permanent equity in our accompanying condensed consolidated balance sheets.

As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we, through Trilogy REIT Holdings LLC, or Trilogy REIT Holdings, in which we indirectly hold a 76.0% ownership interest, owned ~~95.9%~~97.4% and 96.2%, respectively, of the outstanding equity interests of Trilogy. As of ~~both June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, certain members of Trilogy’s management and certain members of an advisory committee to Trilogy’s board of directors owned approximately ~~4.1%~~2.6% and 3.8%, respectively, of the outstanding equity interests of Trilogy. The noncontrolling interests held by such members have redemption features outside of our control and are accounted for as redeemable noncontrolling interests in our accompanying condensed consolidated balance sheets. For the three months ended March 31, 2023, we redeemed a portion of the equity interests owned by current members of Trilogy’s management for an aggregate of $15,870,000. For the three months ended March 31, 2022, we did not redeem any equity interests of Trilogy.

As ~~a result~~ of ~~the Merger~~March 31, 2023 and December 31, 2022, we own, through our operating partnership, ~~as of June 30, 2022 and December 31, 2021, we own~~ approximately 98.0% of the joint ventures with an affiliate of Meridian Senior Living, LLC, or Meridian, that own Central Florida Senior Housing Portfolio, Pinnacle Beaumont ALF and Pinnacle Warrenton ALF. Also as a result of the Merger, as of June 30, 2022 and December 31, 2021, we also own approximately 90.0% of the joint venture with Avalon Health Care, Inc., or Avalon, that owns Catalina West Haven ALF and Catalina Madera ALF. The noncontrolling interests held by Meridian ~~and Avalon~~ have redemption features outside of our control and are accounted for as redeemable noncontrolling interests in our accompanying condensed consolidated balance sheets. ~~Both~~See Note 3, Real Estate Investments, Net and Business Combinations — Disposition of Real Estate Investment, for a disposition within our Central Florida Senior Housing Portfolio.

We previously owned 90.0% of the joint venture with Avalon Health Care, Inc., or Avalon, that owned Catalina West Haven ALF and Catalina Madera ALF. The noncontrolling interests held by Avalon had redemption features outside of our control and were accounted for as redeemable noncontrolling interests until December 1, 2022, when we exercised our right to purchase the remaining 10.0% of the joint ~~ventures with an affiliate of Meridian and~~venture with Avalon ~~described above were acquired on October 1, 2021, upon consummation~~for a contract purchase price of $295,000. As such, 10.0% of the ~~Merger.~~net earnings of such joint venture were allocated to redeemable noncontrolling interests in our accompanying consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

We record the carrying amount of redeemable noncontrolling interests at the greater of: (i) the initial carrying amount, increased or decreased for the noncontrolling interests’ share of net income or loss and distributions or (ii) the redemption value. The changes in the carrying amount of redeemable noncontrolling interests consisted of the following for the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 and ~~2021:~~2022:


		Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021			2023		2022
Beginning balance	Beginning balance	$	72,725,000	$	40,340,000	Beginning balance	$	81,598,000	$	72,725,000
Additional redeemable noncontrolling interest	Additional redeemable noncontrolling interest	173,000		—		Additional redeemable noncontrolling interest	—		173,000
Reclassification from equity	Reclassification from equity	42,000		—		Reclassification from equity	21,000		21,000
Distributions	Distributions	(1,405,000)		(551,000)		Distributions	(454,000)		(695,000)

Repurchase of redeemable noncontrolling interests						Repurchase of redeemable noncontrolling interests	(15,870,000)		—
Adjustment to redemption value	Adjustment to redemption value	3,833,000		899,000		Adjustment to redemption value	(5,043,000)		2,856,000
Net loss attributable to redeemable noncontrolling interests		(31,000)		(514,000)
Net (loss) income attributable to redeemable noncontrolling interests						Net (loss) income attributable to redeemable noncontrolling interests	(368,000)		187,000
Ending balance	Ending balance	$	75,337,000	$	40,174,000	Ending balance	$	59,884,000	$	75,267,000

~~14.~~13. Equity

Preferred Stock

Pursuant to our charter, we are authorized to issue 200,000,000 shares of our preferred stock, par value $0.01 per share. As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, no shares of preferred stock were issued and outstanding.

Common Stock

On March 12, 2015, we terminated the primary portion of our initial public offering. We continued to offer shares of our common stock in the GAHR III initial offering pursuant to the Initial DRIP, until the termination of the distribution reinvestment plan portion of the GAHR III initial offering and deregistration of the GAHR III initial offering on April 22, 2015. On March 25, 2015, we filed a Registration Statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, to register a maximum of $250,000,000 of additional shares of our common stock pursuant to the Initial DRIP through a subsequent offering, or the 2015 GAHR III DRIP Offering, and we commenced offering shares following the deregistration of the GAHR III initial offering until the termination and deregistration of the 2015 GAHR III DRIP Offering on March 29, 2019. Effective October 5, 2016, we amended and restated the Initial DRIP, or the GAHR III Amended and Restated DRIP, to amend the price at which shares of our common stock were issued pursuant to the 2015 GAHR III DRIP Offering.

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

On January 30, 2019, we filed a Registration Statement on Form S-3 under the Securities Act to register a maximum of $200,000,000 of additional shares of our common stock to be issued pursuant to the GAHR III Amended and Restated DRIP, or the 2019 GAHR III DRIP Offering, which we commenced offering on April 1, 2019, following the deregistration of the 2015 GAHR III DRIP Offering. On May 29, 2020, our board authorized the suspension of the 2019 GAHR III DRIP Offering, and consequently, ceased issuing shares pursuant to such offering following the distributions paid in June 2020 to stockholders of record on or prior to the close of business on May 31, 2020. As a result of the Merger, we deregistered the 2019 GAHR III DRIP Offering on October 4, 2021. Further, on October 4, 2021, our board authorized the reinstatement of our distribution reinvestment plan, as amended, or the AHR DRIP. We continue to offer up to $100,000,000 of shares of our common stock to be issued pursuant to the AHR DRIP under an existing Registration Statement on Form S-3 under the Securities Act filed by GAHR IV, or the AHR DRIP Offering. We collectively refer to the Initial DRIP portion of the GAHR III initial offering, the 2015 GAHR III DRIP Offering, the 2019 GAHR III DRIP Offering and the AHR DRIP Offering as our DRIP Offerings. See Note 1, Organization and Description of Business — Public Offering and the “Distribution Reinvestment Plan” section below for a further discussion.

At the effective time of the REIT Merger, on October 1, 2021, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, was converted into the right to receive 0.9266 shares of GAHR IV’s Class I common stock, $0.01 par value per share, resulting in the issuance of 179,637,776 shares of Class I common stock to GAHR III’s stockholders. Also, on October 1, 2021, we filed the Fourth Articles of Amendment and RestatementPursuant to our charter, ~~or the Charter Amendment, which among other things,~~as amended, ~~the common stock~~ we are authorized ~~to issue. The Charter Amendment authorized us~~ to issue 1,000,000,000 shares of our common stock, par value $0.01 per share, whereby 200,000,000 shares are classified as Class T common stock and 800,000,000 shares are classified as Class I common stock.

~~Distribution Reinvestment Plan~~

~~Following~~ As of March 31, 2023, after taking into consideration the ~~deregistration~~Merger and the impact of the ~~Initial~~reverse stock split as discussed below, we had issued 65,445,557 shares for a total of $2,737,716,000 of common stock since February 26, 2014 in our initial public offerings and DRIP ~~on April 22, 2015,~~offerings (includes historical offering amounts sold by GAHR III and GAHR IV prior to the Merger). See “Distribution Reinvestment Plan” section below for a further discussion.

On November 15, 2022 we ~~continued to offer~~effected a one-for-four reverse split of our common stock and a corresponding reverse split of the partnership units in our operating partnership. As a result of the Reverse Splits, every four shares of our common stock, ~~pursuant~~or four partnership units in our operating partnership, were automatically combined and converted into one issued and outstanding share of our common stock of like class, or one partnership unit of like class, as applicable, rounded to the ~~2015 GAHR III~~nearest 1/100th share or unit. The Reverse Splits impacted all classes of common stock and partnership units proportionately and had no impact on any stockholder’s or partner’s ownership percentage. Neither the number of authorized shares nor the par value of the Class T common stock and Class I common stock were ultimately impacted. All numbers of common shares and per share data, as well as partnership units in our operating partnership, in our accompanying condensed consolidated financial statements and related notes have been retroactively adjusted for all periods presented to give effect to the Reverse Splits.

Distribution Reinvestment Plan

Our DRIP ~~Offering and 2019 GAHR III DRIP Offering which resulted in a total of $308,501,000 in~~allowed our stockholders to elect to reinvest an amount equal to the distributions ~~being reinvested that resulted in 33,110,893~~declared on their shares of common stock ~~being issued.~~

in additional shares of our common stock in lieu of receiving cash distributions. However, in connection with the Proposed Listing, on November 14, 2022, our board suspended the DRIP offering beginning with the distributions declared, if any, for the quarter ended December 31, 2022. As a result of the ~~Merger, we deregistered~~suspension of the ~~2019 GAHR III~~ DRIP, ~~Offering on October 4, 2021. Further, on October 4, 2021,~~unless and until our board ~~reinstated distributions and authorized~~reinstates the ~~reinstatement of the AHR~~ DRIP Offering. We continue to offer up to $100,000,000 of shares of our common stock to be issued pursuant to the AHR DRIP under the AHR DRIP Offering. As a result, beginning with the October 2021 distribution, which was paid in November 2021,offering, stockholders who ~~previously enrolled as~~are current participants in the ~~AHR~~ DRIP ~~received~~were or will ~~receive~~be paid distributions in shares of our common stock pursuant to the terms of the AHR DRIP, instead of cash distributions. As of June 30, 2022, a total of $77,083,000 in distributions were reinvested that resulted in 8,180,513 shares of common stock being issued pursuant to the AHR DRIP Offering.cash.

~~Since October 5, 2016, our~~Our board ~~had approved and established~~has been establishing an estimated per share net asset value, or NAV, annually. ~~Commencing with the distribution payment to stockholders paid in the month following such board approval, shares~~Shares of our common stock issued pursuant to our ~~distribution reinvestment plan~~DRIP are issued at the current estimated per share NAV until such time as our board determined an updated estimated per share NAV.

~~The following is a summary of the historical estimated per share NAV for GAHR III and the Combined Company, as applicable:~~


~~Approval Date by our Board~~	Estimated Per Share NAV (Unaudited)



~~10/03/19~~	$	~~9.40~~
~~03/18/21~~	$	~~8.55~~
~~03/24/22~~	$	~~9.29~~

For the three and six months ended June 30, 2022, $11,143,000 and $22,447,000, respectively, in distributions were reinvested and 1,199,427 and 2,425,500 shares of our common stock, respectively, were issued pursuant to our DRIP Offerings. For both the three and six months ended June 30, 2021, there were no distributions reinvested pursuant to our DRIP Offerings.

2722

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The following is a summary of the historical estimated per share NAV:


Approval Date by our Board	Estimated Per Share NAV



03/24/22	$	37.16
03/15/23	$	31.40

For the three months ended March 31, 2023 and 2022, $0 and $11,304,000, respectively, in distributions were reinvested and 0 and 306,518 shares of our common stock, respectively, were issued pursuant to our DRIP offerings.

Share Repurchase Plan

Our share repurchase plan ~~allows~~allowed for repurchases of shares of our common stock by us when certain criteria ~~are~~were met. Share repurchases ~~are~~were made at the sole discretion of our board. Subject to the availability of the funds for share repurchases and other certain conditions, we generally limit the number of shares of our common stock repurchased during any calendar year to 5.0% of the weighted average number of shares of our common stock outstanding during the prior calendar year; provided however, that shares subject to a repurchase requested upon the death or “qualifying disability,” as defined in our share repurchase plan, of a stockholder are not subject to this cap. Funds for the repurchase of shares of our common stock come from the cumulative proceeds we receive from the sale of shares of our common stock pursuant to our DRIP Offerings.

Pursuant to our share repurchase plan, the repurchase price is equal to the lesser of (i) the amount per share that a stockholder paid for their shares of our common stock, or (ii) the most recent estimated value of one share of our common stock, as determined by our board, except that the repurchase price with respect to repurchases resulting from the death or qualifying disability of stockholders is equal to the most recently published estimated per share NAV. On October 4, 2021, as a result of the Merger, our board authorized the partial reinstatement of our share repurchase plan with respect to requests to repurchase shares resulting from the death or qualifying disability of stockholders, effective with respect to qualifying repurchases for the fiscal quarter ending December 31, 2021. All share repurchase requests other than those requests resulting from the death or qualifying disability of stockholders were rejected. On November 14, 2022, our board suspended our share repurchase plan beginning with share repurchase requests for the quarter ending December 31, 2022. All share repurchase requests, including requests resulting from the death or qualifying disability of stockholders, received commencing with the quarter ended December 31, 2022, will not be processed, will be considered canceled in full and ~~shall~~will not be ~~rejected.~~considered outstanding repurchase requests.

~~During~~Funds for the ~~three and six months ended June 30, 2022, we repurchased 699,460 and 1,147,835~~repurchase of shares of our common stock respectively, for an aggregate of $6,449,000 and $10,583,000, respectively, at a repurchase price of $9.22 per share. During the three and six months ended June 30, 2021, we did not repurchase any shares of common stock. In July 2022, we repurchased 608,138 shares of our common stock, for an aggregate of $5,650,000, at a repurchase price of $9.29 per share. All shares were repurchased usingcame from the cumulative proceeds we received from the sale of shares of our common stock pursuant to our DRIP ~~Offerings.~~offerings. Pursuant to our share repurchase plan, the repurchase price with respect to repurchases resulting from the death or qualifying disability of stockholders was equal to the most recently published estimated per share NAV.

For the three months ended March 31, 2023 and 2022, we repurchased 1,681 and 112,094 shares of common stock, respectively, for an aggregate of $62,000 and $4,134,000, respectively, at a repurchase price of $37.16 and $36.88 per share, respectively, pursuant to our share repurchase plan. Such repurchase requests were submitted prior to the suspension of our share repurchase plan.

Noncontrolling Interests in Total Equity

As of ~~both June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, Trilogy REIT Holdings owned approximately ~~95.9%~~97.4% and 96.2%, respectively, of Trilogy. ~~Prior to October 1, 2021, we were~~We are the indirect owner of a ~~70.0%~~76.0% interest inof Trilogy REIT Holdings pursuant to an amended joint venture agreement with an indirect, wholly owned subsidiary of NorthStar Healthcare Income, Inc., or ~~NHI, and a wholly owned subsidiary of GAHR IV Operating Partnership.~~NHI. We serve as the managing member of Trilogy REIT Holdings. As ~~part~~ of ~~the Merger on October 1, 2021, the wholly~~both March 31, 2023 and December 31, 2022, NHI indirectly owned ~~subsidiary of GAHR IV Operating Partnership sold its 6.0%~~a 24.0% membership interest in Trilogy REIT Holdings ~~to GAHR III, thereby increasing our indirect ownership in Trilogy REIT Holdings to 76.0%. Through September 30, 2021, 30.0%~~and as such, for the three months ended March 31, 2023 and 2022, 24.0% of the net earnings of Trilogy REIT Holdings were allocated to noncontrolling ~~interests, and since October 1, 2021, 24.0% of the net earnings of Trilogy REIT Holdings were allocated to a noncontrolling interest.~~interests.

In connection with our ~~acquisition and~~ operation of Trilogy, time-based profit interest units in Trilogy, or the Profit Interests, were issued to Trilogy Management Services, LLC and antwo independent ~~director~~directors of Trilogy, both unaffiliated third parties that manage or direct the day-to-day operations of Trilogy. The Profit Interests ~~consisted of time-based or performance-based commitments. The time-based Profit Interests were~~are measured at their grant date fair value and vest in increments of 20.0% on each anniversary of the respective grant date over a five year period. We ~~amortized~~amortize the ~~time-based~~ Profit Interests on a straight-line basis over the vesting periods, which are recorded to general and administrative in our accompanying condensed consolidated statements of operations and comprehensive loss. The ~~performance-based~~nonvested Profit Interests were subject to a performance commitment and would have vested upon liquidity events as defined in the Profit Interests agreements. The performance-based Profit Interests were measured at their fair value on the adoption date of ASU 2018-07, ~~Improvements to Nonemployee Share-Based Payment Accounting, using a modified retrospective approach. The nonvested awards were~~are presented as noncontrolling interests in total equity in our accompanying condensed consolidated balance sheets, and ~~were~~are re-classified to redeemable noncontrolling interests upon vesting as they had redemption features outside of our control, similar to the common stock units held by Trilogy’s management. See Note ~~13,~~12, Redeemable Noncontrolling Interests, for a further discussion.

In December 2021, we redeemed a part of the time-based Profit Interests, and all of the performance-based Profit Interests that were included in noncontrolling interests in total equity. We redeemed such Profit Interests in cash and through the issuance of additional equity interests in Trilogy that are classified as redeemable noncontrolling interests in our accompanying condensed consolidated balance sheets. There were no canceled, expired or exercised Profit Interests during the three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 and ~~2021.~~2022. For ~~the~~both three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recognized stock compensation expense related to the time-based Profit Interests of ~~$21,000 and $0, respectively, and for the six months ended June 30, 2022 and 2021, we recognized stock compensation expense related to the Profit Interests of $42,000 and $(14,000), respectively.~~

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

$21,000.

One of our consolidated subsidiaries issued non-voting preferred shares of beneficial interests to qualified investors for total proceeds of $125,000. These preferred shares of beneficial interests are entitled to receive cumulative preferential cash dividends at the rate of 12.5% per annum. We classify the value of ~~the~~our subsidiary’s preferred shares of beneficial interests as noncontrolling interests in our accompanying condensed consolidated balance sheets and the dividends of the preferred shares

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

of beneficial interests in net income or loss attributable to noncontrolling interests in our accompanying condensed consolidated statements of operations and comprehensive loss.

As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we owned an 86.0% interest in a consolidated limited liability company that owns Lakeview IN Medical Plaza. As such, 14.0% of the net earnings of Lakeview IN Medical Plaza were allocated to noncontrolling interests in our accompanying condensed consolidated statements of operations and comprehensive loss for the three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 and ~~2021.~~2022.

As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we owned a 90.6% membership interest in a consolidated limited liability company that owns Southlake TX Hospital. As such, 9.4% of the net earnings of Southlake TX Hospital were allocated to noncontrolling interests in our accompanying condensed consolidated statements of operations and comprehensive loss for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022.

As of both March 31, 2023 and December 31, 2022, ~~and 2021.~~

~~On October 1, 2021, upon consummation of the Merger, through our operating partnership,~~ we ~~acquired an approximate~~owned a 90.0% interest in a joint venture that owns the Louisiana Senior Housing Portfolio. As such, 10.0% of the net earnings of the joint venture were allocated to noncontrolling interests in our accompanying condensed consolidated statements of operations and comprehensive loss ~~during~~for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022.

As discussed in Note 1, Organization and Description of Business, as ~~a result~~ of ~~the Merger and the AHI Acquisition, as of June 30, 2022~~both March 31, 2023 and December 31, ~~2021,~~2022, we, through our direct and indirect subsidiaries, own ~~an approximately~~a 95.0% ~~and 94.9%~~ general partnership interest ~~respectively,~~ in our operating partnership and the remaining ~~approximately~~ 5.0% ~~and 5.1%~~ limited partnership interest ~~respectively,~~ in our operating partnership is owned by the NewCo Sellers. As of ~~June 30, 2022~~both March 31, 2023 and December 31, ~~2021, approximately~~2022, 4.0% ~~and 4.1%~~ of our total operating partnership units outstanding ~~respectively,~~ is presented in total equity in our accompanying condensed consolidated balance sheets. See Note ~~13,~~12, Redeemable Noncontrolling Interests, for a further discussion.

AHR 2015 Incentive Plan

~~Upon consummation of~~Pursuant to the ~~Merger, we adopted the~~Amended and Restated 2015 Incentive Plan, ~~as amended and restated,~~ or ~~our incentive plan, pursuant to~~the AHR Incentive Plan, which our board (with respect to options and restricted shares of common stock granted to independent directors), or our compensation committee (with respect to any other award), may make grants of options, restricted shares of common stock, stock purchase rights, stock appreciation rights or other awards to our independent directors, officers, employees and consultants. The maximum number of shares of our common stock that may be issued pursuant to ~~our incentive~~the AHR Incentive plan is ~~4,000,000~~1,000,000 shares.

~~Through June 30, 2022,~~Restricted common stock

Pursuant to the AHR Incentive Plan, through March 31, 2023, we granted an aggregate of ~~1,137,355~~291,259 shares of our restricted common stock, ~~under our incentive plan. Such amount includes: (i) 215,214 shares of our~~or RSAs, which include restricted Class T common stock ~~at a weighted average grant date fair value of $9.53 per share,~~and restricted Class I common stock. RSAs were granted to our independent ~~directors; (ii) 477,901 time-based shares~~directors in connection with their initial election or re-election to our board or in consideration of ~~our~~their past services rendered. In addition, certain executive officers and key employees received grants of restricted Class T common stock, atas defined in the AHR Incentive Plan. RSAs generally have a ~~grant date fair value of $9.22 per share,~~vesting period ranging from one to ~~certain~~four years and are subject to continuous service through the vesting dates.

Restricted stock units

Pursuant to the AHR Incentive Plan, through March 31, 2023, we granted to our executive officers and ~~key employees; (iii) 319,149 shares~~certain employees an aggregate 29,352 of our restricted Class T common stock, at a grant date fair value of $9.22 per share, to certain of our key employees; and (iv) 125,091 shares of our restricted Class I common stock issued upon the conversion of restricted common stock that GAHR III granted prior to the Merger. Also, through June 30, 2022, we granted 113,205 performance-based restricted stock units, ~~pursuant to our incentive plan to certain executive officers~~or PBUs, representing the right to receive shares of our Class T common stock upon vesting, at a grant date fair value of $9.29 per unit, net of 46,096 performance-based restricted stock units that were forfeited during the six months ended June 30, 2022. Further, for the six months ended June 30, 2022, wevesting. We also granted ~~76,800~~to certain employees 19,200 time-based restricted stock units, ~~under our incentive plan, at a grant date fair value of $9.29 per share, to certain employees~~or TBUs, representing the right to receive shares of our Class T common stock upon vesting. PBUs and TBUs are collectively referred to as RSUs. RSUs granted to executive officers and employees generally have a vesting period of up to three years and are subject to continuous service through the vesting dates, and any performance conditions, as applicable.

For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recognized stock ~~based~~ compensation expense related to awards granted pursuant to ~~our incentive plan~~the AHR Incentive Plan of ~~$980,000~~$1,051,000 and ~~$26,000, respectively. For~~$811,000, respectively, based on the ~~six months ended June 30, 2022~~grant date fair value for time based awards and ~~2021, we recognized~~for performance based awards that are probable of vesting, which are equal to the most recently published estimated per share NAV. Such stock ~~based~~ compensation expense ~~related to awards granted pursuant to our incentive plan of $1,791,000 and $53,000, respectively. Such stock based compensation expense was~~is included in general and ~~administrative~~administration in our accompanying condensed consolidated statements of operations and comprehensive loss.

2924

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

~~15. Related Party Transactions~~

~~Fees and Expenses Paid to Affiliates~~

Prior to the closing of the AHI Acquisition on October 1, 2021, our former advisor used its best efforts, subject to the oversight and review of our board, to, among other things, provide asset management, property management, acquisition, disposition and other advisory services on our behalf consistent with our investment policies and objectives. Our former advisor performed its duties and responsibilities under the Advisory Agreement as our fiduciary. Until September 30, 2021, all of our executive officers were officers of our former advisor and officers, limited partners and/or members of one of our former co-sponsors and other affiliates of our former advisor.

On December 20, 2021, the Advisory Agreement was assigned to NewCo and as a result, any fees that would have otherwise been payable to our former advisor are now eliminated in consolidation. Following the consummation of the Merger, we became self-managed and as a result, we no longer incur to our former advisor and its affiliates any fees or expense reimbursements arising from the Advisory Agreement.

~~Fees and expenses incurred to our former advisor or its affiliates for the three and six months ended June 30, 2021 were as follows:~~

Three Months Ended
June 30, 2021 Six Months Ended
June 30, 2021
Asset management fees(1) $ 5,401,000 $ 10,763,000
Property management fees(2) 681,000 1,335,000
Development fees(3) 357,000 640,000
Lease fees(4) 120,000 385,000
Construction management fees(5) 68,000 80,000
Operating expenses(6) 53,000 116,000
Acquisition fees(7) 10,000 1,344,000
$ 6,690,000 $ 14,663,000
~~___________~~

~~(1)Asset management fees were included in general and administrative in our accompanying condensed consolidated statements of operations and comprehensive loss.~~

~~(2)~~Property management fees were included in rental expenses or general and administrative expenses in our accompanying condensed consolidated statements of operations and comprehensive loss, depending on the property type from which the fee was incurred.

~~(3)Development fees were capitalized as part of the associated investments in our accompanying condensed consolidated balance sheets.~~

~~(4)Lease fees were capitalized as costs of entering into new leases and included in other assets, net in our accompanying condensed consolidated balance sheets.~~

~~(5)Construction management fees were capitalized as part of the associated asset and included in real estate investments, net in our accompanying condensed consolidated balance sheets.~~

~~(6)~~We reimbursed our former advisor or its affiliates for operating expenses incurred in rendering services to us, subject to certain limitations. For the 12 months ended June 30, 2021, our operating expenses did not exceed such limitations. Operating expenses were generally included in general and administrative in our accompanying condensed consolidated statements of operations and comprehensive loss.

~~(7)~~Acquisition fees in connection with the acquisition of properties accounted for as asset acquisitions or the acquisition of real estate-related investments were capitalized as part of the associated investments in our accompanying condensed consolidated balance sheets.

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

~~Accounts Payable Due to Affiliates~~

~~We did not have any amounts outstanding to our affiliates as of June 30, 2022~~. ~~The following amounts were outstanding to our affiliates as of December 31, 2021:~~

~~Fee~~

~~December 31, 2021~~

~~Lease commissions~~

~~245,000~~

~~Development fees~~

~~229,000~~

~~Construction management fees~~

~~152,000~~

~~Operating expenses~~

~~100,000~~

~~Asset and property management fees~~

~~83,000~~

~~Acquisition fees~~

~~57,000~~

~~866,000~~

~~16.~~14. Fair Value Measurements

Assets and Liabilities Reported at Fair Value

The table below presents our assets and liabilities measured at fair value on a recurring basis as of ~~June 30, 2022,~~March 31, 2023, aggregated by the level in the fair value hierarchy within which those measurements fall:


		Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Liabilities:	Liabilities:									Liabilities:
Warrants		$	—	$	—	$	733,000	$	733,000
Derivative financial instrument										Derivative financial instrument	$	—	$	195,000	$	—	$	195,000

Total liabilities at fair value	Total liabilities at fair value	$	—	$	—	$	733,000	$	733,000	Total liabilities at fair value	$	—	$	195,000	$	—	$	195,000

~~The table below presents our~~There were no transfers into and out of fair value measurement levels during the three months ended March 31, 2023 and 2022. We did not have any assets and liabilities measured at fair value on a recurring basis as of December 31, ~~2021, aggregated by the level in the fair value hierarchy within which those measurements fall:~~

Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1) Significant Other
Observable Inputs
(Level 2) Significant
Unobservable
Inputs
(Level 3) Total
Liabilities:
Derivative financial instruments $ — $ 500,000 $ — $ 500,000
Warrants — — 786,000 786,000
Total liabilities at fair value $ — $ 500,000 $ 786,000 $ 1,286,000

~~There were no transfers into and out of fair value measurement levels during the six months ended June 30, 2022 and 2021.~~

~~Warrants~~

As of June 30, 2022 and December 31, 2021, we have recorded $733,000 and $786,000, respectively, related to warrants in Trilogy common units held by certain members of Trilogy’s management, which is included in security deposits, prepaid rent and other liabilities in our accompanying condensed consolidated balance sheets. Once exercised, these warrants have redemption features similar to the common units held by members of Trilogy’s management.~~See Note 13, Redeemable Noncontrolling Interests, for a further discussion. As of June 30, 2022 and December 31, 2021, the carrying value is a reasonable estimate of fair value.~~

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

2022.

Derivative Financial Instruments

We ~~used~~entered into an interest rate ~~swaps and interest rate caps~~swap to manage interest rate risk associated with variable-rate debt. We also previously used interest rate swaps or interest rate caps to manage such interest rate risk. The valuation of these instruments was determined using widely accepted valuation techniques including a discounted cash flow analysis on the expected cash flows of each derivative. ~~This analysis~~Such valuation reflected the contractual terms of the derivatives, including the period to maturity, and used observable market-based inputs, including interest rate curves, as well as option volatility. The fair ~~values~~value of our interest rate ~~swaps were~~swap was determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts were based on an expectation of future interest rates derived from observable market interest rate curves.

We incorporated credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value ~~measurements.~~measurement. In adjusting the fair value of our derivative ~~contracts~~contract for the effect of nonperformance risk, we considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.

Although we determined that the majority of the inputs used to value our derivative financial ~~instruments~~instrument fell within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with ~~these instruments~~this instrument utilized Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by us and our counterparty. However, as of ~~December~~March 31, ~~2021,~~2023, we assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative ~~positions~~position and determined that the credit valuation adjustments were not significant to the overall valuation of our ~~derivatives.~~derivative. As a result, we determined that our derivative ~~valuations~~valuation in ~~their~~its entirety ~~were~~was classified in Level 2 of the fair value hierarchy. AsOn January 25, 2022, our prior interest rate swap contracts matured and as of ~~June 30,~~December 31, 2022, we did not have any derivative financial instruments.

Financial Instruments Disclosed at Fair Value

Our accompanying condensed consolidated balance sheets include the following financial instruments: debt security investment, cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable and accrued liabilities, accounts payable due to affiliates, mortgage loans payable and borrowings under our lines of credit and term ~~loans.~~loan.

We consider the carrying values of cash and cash equivalents, restricted cash, accounts and other receivables and accounts payable and accrued liabilities to approximate the fair value for these financial instruments based upon an evaluation of the underlying characteristics, market data and because of the short period of time between origination of the instruments and their expected realization. ~~The fair value~~

Table of accounts payable due to affiliates is not determinable due to the related party nature of the accounts payable. The fair values of the other financial instruments are classified in Level 2 of the fair value hierarchy.Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The fair value of our debt security investment is estimated using a discounted cash flow analysis using interest rates available to us for investments with similar terms and maturities. The fair values of our mortgage loans payable and our lines of credit and term ~~loans~~loan are estimated using discounted cash flow analyses using borrowing rates available to us for debt instruments with similar terms and maturities. We have determined that the valuations of our debt security investment, mortgage loans payable and lines of credit and term ~~loans~~loan are classified in Level 2 within the fair value hierarchy. The carrying amounts and estimated fair values of such financial instruments as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 were as follows:


		June 30, 2022				December 31, 2021					March 31, 2023				December 31, 2022
		Carrying Amount(1)		Fair Value		Carrying Amount(1)		Fair Value			Carrying Amount(1)		Fair Value		Carrying Amount(1)		Fair Value
Financial Assets:	Financial Assets:									Financial Assets:

Debt security investment	Debt security investment	$	81,167,000	$	93,470,000	$	79,315,000	$	93,920,000	Debt security investment	$	83,955,000	$	93,248,000	$	83,000,000	$	93,230,000
Financial Liabilities:	Financial Liabilities:									Financial Liabilities:
Mortgage loans payable	Mortgage loans payable	$	1,134,059,000	$	1,020,652,000	$	1,095,594,000	$	1,075,729,000	Mortgage loans payable	$	1,233,745,000	$	1,097,904,000	$	1,229,847,000	$	1,091,667,000
Lines of credit and term loans		$	1,261,225,000	$	1,270,330,000	$	1,222,853,000	$	1,226,636,000
Lines of credit and term loan										Lines of credit and term loan	$	1,309,427,000	$	1,315,836,000	$	1,277,460,000	$	1,285,205,000

___________

(1)Carrying amount is net of any discount/premium and unamortized deferred financing costs.

~~17.~~15. Income Taxes

As a REIT, we generally will not be subject to U.S. federal income tax on taxable income that we distribute to our stockholders. We have elected to treat certain of our consolidated subsidiaries as taxable REIT subsidiaries, or TRS, pursuant to

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

the Code. TRS may participate in services that would otherwise be considered impermissible for REITs and are subject to federal and state income tax at regular corporate tax rates.

Current Income Tax

Federal and state income taxes are generally a function of the level of income recognized by our TRS. Foreign income taxes are generally a function of our income on our real estate located in the United Kingdom, or UK, and Isle of Man.

Deferred Taxes

Deferred income tax is generally a function of the period’s temporary differences (primarily basis differences between tax and financial reporting for real estate assets and equity investments) and generation of tax net operating loss that may be realized in future periods depending on sufficient taxable income.

We recognize the financial statement effects of an uncertain tax position when it is more likely than not, based on the technical merits of the tax position, that such a position will be sustained upon examination by the relevant tax authorities. If the tax benefit meets the “more likely than not” threshold, the measurement of the tax benefit will be based on our estimate of the ultimate tax benefit to be sustained if audited by the taxing authority. As of both ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we did not have any tax benefits or liabilities for uncertain tax positions that we believe should be recognized in our accompanying condensed consolidated financial statements.

We assess the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A valuation allowance is established if we believe it is more likely than not that all or a portion of the deferred tax assets are not realizable. As of ~~June 30, 2022~~both March 31, 2023 and December 31, ~~2021,~~2022, our valuation allowance fully reserves the net deferred tax assets due to historical losses and inherent uncertainty of future income. We will continue to monitor industry and economic conditions, and our ability to generate taxable income based on our business plan and available tax planning strategies, which would allow us to utilize the tax benefits of the net deferred tax assets and thereby allow us to reverse all, or a portion of, our valuation allowance in the future.

~~18.~~

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

16. Leases

Lessor

We have operating leases with tenants that expire at various dates through 2050. For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recognized ~~$50,060,000~~$42,303,000 and ~~$29,271,000,~~$50,731,000, respectively, of revenues related to operating lease payments, of which ~~$9,663,000~~$10,040,000 and $5,304,000, respectively, was for variable lease payments. For the six months ended June 30, 2022 and 2021, we recognized $100,790,000 and $57,938,000, respectively, of revenues related to operating lease payments, of which $20,076,000 and $9,654,000,$10,413,000, respectively, was for variable lease payments. As of ~~June 30, 2022,~~March 31, 2023, the following table sets forth the undiscounted cash flows for future minimum base rents due under operating leases for the ~~six~~nine months ending December 31, ~~2022~~2023 and for each of the next four years ending December 31 and thereafter for properties that we wholly own:


Year	Year	Amount		Year	Amount
2022		$	77,361,000
2023	2023	150,031,000		2023	$	115,063,000
2024	2024	139,441,000		2024	146,081,000
2025	2025	125,062,000		2025	132,908,000
2026	2026	114,401,000		2026	121,949,000
2027				2027	115,863,000
Thereafter	Thereafter	624,329,000		Thereafter	580,286,000
Total	Total	$	1,230,625,000	Total	$	1,212,150,000

Lessee

We lease certain land, buildings, furniture, fixtures, campus ~~equipment,~~and office equipment and ~~automobiles.~~automobiles . We have lease agreements with lease and non-lease components, which are generally accounted for separately. Most leases include one or more options to renew, with renewal terms that generally can extend at various dates through 2107, excluding extension options. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. As of June 30, 2022, we had future lease payments of $27,229,000 for an operating lease that had not yet commenced. Such operating lease will commence in fiscal year 2022 with a lease term of 15 years.

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Certain of our lease agreements include rental payments that are adjusted periodically based on the United States Bureau of Labor Statistics’ Consumer Price Index, and may also include other variable lease costs (i.e., common area maintenance, property taxes and insurance). Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The components of lease costs were as follows:

Three Months Ended June 30,
Lease Cost Classification 2022 2021
Operating lease cost(1) Property operating expenses, rental expenses or general and administrative expenses $ 5,408,000 $ 5,498,000
Finance lease cost:
Amortization of leased assets Depreciation and amortization 316,000 381,000
Interest on lease liabilities Interest expense 66,000 74,000
Sublease income Resident fees and services revenue or other income (234,000) (6,000)
Total lease cost $ 5,556,000 $ 5,947,000


			Six Months Ended June 30,						Three Months Ended March 31,
Lease Cost	Lease Cost	Classification	2022		2021		Lease Cost	Classification	2023		2022
Operating lease cost(1)	Operating lease cost(1)	Property operating expenses, rental expenses or general and administrative expenses	$	11,764,000	$	11,835,000	Operating lease cost(1)	Property operating expenses, rental expenses or general and administrative expenses	$	11,923,000	$	6,356,000
Finance lease cost:	Finance lease cost:						Finance lease cost:
Amortization of leased assets	Amortization of leased assets	Depreciation and amortization	629,000		793,000		Amortization of leased assets	Depreciation and amortization	303,000		312,000
Interest on lease liabilities	Interest on lease liabilities	Interest expense	140,000		192,000		Interest on lease liabilities	Interest expense	91,000		74,000
Sublease income	Sublease income	Resident fees and services revenue or other income	(382,000)		(6,000)		Sublease income	Resident fees and services revenue or other income	(156,000)		(147,000)
Total lease cost	Total lease cost		$	12,151,000	$	12,814,000	Total lease cost		$	12,161,000	$	6,595,000

___________

(1)Includes short-term leases and variable lease costs, which are immaterial.

~~Additional information related to our leases for the periods presented below was as follows:~~

Lease Term and Discount Rate
June 30,
2022
December 31,
2021
Weighted average remaining lease term (in years):
Operating leases 19.9 16.9
Finance leases 2.9 3.6
Weighted average discount rate:
Operating leases 5.53 % 5.52 %
Finance leases 7.59 % 7.68 %

Six Months Ended June 30,
Supplemental Disclosure of Cash Flows Information 2022 2021
Operating cash outflows related to finance leases $ 140,000 $ 192,000
Financing cash outflows related to finance leases $ 26,000 $ 117,000
Leased assets obtained in exchange for finance lease liabilities $ 56,000 $ 136,000
Right-of-use assets obtained in exchange for operating lease liabilities $ — $ 105,000

3427

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Additional information related to our leases for the periods presented below was as follows:


Lease Term and Discount Rate	March 31, 2023		December 31, 2022
Weighted average remaining lease term (in years):
Operating leases	12.6		12.8
Finance leases	2.0		2.3
Weighted average discount rate:
Operating leases	5.70	%	5.69	%
Finance leases	7.61	%	7.66	%


	Three Months Ended March 31,
Supplemental Disclosure of Cash Flows Information	2023		2022

Operating cash outflows related to finance leases	$	91,000	$	74,000
Financing cash outflows related to finance leases	$	16,000	$	13,000

Right-of-use assets obtained in exchange for operating lease liabilities	$	1,155,000	$	—

Operating Leases

As of ~~June 30, 2022,~~March 31, 2023, the following table sets forth the undiscounted cash flows of our scheduled obligations for future minimum payments for the ~~six~~nine months ending December 31, ~~2022~~2023 and for each of the next four years ending December 31 and thereafter, as well as the reconciliation of those cash flows to operating lease liabilities on our accompanying condensed consolidated balance sheet:


Year	Year	Amount		Year	Amount
2022		$	7,116,000
2023	2023	14,022,000		2023	$	29,017,000
2024	2024	12,836,000		2024	37,779,000
2025	2025	11,627,000		2025	37,197,000
2026	2026	11,045,000		2026	37,255,000
2027				2027	37,890,000
Thereafter	Thereafter	144,289,000		Thereafter	229,083,000
Total undiscounted operating lease payments	Total undiscounted operating lease payments	200,935,000		Total undiscounted operating lease payments	408,221,000
Less: interest	Less: interest	96,742,000		Less: interest	139,634,000
Present value of operating lease liabilities	Present value of operating lease liabilities	$	104,193,000	Present value of operating lease liabilities	$	268,587,000

Finance Leases

As of ~~June 30, 2022,~~March 31, 2023, the following table sets forth the undiscounted cash flows of our scheduled obligations for future minimum payments for the ~~six~~nine months ending December 31, ~~2022~~2023 and for each of the next four years ending December 31 and thereafter, as well as a reconciliation of those cash flows to finance lease liabilities:


Year	Year	Amount		Year	Amount
2022		$	34,000
2023	2023	61,000		2023	$	53,000
2024	2024	75,000		2024	76,000
2025	2025	31,000		2025	31,000
2026	2026	—		2026	—
2027				2027	—
Thereafter	Thereafter	—		Thereafter	—
Total undiscounted finance lease payments	Total undiscounted finance lease payments	201,000		Total undiscounted finance lease payments	160,000
Less: interest	Less: interest	23,000		Less: interest	14,000
Present value of finance lease liabilities	Present value of finance lease liabilities	$	178,000	Present value of finance lease liabilities	$	146,000

~~19.~~

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

17. Segment Reporting

As of ~~June 30, 2022,~~March 31, 2023, we evaluated our business and made resource allocations based on 6six reportable business segments: integrated senior health campuses, ~~medical office buildings, skilled nursing facilities,~~MOBs, SHOP, SNFs, senior housing — leased and hospitals.Our ~~medical office buildings~~MOBs are typically leased to multiple tenants under separate leases, thus requiring active management and responsibility for many of the associated operating expenses (much of which are, or can effectively be, passed through to the tenants). Our integrated senior health campuses ~~include~~each provide a range of independent living, assisted living, memory care, ~~independent living,~~ skilled nursing services and certain ancillary businesses that are owned and operated utilizing a RIDEA structure. Our senior housing — leased and skilled nursing ~~and senior housing~~ facilities are single-tenant properties for which we lease the facilities to unaffiliated tenants under triple-net and generally master leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. In addition, our senior housing —leased segment includes our debt security investment. Our hospital investments are similarly structured to our leased skilled nursing and senior housing facilities. Our SHOP segment includes senior housing facilities, which may provide assisted living care, independent living, memory care or skilled nursing services, that are owned and operated utilizing a RIDEA structure.

While we believe that net income (loss), as defined by GAAP, is the most appropriate earnings measurement, we evaluate our segments’ performance based upon segment net operating income or loss, or NOI. We define segment NOI as total revenues and grant income, less property operating expenses and rental expenses, which excludes depreciation and amortization, general and administrative expenses, business acquisition expenses, interest expense, gain or loss on dispositions

~~Table of Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

of real estate investments, impairment of real estate investments, income or loss from unconsolidated entities, impairment of goodwill, foreign currency gain or loss, gain on re-measurement of previously held equity interest, other income and income tax benefit or expense for each segment. We believe that segment NOI serves as an appropriate supplemental performance measure to net income (loss) because it allows investors and our management to measure unlevered property-level operating results and to compare our operating results to the operating results of other real estate companies and between periods on a consistent basis.

Interest expense, depreciation and amortization and other expenses not attributable to individual properties are not allocated to individual segments for purposes of assessing segment performance. Non-segment assets primarily consist of corporate assets including cash and cash equivalents, other receivables, deferred financing costs and other assets not attributable to individual properties.

On October 1, 2021, as part of the Merger, we acquired 92 buildings, or approximately 4,799,000 square feet of GLA, which expanded our portfolio of real estate properties and SHOP within the segments as outlined above.

3629

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Summary information for the reportable segments during the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~ was as follows:


		Integrated Senior Health Campuses		SHOP		Medical Office Buildings		Senior Housing — Leased		Skilled Nursing Facilities		Hospitals		Three Months Ended June 30, 2022			Integrated Senior Health Campuses		SHOP		MOBs		Senior Housing — Leased		SNFs		Hospitals		Three Months Ended March 31, 2023
Revenues and grant income:
Revenues:																Revenues:
Resident fees and services	Resident fees and services	$	287,582,000	$	38,643,000	$	—	$	—	$	—	$	—	$	326,225,000	Resident fees and services	$	361,770,000	$	46,860,000	$	—	$	—	$	—	$	—	$	408,630,000
Real estate revenue	Real estate revenue	—		—		36,833,000		5,262,000		6,599,000		2,411,000		51,105,000		Real estate revenue	—		—		37,483,000		5,276,000		(1,632,000)		2,469,000		43,596,000
Grant income		10,969,000		—		—		—		—		—		10,969,000
Total revenues and grant income		298,551,000		38,643,000		36,833,000		5,262,000		6,599,000		2,411,000		388,299,000

Total revenues																Total revenues	361,770,000		46,860,000		37,483,000		5,276,000		(1,632,000)		2,469,000		452,226,000
Expenses:	Expenses:															Expenses:
Property operating expenses	Property operating expenses	258,934,000		37,125,000		—		—		—		—		296,059,000		Property operating expenses	328,361,000		41,785,000		—		—		—		—		370,146,000
Rental expenses	Rental expenses	—		—		13,791,000		212,000		521,000		139,000		14,663,000		Rental expenses	—		—		14,408,000		199,000		469,000		119,000		15,195,000
Segment net operating income		$	39,617,000	$	1,518,000	$	23,042,000	$	5,050,000	$	6,078,000	$	2,272,000	$	77,577,000
Segment net operating income (loss)																Segment net operating income (loss)	$	33,409,000	$	5,075,000	$	23,075,000	$	5,077,000	$	(2,101,000)	$	2,350,000	$	66,885,000
Expenses:	Expenses:															Expenses:
General and administrative	General and administrative													$	10,928,000	General and administrative													$	13,053,000
Business acquisition expenses	Business acquisition expenses													1,757,000		Business acquisition expenses													332,000
Depreciation and amortization	Depreciation and amortization													39,971,000		Depreciation and amortization													44,670,000
Other income (expense):	Other income (expense):															Other income (expense):
Interest expense:																Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)																Interest expense (including amortization of deferred financing costs and debt discount/premium)													(39,011,000)
Loss in fair value of derivative financial instruments																Loss in fair value of derivative financial instruments													(195,000)
Loss on disposition of real estate investment																Loss on disposition of real estate investment													(132,000)

Interest expense (including amortization of deferred financing costs, debt discount/premium and gain on debt extinguishments)														(20,345,000)

Loss on dispositions of real estate investments														(73,000)
Impairment of real estate investments														(17,340,000)
Income from unconsolidated entities														638,000
Foreign currency loss														(3,607,000)
Loss from unconsolidated entities																Loss from unconsolidated entities													(306,000)
Gain on re-measurement of previously held equity interest																Gain on re-measurement of previously held equity interest													726,000
Foreign currency gain																Foreign currency gain													1,008,000
Other income	Other income													469,000		Other income													1,608,000
Total net other expense	Total net other expense													(40,258,000)		Total net other expense													(36,302,000)
Loss before income taxes	Loss before income taxes													(15,337,000)		Loss before income taxes													(27,472,000)
Income tax expense	Income tax expense													(205,000)		Income tax expense													(143,000)

Net loss	Net loss													$	(15,542,000)	Net loss													$	(27,615,000)

3730

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)


		Integrated Senior Health Campuses		SHOP		Medical Office Buildings		Senior Housing — Leased		Skilled Nursing Facilities		Hospitals		Three Months Ended June 30, 2021			Integrated Senior Health Campuses		SHOP		MOBs		Senior Housing — Leased		SNFs		Hospitals		Three Months Ended March 31, 2022
Revenues and grant income:	Revenues and grant income:															Revenues and grant income:
Resident fees and services	Resident fees and services	$	255,815,000	$	20,537,000	$	—	$	—	$	—	$	—	$	276,352,000	Resident fees and services	$	281,012,000	$	37,962,000	$	—	$	—	$	—	$	—	$	318,974,000
Real estate revenue	Real estate revenue	—		—		20,635,000		3,606,000		3,661,000		2,740,000		30,642,000		Real estate revenue	—		—		37,837,000		5,298,000		6,393,000		2,415,000		51,943,000
Grant income	Grant income	898,000		201,000		—		—		—		—		1,099,000		Grant income	5,096,000		118,000		—		—		—		—		5,214,000
Total revenues and grant income	Total revenues and grant income	256,713,000		20,738,000		20,635,000		3,606,000		3,661,000		2,740,000		308,093,000		Total revenues and grant income	286,108,000		38,080,000		37,837,000		5,298,000		6,393,000		2,415,000		376,131,000
Expenses:	Expenses:															Expenses:
Property operating expenses	Property operating expenses	232,991,000		17,435,000		—		—		—		—		250,426,000		Property operating expenses	253,150,000		34,010,000		—		—		—		—		287,160,000
Rental expenses	Rental expenses	—		—		7,588,000		30,000		375,000		126,000		8,119,000		Rental expenses	—		—		14,313,000		179,000		686,000		109,000		15,287,000
Segment net operating income	Segment net operating income	$	23,722,000	$	3,303,000	$	13,047,000	$	3,576,000	$	3,286,000	$	2,614,000	$	49,548,000	Segment net operating income	$	32,958,000	$	4,070,000	$	23,524,000	$	5,119,000	$	5,707,000	$	2,306,000	$	73,684,000
Expenses:	Expenses:															Expenses:
General and administrative	General and administrative													$	7,343,000	General and administrative													$	11,119,000
Business acquisition expenses	Business acquisition expenses													2,750,000		Business acquisition expenses													173,000
Depreciation and amortization	Depreciation and amortization													26,357,000		Depreciation and amortization													42,311,000
Other income (expense):	Other income (expense):															Other income (expense):
Interest expense:	Interest expense:															Interest expense:
Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishment)	Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishment)													(18,490,000)		Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishment)													(23,325,000)
Gain in fair value of derivative financial instruments	Gain in fair value of derivative financial instruments													1,775,000		Gain in fair value of derivative financial instruments													500,000
Loss on disposition of real estate investment														(42,000)
Impairment of real estate investment														(3,335,000)
Loss from unconsolidated entities														(901,000)
Foreign currency gain														238,000
Gain on dispositions of real estate investments																Gain on dispositions of real estate investments													756,000

Income from unconsolidated entities																Income from unconsolidated entities													1,386,000
Foreign currency loss																Foreign currency loss													(1,387,000)
Other income	Other income													191,000		Other income													1,260,000
Total net other expense	Total net other expense													(20,564,000)		Total net other expense													(20,810,000)
Loss before income taxes	Loss before income taxes													(7,466,000)		Loss before income taxes													(729,000)
Income tax expense	Income tax expense													(495,000)		Income tax expense													(168,000)

Net loss	Net loss													$	(7,961,000)	Net loss													$	(897,000)

Total assets by reportable segment as of March 31, 2023 and December 31, 2022 were as follows:


	March 31, 2023		December 31, 2022
Integrated senior health campuses	$	2,159,537,000	$	2,157,748,000
MOBs	1,360,364,000		1,379,502,000
SHOP	640,159,000		635,190,000
Senior housing — leased	250,468,000		249,576,000
SNFs	219,382,000		245,717,000
Hospitals	106,345,000		106,067,000
Other	11,426,000		12,898,000
Total assets	$	4,747,681,000	$	4,786,698,000

3831

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Integrated
Senior Health
Campuses SHOP Medical
Office
Buildings Senior
Housing — Leased Skilled
Nursing
Facilities Hospitals
Six Months
Ended
June 30, 2022
Revenues and grant income:
Resident fees and services $ 568,594,000 $ 76,605,000 $ — $ — $ — $ — $ 645,199,000
Real estate revenue — — 74,670,000 10,560,000 12,992,000 4,826,000 103,048,000
Grant income 16,065,000 118,000 — — — — 16,183,000
Total revenues and grant income 584,659,000 76,723,000 74,670,000 10,560,000 12,992,000 4,826,000 764,430,000
Expenses:
Property operating expenses 512,084,000 71,135,000 — — — — 583,219,000
Rental expenses — — 28,104,000 391,000 1,207,000 248,000 29,950,000
Segment net operating income $ 72,575,000 $ 5,588,000 $ 46,566,000 $ 10,169,000 $ 11,785,000 $ 4,578,000 $ 151,261,000
Expenses:
General and administrative $ 22,047,000
Business acquisition expenses 1,930,000
Depreciation and amortization 82,282,000
Other income (expense):
Interest expense:
Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishments) (43,670,000)
Gain in fair value of derivative financial instruments 500,000
Gain on dispositions of real estate investments 683,000
Impairment of real estate investments (17,340,000)
Income from unconsolidated entities 2,024,000
Foreign currency loss (4,994,000)
Other income 1,729,000
Total net other expense (61,068,000)
Loss before income taxes (16,066,000)
Income tax expense (373,000)
Net loss $ (16,439,000)

~~Table~~As of ~~Contents~~

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

Integrated
Senior Health
Campuses SHOP Medical
Office
Buildings Senior
Housing — Leased Skilled
Nursing
Facilities Hospitals
Six Months
Ended
June 30, 2021
Revenues and grant income:
Resident fees and services $ 489,041,000 $ 40,337,000 $ — $ — $ — $ — $ 529,378,000
Real estate revenue — — 40,658,000 7,176,000 7,328,000 5,503,000 60,665,000
Grant income 9,127,000 201,000 — — — — 9,328,000
Total revenues and grant income 498,168,000 40,538,000 40,658,000 7,176,000 7,328,000 5,503,000 599,371,000
Expenses:
Property operating expenses 461,630,000 33,938,000 — — — — 495,568,000
Rental expenses — — 15,125,000 45,000 744,000 260,000 16,174,000
Segment net operating income $ 36,538,000 $ 6,600,000 $ 25,533,000 $ 7,131,000 $ 6,584,000 $ 5,243,000 $ 87,629,000
Expenses:
General and administrative $ 14,600,000
Business acquisition expenses 3,998,000
Depreciation and amortization 52,080,000
Other income (expense):
Interest expense:
Interest expense (including amortization of deferred financing costs, debt discount/premium and loss on debt extinguishment) (38,855,000)
Gain in fair value of derivative financial instruments 3,596,000
Loss on dispositions of real estate investment (377,000)
Impairment of real estate investments (3,335,000)
Loss from unconsolidated entities (2,672,000)
Foreign currency gain 653,000
Other income 463,000
Total net other expense (40,527,000)
Loss before income taxes (23,576,000)
Income tax expense (658,000)
Net loss $ (24,234,000)

~~Total assets~~and for the three months ended March 31, 2023 and 2022, goodwill by reportable segment ~~as of June 30, 2022 and December 31, 2021 were~~was as follows:

June 30,
2022
December 31,
2021
Integrated senior health campuses $ 1,911,026,000 $ 1,896,608,000
Medical office buildings 1,385,279,000 1,412,247,000
SHOP 599,528,000 625,164,000
Skilled nursing facilities 250,019,000 252,869,000
Senior housing — leased 249,499,000 255,555,000
Hospitals 107,488,000 109,834,000
Other 21,061,000 28,062,000
Total assets $ 4,523,900,000 $ 4,580,339,000


	Integrated Senior Health Campuses		SHOP		MOBs		Senior Housing — Leased		SNFs		Hospitals		Total






Balance — December 31, 2022	$	164,846,000	$	—	$	47,812,000	$	5,924,000	$	8,640,000	$	4,389,000	$	231,611,000
Goodwill acquired	3,331,000		—		—		—		—		—		3,331,000




Balance — March 31, 2023	$	168,177,000	$	—	$	47,812,000	$	5,924,000	$	8,640,000	$	4,389,000	$	234,942,000

~~Table of Contents~~


	Integrated Senior Health Campuses		SHOP		MOBs		Senior Housing — Leased		SNFs		Hospitals		Total






Balance — December 31, 2021	$	119,856,000	$	23,277,000	$	47,812,000	$	5,924,000	$	8,640,000	$	4,389,000	$	209,898,000
Goodwill acquired	1,827,000		—		—		—		—		—		1,827,000




Balance — March 31, 2022	$	121,683,000	$	23,277,000	$	47,812,000	$	5,924,000	$	8,640,000	$	4,389,000	$	211,725,000

~~AMERICAN HEALTHCARE REIT, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

~~In connection with the AHI Acquisition, we recorded goodwill of $134,589,000, which was allocated across our reporting segments. As discussed in~~See Note 4,3, Real Estate Investments, Net and Business Combinations, for a further discussion of goodwill recognized in connection with ~~the acquisitions we completed during the six months ended June 30, 2022 that were accounted for as~~our business combinations, we recorded an aggregate goodwill of $2,816,000, which was allocated to our integrated senior health campuses segment. As of June 30, 2022, goodwill of $122,672,000, $47,812,000, $23,277,000, $8,640,000, $5,924,000 and $4,389,000 was allocated to our integrated senior health campuses, medical office buildings, SHOP, skilled nursing facilities, senior housing — leased and hospitals segments, respectively. As of December 31, 2021, goodwill of $119,856,000, $47,812,000, $23,277,000, $8,640,000, $5,924,000 and $4,389,000 was allocated to our integrated senior health campuses, medical office buildings, SHOP, skilled nursing facilities, senior housing — leased and hospitals segments, respectively.combinations.

Our portfolio of properties and other investments are located in the United States, the UK and Isle of Man. Revenues and grant income and assets are attributed to the country in which the property is physically located. The following is a summary of geographic information for our operations for the periods presented:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021		2022		2021				2023		2022
Revenues and grant income:	Revenues and grant income:									Revenues and grant income:
United States	United States	$	387,120,000	$	306,786,000	$	761,999,000	$	596,772,000	United States		$	451,092,000	$	374,879,000
International	International	1,179,000		1,307,000		2,431,000		2,599,000		International		1,134,000		1,252,000
		$	388,299,000	$	308,093,000	$	764,430,000	$	599,371,000			$	452,226,000	$	376,131,000

The following is a summary of real estate investments, net by geographic regions as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021:~~2022:


		June 30, 2022		December 31, 2021			March 31, 2023		December 31, 2022
Real estate investments, net:	Real estate investments, net:					Real estate investments, net:
United States	United States	$	3,448,793,000	$	3,466,019,000	United States	$	3,525,352,000	$	3,539,453,000
International	International	43,052,000		48,667,000		International	42,765,000		42,156,000
		$	3,491,845,000	$	3,514,686,000		$	3,568,117,000	$	3,581,609,000

~~20.~~18. Concentration of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk are primarily our debt security investment, cash and cash equivalents, restricted cash and accounts and other receivables. We are exposed to credit risk with respect to our debt security investment, but we believe collection of the outstanding amount is probable. Cash and cash equivalents are generally invested in investment-grade, short-term instruments with a maturity of three months or less when purchased. We have cash and cash equivalents in financial institutions that are insured by the Federal Deposit Insurance Corporation, or FDIC. As of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, we had cash and cash equivalents in excess of FDIC insured limits. We believe this risk is not significant. Concentration of credit risk with respect to accounts receivable from tenants and residents is limited. We perform credit evaluations of prospective tenants and security deposits are obtained at the time of property acquisition and upon lease execution.

Based on leases ~~in effect~~ as of ~~June 30, 2022,~~March 31, 2023, properties in 1one state in the United States accounted for 10.0% or more of our total property portfolio’s annualized base rent or annualized NOI. Properties located in Indiana accounted for 32.8% of our total property portfolio’s annualized base rent or annualized NOI. Accordingly, there is a geographic concentration of risk subject to fluctuations in such state’s economy.

Based on leases in effect as of June 30, 2022, our 6 reportable business segments, integrated senior health campuses, medical office buildings, skilled nursing facilities, SHOP, senior housing — leased and hospitals accounted for 41.6%, 38.3%, 8.0%, 5.0%, 4.0% and 3.1%, respectively, of our total property portfolio’s annualized base rent or annualized NOI. As of June 30, 2022, none of our tenants at our properties accounted for 10.0% or more of our total property portfolio’s annualized base rent or annualized NOI, which is based on contractual base rent from leases in effect for our non-RIDEA properties and annualized NOI for our SHOP and integrated senior health campuses ~~operations~~ as of ~~June 30, 2022.~~March 31, 2023.

4132

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

~~21.~~Properties located in Indiana accounted for 32.4% of our total property portfolio’s annualized base rent or annualized NOI. Accordingly, there is a geographic concentration of risk subject to fluctuations in such state’s economy.

Based on leases in effect as of March 31, 2023, our six reportable business segments, integrated senior health campuses, MOBs, SHOP, SNFs, senior housing — leased and hospitals accounted for 42.6%, 33.7%, 10.3%, 6.8%, 3.8% and 2.8%, respectively, of our total property portfolio’s annualized base rent or annualized NOI. As of March 31, 2023, none of our tenants at our properties accounted for 10.0% or more of our total property portfolio’s annualized base rent or annualized NOI.

19. Per Share Data

Basic earnings (loss) per share for all periods presented are computed by dividing net income (loss) applicable to common stock by the weighted average number of shares of our common stock outstanding during the period. Net income (loss) applicable to common stock is calculated as net income (loss) attributable to controlling interest less distributions allocated to participating securities of ~~$1,498,000~~$926,000 and ~~$1,000, respectively,~~$1,490,000 for the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021, and $2,988,000 and $1,000, respectively, for the six months ended June 30, 2022 and 2021.~~respectively. Diluted earnings (loss) per share are computed based on the weighted average number of shares of our common stock and all potentially dilutive securities, if any. ~~Time-based restricted stock units,~~TBUs, nonvested shares of our ~~restricted common stock~~RSAs and limited partnership units of our operating partnership are participating securities and give rise to potentially dilutive shares of our common stock.

As of ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ there were ~~886,959~~184,145 and ~~27,000~~222,886 nonvested shares, respectively, of our ~~restricted common stock~~RSAs outstanding, but such shares were excluded from the computation of diluted earnings (loss) per share because such shares were anti-dilutive during these periods. As of ~~June 30,~~both March 31, 2023 and 2022, ~~and 2021,~~ there were ~~14,007,903 and 222~~3,501,976 limited partnership units ~~respectively,~~ of our operating partnership outstanding, but such units were also excluded from the computation of diluted earnings (loss) per share because such units were anti-dilutive during these periods. As of ~~June 30, 2022,~~March 31, 2023, there were ~~76,800~~19,200 nonvested time-based restricted stock units outstanding, which were granted on April 1, 2022, but such units were excluded from the computation of diluted earnings (loss) per share because such restricted stock units were anti-dilutive during the period.

As of ~~June 30, 2022,~~March 31, 2023, there were ~~113,205~~29,352 nonvested performance-based restricted stock units outstanding, which were ~~awarded in October 2021, with a grant date in April 2022, and~~ treated as contingently issuable shares pursuant to ASC Topic 718, Compensation — Stock Compensation. Such contingently issuable shares were excluded from the computation of diluted earnings (loss) per share because they were anti-dilutive during the period.

20. Subsequent Event

Issuance of Restricted Stock Units

On April 3, 2023, pursuant to the AHR Incentive Plan, we granted our executive officers and certain employees 148,311 TBUs, which vest in three equal annual installments on April 3, 2024, April 3, 2025 and April 3, 2026 (subject to continuous employment through each vesting date) and represent the right to receive shares of our Class T common stock upon vesting. In addition, our executive officers and certain employees received 41,399 PBUs representing the right to receive shares of our Class T common stock upon vesting. The PBUs will cliff vest in the first quarter of 2026 (subject to continuous employment through that vesting date) with the amount vesting depending on meeting certain key performance criteria as further described in the AHR Incentive Plan.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to promote understanding of our results of operations and financial condition. ~~The following~~Such discussion is provided as a supplement to, and should be read in conjunction with our accompanying condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q and in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the United States Securities and Exchange Commission, or SEC, on March ~~25, 2022.~~17, 2023. Such condensed consolidated financial statements and information have been prepared to reflect our financial position as of ~~June 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, together with our results of operations and cash flows for the three ~~and six~~ months ended ~~June 30, 2022~~March 31, 2023 and ~~2021.~~

~~In connection with the Merger (as discussed~~2022. Our results of operations and ~~defined below), GAHR IV was the legal acquiror of GAHR III, whereas GAHR III was the accounting acquiror of GAHR IV in accordance with accounting principles generally accepted~~financial condition, as reflected in the ~~United States of America, or GAAP, and as discussed in Note 1, Organization and Description of Business, to our~~ accompanying condensed consolidated financial ~~statements. Thus,~~statements and related notes, are subject to management’s evaluation and interpretation of business conditions, changing capital market conditions, and other factors that could affect the ~~financial information set forth herein subsequent to the Merger reflects results~~ongoing viability of ~~the Combined Company (as defined below),~~our tenants and ~~the financial information set forth herein prior to the Merger reflects GAHR III’s results. For this reason, period to period comparisons may not be meaningful.~~residents.

Forward-Looking Statements

~~Historical results and trends should not be taken as indicative of future operations. Our~~Certain statements contained in this report, ~~that are not~~other than historical facts, ~~are forward-looking. Actual results~~ may ~~differ materially from those included~~be considered forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995 (collectively with the “Securities Act and Exchange Act, or the Acts”). We intend for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in the Acts. Such forward-looking ~~statements. Forward-looking~~ statements ~~which are based on certain assumptions and describe future plans, strategies and expectations, are~~ generally ~~identifiable~~can be identified by the use of ~~the words “expect,” “project,”~~forward-looking terminology such as “may,” “will,” ~~“should,~~“can,” ~~“could,” “would,~~“expect,” “intend,~~” “plan,~~” “anticipate,” “estimate,” “believe,” “continue,” ~~“opinion,~~“possible,” ~~“predict,~~“initiatives,” “focus,” “seek,” “objective,” “goal,” “strategy,” “plan,” “potential,” ~~“seek”~~“potentially,” “preparing,” “projected,” “future,” “long-term,” “once,” “should,” “could,” “would,” “might,” “uncertainty,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this report is filed with the SEC.

Any such forward-looking statements are based on current expectations, estimates and ~~any other comparable~~projections about the industry and ~~derivative terms or the negatives thereof. Our ability to predict results or the actual effect~~markets in which we operate, and beliefs of, ~~future plans~~ and ~~strategies is inherently uncertain. Factors which~~assumptions made by, our management and involve uncertainties that could ~~have a material adverse effect on~~significantly affect our ~~operations on a consolidated basis~~financial results. Such statements include, but are not limited to: (i) statements about our plans, strategies, initiatives and prospects; including our proposed listing and future capital-raising initiatives; (ii) statements about the coronavirus, or COVID-19, pandemic, including its duration and potential or expected impact on our business and our view on forward trends; and (iii) statements about our future results of operations, capital expenditures and liquidity. Such statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated, including, without limitation: changes in economic conditions generally and the real estate market specifically; the ~~company’s ability to recover from the~~ continuing adverse effects of the ~~coronavirus, or~~ COVID-19 pandemic, including its effects on the healthcare industry, senior housing and skilled nursing facilities, or SNFs, and the economy in general; legislative and regulatory changes, including changes to laws governing the taxation of real estate investment trusts, or REITs; the availability of capital; our ability to pay down, refinance, restructure or extend our indebtedness as it becomes due; our ability to maintain our qualification as a REIT for U.S. federal income tax purposes; changes in interest rates and foreign currency risk; uncertainty from the discontinuance of the London Inter-bank Offered Rate, or LIBOR, and the transition to the Secured Overnight Financing Rate, or SOFR; competition in the real estate industry; changes in GAAP policies and guidelines applicable to REITs; the success of our investment strategy; ~~the availability of financing;~~information technology security breaches; our ability to retain our ~~executives~~executive officers and key employees; and unexpected labor costs and inflationary pressures. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Forward-looking statements in this Quarterly Report on Form 10-Q speak only as of the date on which such statements are made, and undue reliance should not be placed on such statements. We undertake no obligation to update any such statements that may become untrue because of subsequent events. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

4334

Table of Contents

Overview and Background

American Healthcare REIT, Inc., a Maryland corporation, is a self-managed real estate investment trust, or REIT, that owns a diversified portfolio of clinical healthcare real estate properties, focusing primarily on medical office buildings, ~~skilled nursing~~or MOBs, senior housing facilities, ~~senior housing,~~SNFs, hospitals and other healthcare-related facilities. We also operate healthcare-related facilities utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007, which is commonly referred to as a “RIDEA” structure (the provisions of the Internal Revenue Code of 1986, as amended, or the Code, authorizing the RIDEA structure were enacted as part of the Housing and Economic Recovery Act of 2008). Our healthcare facilities operated under a RIDEA structure include our senior housing operating properties, or SHOP, ~~(formerly known as senior housing — RIDEA),~~ and our integrated senior health campuses. We have originated and acquired secured loans and may also originate and acquire other real estate-related investments on an infrequent and opportunistic basis. We generally seek investments that produce current income; however, we have selectively developed, and may continue to selectively develop, healthcare real estate properties. We ~~qualified~~have elected to be taxed as a ~~real estate investment trust, or~~ REIT ~~under the Code~~ for U.S. federal income tax ~~purposes,~~purposes. We believe that we have been organized and operated, and we intend to continue to ~~qualify to be taxed~~operate, in conformity with the requirements for qualification and taxation as a ~~REIT.~~REIT under the Code.

~~Merger of~~On October 1, 2021, Griffin-American Healthcare REIT III, Inc. ~~and Griffin-American Healthcare REIT IV, Inc.~~

At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, converted into the right to receive 0.9266 shares of GAHR IV’s Class I common stock, $0.01 par value per share. Further, at the effective time of the Partnership Merger, (i) each unit of limited partnership interest in the surviving partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership, as amended, of the surviving partnership, and (ii) each unit of limited partnership interest in GAHR IV Operating Partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class.

~~AHI Acquisition~~LP, or our operating partnership.

Also on October 1, 2021, immediately prior to the consummation of the Merger, and pursuant to a contribution and exchange agreement dated June 23, 2021, GAHR III acquired a newly formed entity, American Healthcare Opps Holdings, LLC, or NewCo, which we refer to as the AHI Acquisition, pursuant to a contribution and exchange agreement dated June 23, 2021, or the Contribution Agreement, between GAHR III; our operating partnership; American Healthcare Investors, LLC, or AHI; Griffin Capital Company, LLC, or Griffin Capital; Platform Healthcare Investor T-II, LLC; Flaherty Trust; and Jeffrey T. Hanson, our former Chief Executive Officer and current Chairman of the Board of Directors, Danny Prosky, our former Chief Operating Officer and current Chief Executive Officer and President, and Mathieu B. Streiff, our former Executive Vice President, General Counsel and Chief Operating Officer, and current Executive Vice President, or collectively, the AHI Principals. NewCo owned substantially all of the business and operations of AHI, as well as all of the equity interests in (i) Griffin-American Healthcare REIT IV Advisor, LLC, or GAHR IV Advisor, a subsidiary of AHI that served as the external advisor of GAHR IV, and (ii) Griffin-American Healthcare REIT III Advisor, LLC, or GAHR III Advisor, also referred to as our former advisor, a subsidiary of AHI that served as the external advisor of GAHR III. See “Operating Partnership and Former Advisor” below for a further discussion.

~~Table of Contents~~

~~partnership OP units as consideration, or the Closing Date Consideration.~~Acquisition. Following ~~the consummation of~~ the Merger and the AHI Acquisition, ~~the Combined Company~~our company became self-managed. Such surviving partnership OP units are owned by AHI Group Holdings, LLC, or AHI Group Holdings, which is owned and controlled by the AHI Principals, Platform Healthcare Investor T-II, LLC, Flaherty Trust and a wholly owned subsidiary of Griffin Capital, or collectively, the NewCo Sellers.

The AHI Acquisition was treated as a business combination for accounting purposes, with GAHR III as both the legal and accounting acquiror of NewCo. While GAHR IV was the legal acquiror of GAHR III in the REIT Merger, GAHR III was determined to be the accounting acquiror in the REIT Merger in accordance with Financial Accounting Standards Board Accounting Standards Codification, Topic 805, ~~Business Combinations~~, after considering the relative share ownership and the composition of the governing body of the Combined Company. Thus, the financial information set forth herein subsequent to the consummation of the Merger and the AHI Acquisition reflects results of the Combined Company, and the financial information set forth herein prior to the Merger and the AHI Acquisition reflects GAHR III’s results. For this reason, period to period comparisons may not be meaningful.

Operating Partnership ~~and Former Advisor~~

~~Prior to the Merger and the AHI Acquisition, our former advisor was 75.0% owned and managed by wholly owned subsidiaries of AHI, and 25.0% owned by~~ a wholly owned subsidiary of Griffin Capital Company, LLC, or collectively, ~~our former co-sponsors. Prior to~~ the ~~AHI Acquisition, AHI was 47.1% owned by AHI Group Holdings, 45.1% indirectly owned by Digital Bridge Group, Inc. (NYSE: DBRG), or Digital Bridge,~~NewCo Sellers. See Note 12, Redeemable Noncontrolling Interests, and 7.8% owned by James F. Flaherty III. We were not affiliated with Griffin Capital, Digital Bridge or Mr. Flaherty; however, we were affiliated with our former advisor, AHI and AHI Group Holdings. Please see the “Merger of Griffin-American Healthcare REIT III, Inc. and Griffin-American Healthcare REIT IV, Inc.” and “AHI Acquisition” sections aboveNote 13, Equity — Noncontrolling Interests in Total Equity, for a further discussion of the ownership in our ~~operations effective October 1, 2021.~~operating partnership.

Public Offerings

As of March 31, 2023, after taking into consideration the Merger and the impact of the reverse stock split as discussed below, we had issued 65,445,557 shares for a total of $2,737,716,000 of common stock since February 26, 2014 in our initial public offerings and our distribution reinvestment plan, or DRIP, offerings (includes historical offering amounts sold by GAHR III and GAHR IV prior to the Merger).

On September 16, 2022, we filed with the SEC a Registration Statement on Form S-11 (File No. 333-267464) with respect to a proposed public offering by us of our shares of common stock in conjunction with a contemplated listing of our common stock on the New York Stock Exchange, or the Proposed Listing. Such registration statement and contemplated listing are not yet effective.

Table of Contents

On November 15, 2022 we effected a one-for-four reverse stock split of our common stock and a corresponding reverse split of the OP units, or the Reverse Splits. All numbers of common shares and per share data, as well as the OP units, in our accompanying condensed consolidated financial statements and related notes have been retroactively adjusted for all periods presented to give effect to the Reverse Splits. See Note 13, ~~Redeemable Noncontrolling Interests, and Note 14, Equity — Noncontrolling Interests in Total~~ Equity, to our accompanying condensed consolidated financial statements, for a further discussion of ~~the ownership in~~ our ~~operating partnership.~~

~~Public Offering~~

~~GAHR IV raised $754,118,000 through a best efforts initial~~ public offering, or the initial offering, and issued 75,639,681 aggregate shares of its Class T and Class I common stock. In addition, during the initial offering, GAHR IV issued 3,253,535 aggregate shares of its Class T and Class I common stock pursuant to GAHR IV’s distribution reinvestment plan, as amended, or the DRIP, for a total of $31,021,000 in distributions reinvested. Following the deregistration of the initial offering, GAHR IV continued issuing shares of its common stock pursuant to the DRIP through a subsequent offering, or the 2019 GAHR IV DRIP Offering. GAHR IV commenced offering shares pursuant to the 2019 GAHR IV DRIP Offering on March 1, 2019, following the termination of the initial offering on February 15, 2019. On March 18, 2021, the GAHR IV board of directors authorized the suspension of the DRIP, effective as of April 1, 2021.

~~On October 4, 2021,~~ our board authorized the reinstatement of the DRIP, as amended, or the AHR DRIP. We continue to offer up to $100,000,000 of shares of our common stock to be issued pursuant to the AHR DRIP under an existing Registration Statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, previously filed by GAHR IV. As of June 30, 2022, a total of $77,083,000 in distributions were reinvested that resulted in 8,180,513 shares of common stock being issued pursuant to the AHR DRIP. See Note 14, Equity — Distribution Reinvestment Pl~~an,~~ ~~to our accompanying condensed consolidated financial statements~~ ~~for a further discussion.~~offerings.

On March ~~24, 2022,~~15, 2023, our board, at the recommendation of the audit committee of our board, which is comprised solely of independent directors, unanimously approved and established an updated estimated per share net asset value, or NAV, of our common stock of ~~$9.29.~~$31.40. We provide this updated estimated per share NAV annually to assist broker-dealers in connection with their obligations under Financial Industry Regulatory Authority, or FINRA, Rule 2231 with respect to customer account statements. The updated estimated per share NAV is based on the estimated value of our assets less the estimated value of our liabilities, divided by the number of shares outstanding on a fully diluted basis, calculated as of December 31, ~~2021.~~2022. The valuation was performed in accordance with the methodology provided in Practice Guideline 2013-01,Valuations of Publicly

~~Table of Contents~~

Registered Non-Listed REITs, issued by the Institute for Portfolio Alternatives, or the IPA, in April 2013, in addition to guidance from the SEC. See our Current Report on Form 8-K filed with the SEC on March ~~25, 2022~~17, 2023 for more information on the methodologies and assumptions used to determine, and the limitations and risks of, our updated estimated per share NAV.

Our Real Estate Investments Portfolio

We currently operate through six reportable business segments: integrated senior health campuses, ~~medical office buildings, skilled nursing facilities,~~MOBs, SHOP, SNFs, senior housing — leased and hospitals. As of ~~June 30, 2022,~~March 31, 2023, we owned and/or operated ~~313~~314 buildings and integrated senior health campuses, including completed development and expansion projects, or approximately ~~19,461,000~~19,956,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of ~~$4,370,459,000, including the fair value of the properties acquired in the Merger.~~$4,626,119,000. In addition, as of ~~June 30, 2022,~~March 31, 2023, we also owned a real estate-related debt investment purchased for $60,429,000.

Critical Accounting Estimates

Our accompanying condensed consolidated financial statements are prepared in conformity with GAAP, which requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying footnotes. These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions. The complete listing of our Critical Accounting Estimates was previously disclosed in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022,~~17, 2023, and there have been no material changes to our Critical Accounting Estimates as disclosed therein, except as ~~noted below or~~ included within Note 2, Summary of Significant Accounting Policies, to our accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

For a discussion of interim unaudited financial data, see Note 2, Summary of Significant Accounting Policies — Interim Unaudited Financial Data, to our accompanying condensed consolidated financial statements. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022.~~17, 2023.

Acquisitions and Dispositions in ~~2022~~2023

For a discussion of our acquisitions and dispositions of investments in ~~2022,~~2023, see Note 3, Real Estate Investments, Net and ~~Note 4,~~ Business Combinations, to our accompanying condensed consolidated financial statements.

Factors Which May Influence Results of Operations

In connection with the Merger, GAHR IV was the legal acquiror and GAHR III was the accounting acquiror for financial reporting purposes, as discussed in Note 1, Organization and Description of Business, to our accompanying condensed consolidated financial statements. Thus, the financial information set forth herein subsequent to the Merger reflects results of the Combined Company, and the financial information set forth herein prior to the Merger reflects GAHR III’s results. Furthermore, as a result of the closing of the AHI Acquisition on October 1, 2021, and following the Merger, our company is now self-managed and employs all the employees necessary to operate as a self-managed company. The impact of being a self-managed company on our results of operations is predominantly an increase in general and administrative costs related to employing the workforce necessary to operate as a self-managed company and cost savings associated with no longer paying advisory fees to our former advisor. For these reasons, period to period comparisons may not be meaningful.

Other than the effects of ~~the Merger~~inflation and the ~~AHI Acquisition discussed above, and~~lasting effects of the COVID-19 pandemic discussed below, as well as other national economic conditions affecting real estate generally, or as otherwise disclosed in our risk factors, we are not aware of any material trends or uncertainties that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the acquisition, disposition, management and operation of our properties. For a further discussion of these and other factors that could impact our future results or performance, see “Forward-Looking Statements” above and Part I, Item 1A, Risk Factors, previously disclosed in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022.~~17, 2023.

COVID-19

Table of Contents

of the economic recovery from the COVID-19 pandemic is dependent upon many factors, including the emergence and severity of new COVID-19 variants, the ~~continued~~ effectiveness ~~and frequency~~ of ~~booster vaccinations~~vaccines, the actions taken to contain the pandemic or mitigate its impact and the ~~duration~~direct and ~~implications~~indirect economic effects of ~~continued restrictions~~the pandemic and ~~safety measures.~~containment measures, among others. As the lasting economic effects of the responses to the COVID-19 pandemic, issuch as inflation and labor market challenges, are still impacting the healthcare system to a certain extent, ~~it continues~~such effects continue to present challenges for us as an owner and operator of healthcare facilities, making it difficult to ascertain

~~Table of Contents~~

the long-term impact the COVID-19 pandemic will have on real estate markets in which we own and/or operate properties and our portfolio of investments. COVID-19 is particularly dangerous among the senior population and results in heightened risk to our senior housing and ~~skilled nursing facilities,~~SNFs, and we continue to work diligently to maintain aggressive protocols at such facilities as well as actively collaborate with our tenants, operating partners and managers to respond and take action to mitigate the impact of the COVID-19 pandemic.

The COVID-19 pandemic resulted in a significant decline in resident occupancies at our ~~leased~~ senior housing facilities and ~~skilled nursing facilities, SHOP~~SNF’s. We have also incurred increased operational costs as a result of public health measures and ~~integrated senior~~other regulations affecting our properties, as well as additional health ~~campuses~~ and ~~an increase~~safety measures adopted by us and our operators related to the COVID-19 pandemic, including increases in ~~COVID-19 related~~labor, personal protective equipment and sanitation. We expect total property operating expenses ~~with more costly short-term hires due~~ to ~~the shortage~~remain elevated as many of ~~healthcare personnel.~~these additional health and safety measures have become standard practice. Therefore, our focus at such ~~properties~~facilities continues to be on resident occupancy recovery and operating expense management. ~~While~~As of March 31, 2023, resident occupancies at our ~~integrated senior health campuses and leased~~ senior housing facilities and ~~skilled nursing~~SNFs have almost returned to pre-pandemic levels. We believe the operational recovery of such facilities ~~have gradually improved to near pre-pandemic levels, our SHOP have been slower to recover.~~

~~To date,~~from the ~~impacts~~impact of the COVID-19 pandemic ~~have been significant, rapidly evolving~~will generally continue and ~~may continue into~~that such recovery over time towards pre-pandemic levels will drive our overall portfolio performance.

As a result of the ~~future. The information~~federal government's COVID-19 public health emergency declaration in ~~this Quarterly Report on Form 10-Q is based on data currently~~January 2020, certain federal and state pandemic-related relief measures, such as funding, procedural waivers and/or reimbursement increases, became available to ussome of our tenants and ~~will likely change as~~operators that mitigated some of the ~~COVID-19 pandemic progresses. Future actions that may be taken by state and local governments to mitigate the~~financial impact of COVID-19 variants that may emerge could disrupt our business, activities and operations, the extent to which are highly uncertain. We continue to closely monitor COVID-19 developments and are continuously assessing the implications to our business, residents, tenants, operating partners, managers and our portfolio of investments. We cannot predict with reasonable certainty when demand for healthcare services at our senior housing and skilled nursing facilities will return to pre-COVID-19 pandemic levels.

~~The lasting effect~~ of the COVID-19 ~~pandemic over~~pandemic. On May 11, 2023, the ~~next 12 months could~~Biden Administration ended such COVID-19 public health emergency declaration, creating uncertainty as to how widespread these measures will continue to be ~~significant~~ and ~~will largely depend on future developments, including COVID-19 booster rates; the long term efficacy of COVID-19 vaccinations~~to what extent they may be distributed to and ~~boosters;~~benefit our tenants and ~~the potential emergence of new, more transmissible or severe variants, which cannot be predicted with confidence at this time.~~ operators.

See the “Results of Operations” and “Liquidity and Capital Resources” sections below, for a further discussion.

Inflation

During the three months ended March 31, 2023 and 2022, inflation has affected our operations. The annual rate of inflation in the United States was 4.9% in April 2023, as measured by the Consumer Price Index. We believe inflation has impacted our operations such that we have experienced, and continue to experience, increases in the cost of labor, services, energy and supplies, and therefore continued inflationary pressures on our integrated senior health campuses and SHOP could continue to impact our profitability in future periods. For properties that are not operated under a RIDEA structure, there are provisions in the majority of our tenant leases that help us mitigate the impact of inflation. These provisions include negotiated rental increases, which historically range from 2% to 3% per year, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements. However, due to the long-term nature of existing leases, among other factors, the leases may not reset frequently enough to cover inflation. A period of inflation could also cause an increase in the cost of our variable-rate debt due to rising interest rates. See Item 3. Quantitative and Qualitative Disclosures About Market Risk — Interest Rate Risk section below, for a further discussion.

Scheduled Lease Expirations

Excluding our SHOP and integrated senior health campuses, as of ~~June 30, 2022,~~March 31, 2023, our properties were ~~93.1%~~91.7% leased, and during the remainder of ~~2022, 4.8%~~2023, 6.2% of the leased GLA is scheduled to expire. Our leasing strategy focuses on negotiating renewals for leases scheduled to expire during the next twelve months. In the future, if we are unable to negotiate renewals, we will try to identify new tenants or collaborate with existing tenants who are seeking additional space to occupy. As of ~~June 30, 2022,~~March 31, 2023, our remaining weighted average lease term was ~~7.1~~6.9 years, excluding our SHOP and integrated senior health campuses.

Our combined SHOP and integrated senior health campuses were ~~79.5%~~82.4% leased as of ~~June 30, 2022.~~March 31, 2023. Substantially all of our leases with residents at such properties are for a term of one year or less.

4737

Table of Contents

Results of Operations

Comparison of Three ~~and Six~~ Months Ended ~~June 30,~~March 31, 2023 and 2022 ~~and 2021~~

Our operating results are primarily comprised of income derived from our portfolio of properties and expenses in connection with the acquisition and operation of such properties. Our primary sources of revenue include rent generated by our leased, non-RIDEA properties, and resident fees and services revenue from our RIDEA properties. Our primary expenses include property operating expenses and rental expenses. In addition, beginning in the fourth quarter of 2021, following the AHI Acquisition that resulted in our company being self managed, general and administrative expenses include payroll and other corporate operating expenses but no longer include advisory fees to our former advisor. In general, and under a normal operating environment without the ~~disruption~~adverse effect of the COVID-19 pandemic and challenging economic conditions resulting from inflation, we expect ~~amounts~~revenues and expenses related to our portfolio of ~~operating~~leased, non-RIDEA properties to increase in the future primarily due to fixed annual rent escalations onand revenues and expenses related to our portfolio of ~~properties. The ability~~RIDEA properties to ~~compare one period to another is also impacted by the closing of the AHI Acquisition and the~~ increase in ~~size~~the future primarily due to an overall increase in occupancies and market rents as well as an increase in the pricing of ~~our real estate portfolio as a result of the Merger. See Note 1, Organization and Description of Business, to our accompanying condensed consolidated financial statements for a further discussion.~~care services provided.

We segregate our operations into reporting segments in order to assess the performance of our business in the same way that management reviews our performance and makes operating decisions. As of ~~June 30, 2022,~~March 31, 2023, we operated through six reportable business segments: integrated senior health campuses, ~~medical office buildings, skilled nursing facilities,~~MOBs, SHOP, SNFs, senior housing — leased and hospitals.

Except where otherwise noted, the changes in our consolidated results of operations for ~~2022~~2023 as compared to ~~2021~~2022 are primarily due to the ~~acquisition~~adverse effect of ~~GAHR IV’s portfolio~~inflation, which resulted in increases in the cost of ~~92 buildings, or approximately 4,799,000 square feet~~labor, services, energy and supplies for the three months ended March 31, 2023 compared to the same period last year. There were also changes in our results of ~~GLA, as a result~~operations by reporting segment due to the transition of the ~~Merger~~operations of skilled nursing facilities within Central Wisconsin Senior Care Portfolio on ~~October~~March 1, ~~2021, the disruption~~2023 to a RIDEA structure, which facilities are included within our ~~normal operations~~SHOP segment as ~~a result~~ of ~~the COVID-19 pandemic and grant income received.~~March 31, 2023. As of ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we owned and/or operated the following types of properties:


		June 30,											March 31,
		2022					2021						2023					2022
		Number of Buildings/ Campuses	Aggregate Contract Purchase Price		Leased %		Number of Buildings/ Campuses	Aggregate Contract Purchase Price		Leased %			Number of Buildings/ Campuses	Aggregate Contract Purchase Price		Leased %		Number of Buildings/ Campuses	Aggregate Contract Purchase Price		Leased %
Integrated senior health campuses	Integrated senior health campuses	122	$	1,865,786,000	(1)		120	$	1,754,233,000	(1)		Integrated senior health campuses	122	$	1,909,591,000	(1)		122	$	1,795,199,000	(1)
Medical office buildings		105	1,249,658,000		90.3	%	63	657,885,000		89.3	%
MOBs												MOBs	104	1,369,596,000		88.7	%	105	1,378,996,000		89.7	%
SHOP	SHOP	47	708,050,000		(2)		20	433,891,000		(2)		SHOP	51	804,367,000		(2)		47	706,871,000		(2)
Senior housing — leased	Senior housing — leased	20	169,885,000		100	%	9	89,535,000		100	%	Senior housing — leased	20	179,285,000		100	%	20	179,285,000		100	%
Skilled nursing facilities		17	237,300,000		100	%	6	119,500,000		100	%
SNFs												SNFs	15	223,500,000		100	%	17	249,200,000		100	%
Hospitals	Hospitals	2	139,780,000		100	%	2	139,780,000		100	%	Hospitals	2	139,780,000		100	%	2	139,780,000		100	%
Total/weighted average(3)	Total/weighted average(3)	313	$	4,370,459,000	93.1	%	220	$	3,194,824,000	92.0	%	Total/weighted average(3)	314	$	4,626,119,000	91.7	%	313	$	4,449,331,000	92.7	%

___________

(1)The leased percentage for the resident units of our integrated senior health campuses was ~~81.7%~~84.6% and ~~77.4%~~80.0% as of ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ respectively.

(2)The leased percentage for the resident units of our SHOP was ~~73.7%~~76.4% and ~~73.9%~~71.9% as of ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ respectively.

(3)Leased percentage includes all third-party leased space at our non-RIDEA properties (including master leases), and excludes our SHOP and integrated senior health ~~campuses.~~campuses where leased percentage represents resident occupancy on the available units/beds therein.

4838

Table of Contents

Revenues and Grant Income

Our primary sources of revenue include ~~rent generated by our leased, non-RIDEA properties, and~~ resident fees and services revenue generated by our RIDEA properties and rent from our leased, non-RIDEA properties. For three months ended March 31, 2023 and 2022, resident fees and services revenue primarily consisted of rental fees related to resident leases, extended health care fees and other ancillary services, and real estate revenue primarily consisted of base rent and expense recoveries. The amount of revenues generated by our RIDEA properties depends principally on our ability to maintain resident occupancy rates at our RIDEA properties. The amount of revenues generated by our non-RIDEA properties ~~depends principally~~is dependent on our ability to maintain ~~the~~tenant occupancy rates of currently leased space and to lease available space at the then existing rental rates. We also receive grant income. Revenues and grant income by reportable segment consisted of the following for the periods then ended:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021		2022		2021				2023		2022
Resident Fees and Services Revenue	Resident Fees and Services Revenue									Resident Fees and Services Revenue
Integrated senior health campuses	Integrated senior health campuses	$	287,582,000	$	255,815,000	$	568,594,000	$	489,041,000	Integrated senior health campuses		$	361,770,000	$	281,012,000
SHOP	SHOP	38,643,000		20,537,000		76,605,000		40,337,000		SHOP		46,860,000		37,962,000
Total resident fees and services revenue	Total resident fees and services revenue	326,225,000		276,352,000		645,199,000		529,378,000		Total resident fees and services revenue		408,630,000		318,974,000
Real Estate Revenue	Real Estate Revenue									Real Estate Revenue
Medical office buildings		36,833,000		20,635,000		74,670,000		40,658,000
Skilled nursing facilities		6,599,000		3,661,000		12,992,000		7,328,000
MOBs										MOBs		37,483,000		37,837,000
SNFs										SNFs		(1,632,000)		6,393,000
Senior housing — leased	Senior housing — leased	5,262,000		3,606,000		10,560,000		7,176,000		Senior housing — leased		5,276,000		5,298,000
Hospitals	Hospitals	2,411,000		2,740,000		4,826,000		5,503,000		Hospitals		2,469,000		2,415,000
Total real estate revenue	Total real estate revenue	51,105,000		30,642,000		103,048,000		60,665,000		Total real estate revenue		43,596,000		51,943,000
Grant Income	Grant Income									Grant Income
Integrated senior health campuses	Integrated senior health campuses	10,969,000		898,000		16,065,000		9,127,000		Integrated senior health campuses		—		5,096,000
SHOP	SHOP	—		201,000		118,000		201,000		SHOP		—		118,000
Total grant income	Total grant income	10,969,000		1,099,000		16,183,000		9,328,000		Total grant income		—		5,214,000
Total revenues and grant income	Total revenues and grant income	$	388,299,000	$	308,093,000	$	764,430,000	$	599,371,000	Total revenues and grant income		$	452,226,000	$	376,131,000

Resident Fees and Services Revenue

For ~~the three and six months ended June 30, 2022 and 2021,~~our integrated senior health campuses segment, we experienced an increase in resident fees and services revenue ~~primarily consisted~~ of ~~rental fees related~~$43,080,000 for the three months ended March 31, 2023, as compared to ~~resident leases, extended~~the three months ended March 31, 2022, due to our acquisition of the 50.0% controlling interest in a privately held company, RHS Partners, LLC, or RHS, on August 1, 2022, which owns and/or operates 16 integrated senior health ~~care~~campuses located in Indiana. The remaining increase in resident fees and ~~other ancillary~~ services revenue for our integrated senior health campuses segment was primarily attributable to improved resident occupancy and ~~real estate~~higher resident fees as a result of an increase in billing rates. Such amounts were partially offset by a decrease in total resident fees and services revenue ~~primarily consisted~~ of ~~base rent~~$4,127,000 due to dispositions within our integrated senior health campuses segment during the third and ~~expense recoveries.~~ fourth quarter of 2022.

For our SHOP segment, we experienced an increase in resident fees and services revenue of $6,836,000 for the three ~~and six~~ months ended ~~June 30,~~March 31, 2023, as compared to the three months ended March 31, 2022, ~~$14,429,000 and $28,542,000, respectively,~~due to our acquisition of a portfolio of seven senior housing facilities in Texas within our SHOP segment on December 5, 2022, as well as an increase of $1,388,000 due to transitioning the SNFs within the Central Wisconsin Senior Care Portfolio to a RIDEA structure in March 2023. The remaining increase in resident fees and services revenue for our SHOP ~~was due to the increase in the size of our portfolio as a result of the Merger. The remaining increase in resident fees and services revenue~~segment was primarily attributable to improved ~~occupancy for our integrated senior health campuses, as well as increases in~~resident occupancy and Medicaid reimbursement rates at our SHOP. In addition, for the three and six months ended June 30, 2022, $22,297,000 and $44,629,000, respectively, of real estate revenue was primarily due to the increase in the size of our portfoliohigher resident fees as a result of ~~the Merger.~~an increase in billing rates. Such amounts were partially offset by a decrease ~~in rental revenue for our medical office buildings segment~~ of ~~$1,029,000 and $910,000 for the three and six months ended June 30, 2022, respectively, primarily~~$1,312,000 due to ~~a one-time lease termination fee recognized in June 2021 for one~~real estate dispositions within our SHOP segment during the fourth quarter of ~~our medical office buildings.~~2022.

Real Estate Revenue

For the three months ended ~~June 30,~~March 31, 2023, we experienced a decrease in rental revenue for our SNFs segment of $7,789,000 due to transitioning the SNFs within the Central Wisconsin Senior Care Portfolio to a RIDEA structure in March 2023, which amount predominantly included the full amortization of $8,073,000 of above-market leases. We also experienced a modest decrease in rental revenue for our MOBs segment primarily due to a disposition of a medical office building in Tennessee in December 2022.

Grant Income

For the three months ended March 31, 2023 and 2022, ~~and 2021,~~ we recognized ~~$10,969,000~~$0 and ~~$1,099,000,~~$5,214,000, respectively, of grant income at

Table of Contents

our integrated senior health campuses and SHOP primarily related to government grants received through the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, economic stimulus programs. For the six months ended June 30, 2022 and 2021, we recognized $16,183,000 and $9,328,000, respectively, of grant income at our integrated senior health campuses and SHOP related to government grants received through the CARES Act, economic stimulus programs.

~~Table of Contents~~

Property Operating Expenses and Rental Expenses

Property operating expenses and property operating expenses as a percentage of resident fees and services revenue and grant income, as well as rental expenses and rental expenses as a percentage of real estate revenue, by reportable segment consisted of the following for the periods then ended:


		Three Months Ended June 30,								Six Months Ended June 30,									Three Months Ended March 31,
		2022				2021				2022				2021						2023	2022
Property Operating Expenses	Property Operating Expenses																	Property Operating Expenses
Integrated senior health campuses	Integrated senior health campuses	$	258,934,000	86.7	%	$	232,991,000	90.8	%	$	512,084,000	87.6	%	$	461,630,000	92.7	%	Integrated senior health campuses			$	328,361,000	90.8	%	$	253,150,000	88.5	%
SHOP	SHOP	37,125,000		96.1	%	17,435,000		84.1	%	71,135,000		92.7	%	33,938,000		83.7	%	SHOP			41,785,000		89.2	%	34,010,000		89.3	%
Total property operating expenses	Total property operating expenses	$	296,059,000	87.8	%	$	250,426,000	90.3	%	$	583,219,000	88.2	%	$	495,568,000	92.0	%	Total property operating expenses			$	370,146,000	90.6	%	$	287,160,000	88.6	%

Rental Expenses	Rental Expenses																	Rental Expenses
Medical office buildings		$	13,791,000	37.4	%	$	7,588,000	36.8	%	$	28,104,000	37.6	%	$	15,125,000	37.2	%
Skilled nursing facilities		521,000		7.9	%	375,000		10.2	%	1,207,000		9.3	%	744,000		10.2	%
MOBs																		MOBs			$	14,408,000	38.4	%	$	14,313,000	37.8	%
SNFs																		SNFs			469,000		(28.7)	%	686,000		10.7	%
Senior housing — leased																		Senior housing — leased			199,000		3.8	%	179,000		3.4	%
Hospitals	Hospitals	139,000		5.8	%	126,000		4.6	%	248,000		5.1	%	260,000		4.7	%	Hospitals			119,000		4.8	%	109,000		4.5	%
Senior housing — leased		212,000		4.0	%	30,000		0.8	%	391,000		3.7	%	45,000		0.6	%
Total rental expenses	Total rental expenses	$	14,663,000	28.7	%	$	8,119,000	26.5	%	$	29,950,000	29.1	%	$	16,174,000	26.7	%	Total rental expenses			$	15,195,000	34.9	%	$	15,287,000	29.4	%

Integrated senior health campuses and SHOP typically have a higher percentage of direct operating expenses to revenue than ~~medical office buildings,~~MOBs, hospitals, and leased senior housing and ~~skilled nursing facilities~~SNFs due to the nature of ~~RIDEA — type~~RIDEA-type facilities where we conduct day-to-day operations. For the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, rental expenses increased by $6,379,000 and $12,921,000, respectively, and property operating expenses increased by $16,212,000 and $30,671,000, respectively, for our SHOP due to the increase in the size of our portfolio as a result of the Merger. Further, the remainingThe increase in total property operating expenses for our integrated senior health campuses segment was predominately due to an increase of $41,946,000 in property operating expenses attributable to our acquisition of the 50.0% controlling interest in RHS, as well as higher operating expenses as a result of increased occupancy. Such amounts were partially offset by a decrease in total property operating expenses of $3,599,000 due to dispositions within our integrated senior health campuses segment during the third and fourth quarters of 2022.

For the three months ended March 31, 2023, as compared to the three months ended March 31, 2022, total property operating expenses for our SHOP segment primarily increased due to: (i) an increase of $5,182,000 due to the acquisition of a portfolio of seven senior housing facilities within our SHOP segment in Texas on December 5, 2022; (ii) an increase of $1,211,000 due to transitioning the SNFs within the Central Wisconsin Senior Care Portfolio to a RIDEA structure in March 2023; (iii) higher operating expenses as a result of increased occupancy; and (iv) higher labor costs due to an increase in ~~labor costs at~~employee wages. Such amounts were partially offset by a decrease in total property operating expenses of $1,374,000 due to real estate dispositions within our SHOP ~~and integrated senior health campuses, such as a significant increase in employee wages, agency fees and temporary labor expenses.~~segment during the fourth quarter of 2022.

General and Administrative

For the three months ended ~~June 30, 2022,~~March 31, 2023, general and administrative expenses were ~~$10,928,000~~$13,053,000 compared to ~~$7,343,000~~$11,119,000 for the three months ended ~~June 30, 2021.~~March 31, 2022. The increase in general and administrative expenses of ~~$3,585,000~~$1,928,000 was primarily the result of an increase of: (i) ~~$5,398,000~~$1,043,000 in ~~payroll and compensation costs for the personnel hired as a result of the AHI Acquisition; (ii) $1,814,000 in~~ professional fees and legal fees; (ii) $514,000 in transition related expenses related to the transition of SNFs within the Central Wisconsin Senior Care Portfolio to a RIDEA structure; and (iii) ~~$1,173,000 in corporate operating expenses; and (iv) $1,001,000~~$295,000 in stock compensation expenses. ~~Such increases were partially offset by a decrease in our asset management and property management oversight fees of $5,723,000 as a result of the AHI Acquisition.~~

For the six months ended June 30, 2022, general and administrative expenses were $22,047,000 compared to $14,600,000 for the six months ended June 30, 2021. The increase in general and administrative expenses; of $7,447,000 was primarily the result of an increase of: (i) $11,272,000 in payroll and compensation costs for the personnel hired as a result of the AHI Acquisition; (ii) $3,133,000 in professional and legal fees; (iii) $2,131,000 in corporate operating expenses; and (iv) $1,226,000 in stock compensation expenses. Such increases were partially offset by a decrease in our asset management and property management oversight fees of $11,401,000 as a result of the AHI Acquisition.

~~Business Acquisition Expenses~~

For the three months ended June 30, 2022 and 2021, we recorded business acquisition expenses of $1,757,000 and $2,750,000, respectively, and for the six months ended June 30, 2022 and 2021, we recorded business acquisition expenses of $1,930,000 and $3,998,000, respectively. For the three and six months ended June 30, 2022, the decrease in such expenses primarily related to a decrease of $2,487,000 and $3,682,000, respectively, in third-party legal costs and professional services incurred related to the Merger and the AHI Acquisition, partially offset by $938,000 in transaction costs related to the acquisition of a pharmaceutical business in April 2022 and $556,000 and $676,000, respectively, in dead-deal costs incurred in the pursuit of real estate investments that did not close. See Note 4, Business Combinations, to our accompanying condensed consolidated financial statements for a further discussion of our acquisition of a pharmaceutical business.

~~Table of Contents~~

Depreciation and Amortization

For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ depreciation and amortization was ~~$39,971,000~~$44,670,000 and ~~$26,357,000,~~$42,311,000, respectively, which primarily consisted of depreciation on our operating properties of ~~$34,328,000~~$35,899,000 and ~~$24,663,000,~~$34,422,000, respectively, and amortization of our identified intangible assets of ~~$5,008,000~~$7,988,000 and ~~$1,244,000,~~$7,125,000, respectively. For the six months ended June 30, 2022 and 2021, depreciation and amortization was $82,282,000 and $52,080,000, respectively, which primarily consisted of depreciation on our operating properties of $68,750,000 and $48,853,000, respectively, and amortization of our identified intangible assets of $12,133,000 and $2,357,000, respectively.

For the three ~~and six~~ months ended ~~June 30, 2022,~~March 31, 2023, the increase in depreciation and amortization of ~~$13,614,000 and $30,202,000, respectively,~~$2,359,000 was primarily ~~the~~due to an increase in depreciation and amortization within our SHOP segment and our integrated senior health campuses segment of $2,668,000 and $2,348,000, respectively, as a result of acquisitions that occurred subsequent to March 31, 2022, as well as the ~~increase~~full amortization of $885,000 of in-place leases related to transition of SNFs within the Central Wisconsin Senior Care Portfolio to a RIDEA structure. Such amounts were partially offset by a decrease of $3,581,000 in depreciation and amortization primarily due to a decrease in depreciable assets in our portfolio as a result of ~~the Merger resulting in depreciation~~real estate dispositions within our SHOP segment and ~~amortization expense~~our MOBs segment subsequent to March 31, 2022.

Table of ~~$12,432,000 and $27,386,000, respectively.~~Contents

Interest Expense

Interest expense, including gain or loss in fair value of derivative financial instruments, consisted of the following for the periods presented:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021		2022		2021				2023		2022
Interest expense:	Interest expense:									Interest expense:
Lines of credit and term loans and derivative financial instruments		$	9,027,000	$	7,880,000	$	16,576,000	$	15,474,000
Lines of credit and term loan and derivative financial instruments										Lines of credit and term loan and derivative financial instruments		$	23,269,000	$	7,549,000
Mortgage loans payable	Mortgage loans payable	9,608,000		8,715,000		19,152,000		17,300,000		Mortgage loans payable		13,160,000		9,544,000
Amortization of deferred financing costs:	Amortization of deferred financing costs:									Amortization of deferred financing costs:
Lines of credit and term loans		724,000		1,075,000		1,533,000		2,150,000
Lines of credit and term loan										Lines of credit and term loan		856,000		809,000
Mortgage loans payable	Mortgage loans payable	492,000		380,000		933,000		719,000		Mortgage loans payable		577,000		441,000
Amortization of debt discount/premium, net	Amortization of debt discount/premium, net	347,000		202,000		330,000		405,000		Amortization of debt discount/premium, net		885,000		(17,000)
Gain in fair value of derivative financial instruments		—		(1,775,000)		(500,000)		(3,596,000)
(Gain) loss on extinguishments of debt		(181,000)		5,000		4,410,000		2,293,000
Gain (loss) in fair value of derivative financial instruments										Gain (loss) in fair value of derivative financial instruments		195,000		(500,000)
Loss on extinguishments of debt										Loss on extinguishments of debt		—		4,591,000
Interest on finance lease liabilities	Interest on finance lease liabilities	66,000		74,000		140,000		192,000		Interest on finance lease liabilities		91,000		74,000
Interest expense on financing obligations and other liabilities	Interest expense on financing obligations and other liabilities	262,000		159,000		596,000		322,000		Interest expense on financing obligations and other liabilities		173,000		334,000
Total	Total	$	20,345,000	$	16,715,000	$	43,170,000	$	35,259,000	Total		$	39,206,000	$	22,825,000

~~For the three months ended June 30, 2022,~~The increase in total interest expense ~~was $20,345,000 compared to $16,715,000~~ for the three months ended ~~June 30, 2021. The increase in total interest expense~~March 31, 2023, as compared to the three months ended March 31, 2022, was primarily related to an increase in variable interest ~~expense incurred~~rates on our ~~lines of credit~~outstanding variable rate debt and term loans and mortgage loans payable due to a larger debt portfolio as a result of the Merger, as well as a $1,775,000 decrease in the gain in fair value recognized on our interest rate swap contracts that matured on January 25, 2022. For the six months ended June 30, 2022, interest expense was $43,170,000 compared to $35,259,000 for the six months ended June 30, 2021. The increase in total interest expense was primarily related to an increase in interest expense incurred on our lines of credit and term loans and mortgage loans payable due to a larger debt portfolio as a result of the Merger, as well as a decrease in the ~~gain in~~ fair value recognized on our derivative financial instruments of ~~$3,096,000 and an increase~~$695,000, partially offset by a decrease in loss on debt extinguishment of ~~$2,117,000.~~$4,591,000. See Note 8,7, Mortgage Loans Payable, Net, and Note 9,8, Lines of Credit and Term ~~Loans,~~Loan, to our accompanying condensed consolidated financial statements for a further discussion on debt extinguishments.

~~Impairment~~Gain on Re-measurement of ~~Real Estate Investments~~Previously Held Equity Interest

For the three ~~and six~~ months ended ~~June 30, 2022,~~March 31, 2023, we recognized ~~an impairment charge~~a $726,000 gain on re-measurement of ~~$17,340,000 on four~~the fair value of our ~~SHOP within the Central Florida Senior Housing Portfolio.~~previously held equity interest in Memory Care Partners, LLC, or MCP. For the three ~~and six~~ months ended ~~June 30, 2021,~~March 31, 2022, we ~~recognized an impairment charge~~did not recognize a gain on re-measurement of ~~$3,335,000 on a medical office building, Mount Dora Medical Center.~~previously held equity interest. See Note 3, Real Estate Investments, Net and Business Combinations, to our accompanying condensed consolidated financial statements for a further discussion.

Liquidity and Capital Resources

In the normal course of business, our material cash requirements consist of payment of operating expenses, capital improvement expenditures, interest on our indebtedness, distributions to our stockholders (including distributions necessary to maintain our qualification as a REIT), and ~~repurchases of our common stock~~general and administrative expenses. Our sources of funds primarily consist of operating cash flows and borrowings. We do not have any material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

~~Table of Contents~~

Material Cash Requirements

Capital Improvement Expenditures

A capital plan for each investment is established upon acquisition that contemplates the estimated capital needs of that investment, including costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan also sets forth the anticipated sources of the necessary capital, which may include operating cash generated by the investment, capital reserves, a line of credit or other loan established with respect to the investment, other borrowings or additional equity investments from us and joint venture partners. The capital plan for each investment is adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. As of ~~June 30, 2022,~~March 31, 2023, we had ~~$17,736,000~~$17,202,000 of restricted cash in loan impounds and reserve accounts to fund a portion of such capital expenditures. Based on the budget for the properties we owned as of ~~June 30, 2022,~~March 31, 2023, we estimated that unspent discretionary expenditures for capital and tenant improvements as of such date are equal to ~~$82,920,000~~$57,115,000 for the remaining ~~six~~nine months of ~~2022,~~2023, although actual expenditures are dependent on many factors which are not presently known.

Table of Contents

Contractual Obligations

The following table provides information with respect to: (i) the maturity and scheduled principal repayment of our secured mortgage loans payable and our lines of credit and term ~~loans;~~loan; (ii) interest payments on our mortgage loans payable and lines of credit and term ~~loans;~~loan, excluding the effect of our interest rate swap (for information on our interest rate swap, see Note 9, Derivative Financial Instruments, to our accompanying condensed consolidated financial statements); (iii) ground and other lease obligations; and (iv) financing obligations as of ~~June 30, 2022:~~March 31, 2023:


		Payments Due by Period											Payments Due by Period
		2022		2023-2024		2025-2026		Thereafter		Total			2023		2024-2025		2026-2027		Thereafter		Total
Principal payments — fixed-rate debt	Principal payments — fixed-rate debt	$	25,507,000	$	106,157,000	$	184,034,000	$	510,768,000	$	826,466,000	Principal payments — fixed-rate debt	$	14,270,000	$	208,919,000	$	189,173,000	$	468,408,000	$	880,770,000
Interest payments — fixed-rate debt	Interest payments — fixed-rate debt	12,890,000		46,823,000		38,564,000		202,140,000		300,417,000		Interest payments — fixed-rate debt	21,319,000		48,168,000		31,924,000		183,891,000		285,302,000
Principal payments — variable-rate debt	Principal payments — variable-rate debt	221,000		610,976,000		413,626,000		569,345,000		1,594,168,000		Principal payments — variable-rate debt	450,203,000		234,681,000		978,298,000		27,239,000		1,690,421,000
Interest payments — variable-rate debt (based on rates in effect as of June 30, 2022)		29,239,000		83,219,000		51,603,000		4,235,000		168,296,000
Interest payments — variable-rate debt (based on rates in effect as of March 31, 2023)												Interest payments — variable-rate debt (based on rates in effect as of March 31, 2023)	76,739,000		141,235,000		43,580,000		6,125,000		267,679,000
Ground and other lease obligations	Ground and other lease obligations	7,116,000		26,858,000		22,672,000		144,289,000		200,935,000		Ground and other lease obligations	29,017,000		74,975,000		75,146,000		229,083,000		408,221,000
Financing obligations	Financing obligations	2,702,000		5,366,000		3,048,000		16,241,000		27,357,000		Financing obligations	28,422,000		5,228,000		3,732,000		14,963,000		52,345,000
Total	Total	$	77,675,000	$	879,399,000	$	713,547,000	$	1,447,018,000	$	3,117,639,000	Total	$	619,970,000	$	713,206,000	$	1,321,853,000	$	929,709,000	$	3,584,738,000

Distributions and Share Repurchases

For information on distributions, see the “Distributions” section below. For information on our share repurchase plan, see Note ~~14,~~13, Equity — Share Repurchase Plan, to our accompanying condensed consolidated financial statements.

Credit Facilities

~~On January 19, 2022, we terminated our~~We are party to a credit agreement, as amended, ~~for our line of credit and term loans~~ with an aggregate maximum principal amount of $530,000,000, or the 2018 Credit Facility, and, through our operating partnership, entered into an agreement that superseded and replaced our amended credit facility with a maximum principal amount of $480,000,000, or the 2019 Credit Facility, with a credit facility with an aggregate maximum principal amount of up to ~~$1,050,000,000,~~$1,050,000,000, or the 2022 Credit Facility. ~~See Note 9, Lines of Credit and Term Loans, to our accompanying condensed consolidated financial statements for a further discussion.~~ In addition, we are ~~subject~~party to an agreement, as amended, ~~and restated loan agreement~~ regarding a senior secured revolving credit facility with an aggregate maximum principal amount of ~~$360,000,000,~~$400,000,000, or the 2019 Trilogy Credit ~~Facility. Our total capacity~~Facility, which is scheduled to mature on September 5, 2023. See Note 8, Lines of Credit and Term Loan, to our accompanying condensed consolidated financial statements for a further discussion. We intend to satisfy the certain conditions pursuant to the 2019 Trilogy Credit Facility and pay ~~operating expenses, capital improvement expenditures, interest, distributions and repurchases is a function of~~the required extension fee in order to exercise our ~~current cash position, our borrowing capacity on our lines of credit and term loans, as well as any future indebtedness that we may incur.~~option to extend the maturity date for one 12-month period.

As of ~~June 30, 2022,~~March 31, 2023, our aggregate borrowing capacity under the 2022 Credit Facility and the 2019 Trilogy Credit Facility was ~~$1,410,000,000.~~$1,450,000,000. As of ~~June 30, 2022,~~March 31, 2023, our aggregate borrowings outstanding under our credit facilities was ~~$1,267,634,000~~$1,314,134,000 and we had an aggregate of ~~$142,366,000~~$135,866,000 available on such facilities. We believe that the resources described above will be sufficient to satisfy our cash requirements for the ~~foreseeable future.~~

~~Table of Contents~~

next 12 months and the longer term thereafter.

Cash Flows

The following table sets forth changes in cash flows:


		Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021			2023		2022
Cash, cash equivalents and restricted cash — beginning of period	Cash, cash equivalents and restricted cash — beginning of period	$	125,486,000	$	152,190,000	Cash, cash equivalents and restricted cash — beginning of period	$	111,906,000	$	125,486,000
Net cash provided by operating activities	Net cash provided by operating activities	56,138,000		3,579,000		Net cash provided by operating activities	23,862,000		22,360,000
Net cash used in investing activities	Net cash used in investing activities	(97,364,000)		(124,165,000)		Net cash used in investing activities	(33,319,000)		(27,367,000)
Net cash provided by financing activities		19,924,000		86,471,000
Net cash used in financing activities						Net cash used in financing activities	(14,300,000)		(1,307,000)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	Effect of foreign currency translation on cash, cash equivalents and restricted cash	(8,000)		(27,000)		Effect of foreign currency translation on cash, cash equivalents and restricted cash	80,000		(2,000)
Cash, cash equivalents and restricted cash — end of period	Cash, cash equivalents and restricted cash — end of period	$	104,176,000	$	118,048,000	Cash, cash equivalents and restricted cash — end of period	$	88,229,000	$	119,170,000

The following summary discussion of our changes in our cash flows is based on our accompanying condensed consolidated statements of cash flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.

Table of Contents

Operating Activities

~~The increase in net~~For the three months ended March 31, 2023 and 2022, cash flows provided by operating activities ~~of $52,559,000 was~~were primarily ~~due~~related to the ~~increase in the size~~cash flows provided by our property operations, offset by payments of general and administrative expenses and interest payments on our ~~portfolio as a result of the Merger on October 1, 2021, thereby increasing our net operating income during the six months ended June 30, 2022, as compared to the prior year period.~~outstanding indebtedness. In general, cash flows from operating activities are affected by the timing of cash receipts and payments. See the “Results of Operations” section above for a further discussion.

Investing Activities

The ~~decrease~~increase in net cash used in investing activities of ~~$26,801,000~~$5,952,000 was primarily due to a ~~$12,602,000 increase~~$7,173,000 decrease in proceeds from dispositions of real estate, a ~~$10,669,000 decrease~~$5,800,000 increase in investments in unconsolidated entities and a $644,000 increase in developments and capital ~~expenditures~~expenditures. Such amounts were partially offset by an $8,198,000 decrease in cash paid to acquire real estate investments. See Note 3, Real Estate Investments, Net and Business Combinations, to our accompanying condensed consolidated financial statements for a further discussion of our acquisitions.

Financing Activities

The increase in net cash used in financing activities of $12,993,000 was primarily due to a $15,803,000 payment to redeem a portion of the equity interests owned by a current member of Trilogy Investors, LLC management and a ~~$3,421,000~~ decrease in ~~property acquisitions~~borrowings under our mortgage loans payable of $14,789,000 during the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 as compared to the prior year period.

~~Financing Activities~~

The decrease in net cash provided by financing activities of $66,547,000 was primarily due to a decrease in net borrowings under our mortgage loans payable of $55,177,000 and a $6,697,000 increase in distributions to noncontrolling interests during the six months ended June 30, 2022 as compared to the prior year period, as well as the $30,247,000 payment of distributions to our common stockholders and a $10,583,000 payment to repurchase our common stock for the six months ended June 30, 2022. Such amounts were partially offset by an increase in net borrowings under our lines of credit and term loans of $47,400,000 during the six months ended June 30, 2022 as compared to the prior year period. The change in distributions paid to common stockholders was due to the suspension of all stockholder distributions on May 29, 2020 in response to the impact of the COVID-19 pandemic, which the board of directors of GAHR III subsequently reinstated in June 2021. The change in share repurchases was due to the suspension of the GAHR III share repurchase plan from May 31, 2020 through October 4, 2021, when the partial reinstatement of our share repurchase plan was approved by our board.$19,000,000.

Distributions

The following information represents distributions of GAHR IV for the period before the consummation of the Merger between GAHR III and GAHR IV on October 1, 2021. Since October 1, 2021, the information included below represents the distributions of the Combined Company.

Prior to March 31, 2020, the GAHR IV board authorized a daily distribution to our stockholders of record as of the close of business on each day of the period commencing on May 1, 2016 and ending on March 31, 2020. The daily distributions were calculated based on 365 days in the calendar year and were equal to $0.001643836 per share of our Class T and Class I common stock, which was equal to an annualized distribution rate of $0.60 per share. These distributions were aggregated and paid in cash or shares of our common stock pursuant to the DRIP on a monthly basis, in arrears, only from legally available funds.

In response to the COVID-19 pandemic and its effects to our business and operations, at the end of the first quarter of 2020, the GAHR IV board decided to take steps to protect our capital and maximize our liquidity in an effort to strengthen our long-term financial prospects by reducing our distribution payments to stockholders. Consequently, the GAHR IV board authorized a daily distribution to our stockholders of record as of the close of business on each day of the period commencing on April 1, 2020 and ending on August 31, 2021, which was calculated based on 365 days in the calendar year and was equal to $0.001095890 per share of our Class T and Class I common stock. Such daily distribution was equal to an annualized

~~Table of Contents~~

distribution rate of $0.40 per share. The distributions were aggregated and paid in cash or shares of our common stock pursuant to the DRIP on a monthly basis, in arrears, only from legally available funds.

The GAHR IV board of directors also authorized distributions to our Class T and Class I stockholders of record as of the close of business on September 17, 2021, equal to $0.0328767 per share of our common stock, which was equal to an annualized distribution of $0.40 per share. Further, ourOur board authorized record date distributions to our Class T common stockholders and Class I common stockholders of record as of each monthly record date from ~~October 2021~~January 2022 through June 2022, equal to ~~$0.033333333~~$0.133333332 per share of our common stock, which was equal to an annualized distribution rate of ~~$0.40~~$1.60 per share. The distributions were paid in cash or shares of our common stock pursuant to the ~~DRIP. Beginning~~DRIP offering. Effective beginning with the third quarter of 2022, distributions, if any, were or shall be authorized by our board on a quarterly basis, in such amounts as our board determined or shall determine, and each quarterly record date for the purposes of such distributions was or shall be determined and ~~declared~~authorized by our board in the last month of each calendar quarter until such time as our board changes ~~such~~our distribution policy. ~~Stockholders who have elected~~Our board authorized a quarterly distribution to ~~participate in~~ our ~~DRIP will continue~~Class T common stockholders and Class I common stockholders of record as of the close of business on September 29, 2022. Such quarterly distribution was equal to ~~have their distributions reinvested to purchase additional shares~~$0.40 per share of our common stock, ~~but on a quarterly basis beginning with any third quarter 2022~~which was equal to an annualized distribution ~~declared.~~

~~On March 18, 2021, in connection with the GAHR IV special committee's strategic alternative review process, the GAHR IV board~~rate of ~~directors authorized the suspension of the DRIP, effective as of April 1, 2021. As a result, beginning with the April 2021 distributions, which were~~$1.60 per share and paid in ~~May 2021, there were no further issuances of shares pursuant to the DRIP, and stockholders who were participants in the DRIP received~~ cash distributions instead. On October 4, 2021, our board authorized the reinstatement of the DRIP and as a result, beginning with the October 2021 distribution, which was paid in November 2021, stockholders who previously enrolled as participants in the DRIP (including former GAHR III stockholders who participated in the GAHR III distribution reinvestment plan) received distributions inor shares of our common stock pursuant to the ~~terms~~DRIP offering, only from legally available funds.

On November 14, 2022, our board suspended the DRIP offering beginning with distributions declared, if any, for the quarter ending December 31, 2022. As a result of the suspension of the DRIP ~~instead~~offering, unless and until our board reinstates the DRIP offering, stockholders who are current participants in the DRIP will be paid distributions in cash. Our board authorized a quarterly distribution to our Class T common stockholders and Class I common stockholders of ~~cash distributions.~~

~~The amount~~record as of the close of business on December 29, 2022. Such quarterly distribution was equal to $0.40 per share of our common stock, which was equal to an annualized distribution rate of $1.60 per share and paid in cash, only from legally available funds.

In response to interest rates that have increased drastically since the beginning of 2022, and greater uncertainty surrounding further interest rate movements, our board elected to reduce our quarterly distribution to $0.25 per share in order to preserve our liquidity, better align distributions ~~paid~~with available cash flows and position our company for its long-term strategic goals. Our board authorized a reduced quarterly distribution from $0.40 per share to $0.25 per share to our Class T common stockholders ~~was determined quarterly or monthly,~~and Class I common stockholders of record as ~~applicable, by our board and was dependent on a number~~ of factors, including funds available for payment of distributions, our financial condition, capital expenditure requirements and annual distribution requirements needed to maintain our qualification as a REIT under the Code. We have not established any limit on the amount of borrowings that may be used to fund distributions, except that, in accordance with our organizational documents and Maryland law, we may not make distributions that would: (i) cause us to be unable to pay our debts as they become due in the usual courseclose of business ~~or (ii) cause~~on April 4, 2023. Such quarterly distribution was equal to an annualized distribution rate of $1.00 per share and paid in cash, only from legally available funds. See our ~~total assets to be less than~~Current Report on Form 8-K filed with the ~~sum~~SEC on March 17, 2023 for more information.

Table of ~~our total liabilities plus senior liquidation preferences.~~Contents

~~GAHR III did not pay any distributions for the six months ended June 30, 2021.~~ The following tables reflect distributions we paid for the ~~six~~three months ended ~~June 30,~~March 31, 2023 and 2022, along with the amount of distributions reinvested pursuant to the ~~AHR~~ DRIP and the sources of ~~our~~ distributions as compared to cash flows from operations or funds from operations attributable to controlling interest, or FFO, a non-GAAP financial measure:


									Three Months Ended March 31,
		Six Months Ended June 30, 2022			2023						2022
Distributions paid in cash	Distributions paid in cash		$	30,247,000				Distributions paid in cash	$	26,492,000			$	15,010,000
Distributions reinvested	Distributions reinvested		22,447,000					Distributions reinvested	—				11,304,000
			$	52,694,000					$	26,492,000			$	26,314,000
Sources of distributions:	Sources of distributions:							Sources of distributions:
Cash flows from operations	Cash flows from operations		$	52,694,000		100	%	Cash flows from operations	$	23,862,000	90.1	%	$	22,360,000	85.0	%
Proceeds from borrowings	Proceeds from borrowings		—			—		Proceeds from borrowings	2,630,000		9.9		3,954,000		15.0

			$	52,694,000		100	%		$	26,492,000	100	%	$	26,314,000	100	%

Six Months Ended
June 30, 2022
Distributions paid in cash $ 30,247,000
Distributions reinvested 22,447,000
$ 52,694,000
Sources of distributions:
FFO attributable to controlling interest $ 52,694,000 100 %
Proceeds from borrowings — —
$ 52,694,000 100 %

~~Table of Contents~~


	Three Months Ended March 31,
	2023				2022
Distributions paid in cash	$	26,492,000			$	15,010,000
Distributions reinvested	—				11,304,000
	$	26,492,000			$	26,314,000
Sources of distributions:
FFO attributable to controlling interest	$	11,691,000	44.1	%	$	26,314,000	100	%
Proceeds from borrowings	14,801,000		55.9		—		—

	$	26,492,000	100	%	$	26,314,000	100	%

As of ~~June 30, 2022,~~March 31, 2023, any distributions of amounts in excess of our current and accumulated earnings and profits have resulted in a return of capital to our stockholders, and some portion of a distribution to our stockholders may have been paid from borrowings. For a further discussion of FFO, including a reconciliation of our GAAP net loss to FFO, see “Funds from Operations and ~~Modified~~Normalized Funds from Operations,” below.

Financing

We anticipate that our overall leverage will ~~not exceed~~approximate 50.0% of the combined fair market value of all of our properties, and other real estate-related investments, as determined at the end of each calendar year. For these purposes, the market value of each asset will be equal to the contract purchase price paid for the asset or, if the asset was appraised subsequent to the date of purchase, then the market value will be equal to the value reported in the most recent independent appraisal of the asset. Our policies do not limit the amount we may borrow with respect to any individual investment. As of ~~June 30, 2022,~~March 31, 2023, our aggregate borrowings were ~~47.4%~~53.4% of the combined market value of all of our real estate and real estate-related investments.

Mortgage Loans Payable, Net

For a discussion of our mortgage loans payable, see Note 8,7, Mortgage Loans Payable, Net, to our accompanying condensed consolidated financial statements.

Lines of Credit and Term ~~Loans~~Loan

For a discussion of our lines of credit and term ~~loans,~~loan, see Note 9,8, Lines of Credit and Term ~~Loans,~~Loan, to our accompanying condensed consolidated financial statements.

Table of Contents

REIT Requirements

In order to maintain our qualification as a REIT for U.S. federal income tax purposes, we are required to distribute to our stockholders a minimum of 90.0% of our ~~annual~~REIT taxable ~~income, excluding net capital gains.~~income. Existing Internal Revenue Service, or IRS, guidance includes a safe harbor pursuant to which publicly offered REITs can satisfy the distribution requirement by distributing a combination of cash and stock to stockholders. In general, to qualify under the safe harbor, each stockholder must elect to receive either cash or stock, and the aggregate cash component of the distribution to stockholders must represent at least 20.0% of the total distribution. In the event that there is a shortfall in net cash available due to factors including, without limitation, the timing of such distributions or the timing of the collection of receivables, we may seek to obtain capital to ~~pay~~make distributions by means of secured and unsecured debt financing through one or more unaffiliated third parties. We may also ~~pay~~make distributions ~~from~~with cash from capital transactions including, without limitation, the sale of one or more of our properties.

Commitments and Contingencies

For a discussion of our commitments and contingencies, see Note ~~12,~~11, Commitments and Contingencies, to our accompanying condensed consolidated financial statements.

Debt Service Requirements

A significant liquidity need is the payment of principal and interest on our outstanding indebtedness. As of ~~June 30, 2022,~~March 31, 2023, we had ~~$1,152,998,000~~$1,257,057,000 of fixed-rate and variable-rate mortgage loans payable outstanding secured by our properties. As of ~~June 30, 2022,~~March 31, 2023, we had ~~$1,267,634,000~~$1,314,134,000 outstanding and ~~$142,366,000~~$135,866,000 remained available under our lines of credit. The weighted average effective interest rate on our outstanding debt, factoring in our interest rate swap, was ~~3.43%~~5.56% per annum as of ~~June 30, 2022.~~March 31, 2023. See Note 8,7, Mortgage Loans Payable, Net and Note 9,8, Lines of Credit and Term ~~Loans,~~Loan, to our accompanying condensed consolidated financial statements.

We are required by the terms of certain loan documents to meet various financial and non-financial covenants, such as leverage ratios, net worth ratios, debt service coverage ratios and fixed charge coverage ratios. As of ~~June 30, 2022,~~March 31, 2023, we were in compliance with all such covenants and requirements on our mortgage loans payable and our lines of credit and term loans. While the extent and severity of the COVID-19 pandemic on our business has been subsiding, any potential future deterioration of operations in excess of management's projections as a result of COVID-19 could impact future compliance with these covenants.loan. If any future covenants are violated, we anticipate seeking a waiver or amending the debt covenants with the lenders when and if such event should occur. However, there can be no assurances that management will be able to effectively achieve such plans.

~~Table of Contents~~

~~Inflation~~

During the six months ended June 30, 2022 and 2021, inflation has not significantly affected our operations; however, the annual rate of inflation in the United States reached 8.5% in July 2022, as measured by the Consumer Price Index, and while we believe inflation has not significantly impacted our operations, we have experienced, and continue to experience, increases in the cost of labor, services and personal protective equipment and therefore continued inflationary pressures could impact our profitability in future periods. There are provisions in the majority of our tenant leases that will protect us from the impact of inflation. These provisions include negotiated rental increases, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements. However, due to the long-term nature of the anticipated leases, among other factors, the leases may not reset frequently enough to cover inflation.

~~Related Party Transactions~~

~~For a summary of related party transactions, see Note 15, Related Party Transactions, to our accompanying condensed consolidated financial statements~~, ~~and Note 15, Related Party Transactions, to the consolidated financial statements that are a part of our 2021 Annual Report on Form 10-K, as filed with the SEC on March 25, 2022.~~

Funds from Operations and ~~Modified~~Normalized Funds from Operations

Due to certain unique operating characteristics of real estate companies, the National Association of Real Estate Investment Trusts, or NAREIT, an industry trade group, has promulgated a measure known as funds from operations, a non-GAAP financial measure, which we believe to be an appropriate supplemental performance measure to reflect the operating performance of a REIT. The use of funds from operations is recommended by the REIT industry as a supplemental performance measure, and our management uses FFO to evaluate our performance over time. FFO is not equivalent to our net income (loss) as determined under GAAP.

We define FFO, a non-GAAP financial measure, consistent with the standards established by the White Paper on funds from operations approved by the Board of Governors of NAREIT, or the White Paper. The White Paper defines funds from operations as net income (loss) computed in accordance with GAAP, excluding gains or losses from sales of certain real estate assets, gains or losses upon consolidation of a previously held equity interest, and impairment writedowns of certain real estate assets and investments, plus depreciation and amortization related to real estate, and after adjustments for unconsolidated partnerships and joint ventures. While impairment charges are excluded from the calculation of FFO as described above, investors are cautioned that impairments are based on estimated future undiscounted cash flows. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect funds from operations. Our FFO calculation complies with NAREIT’s policy described above.

Historical accounting for real estate involves the use of GAAP. Any other method of accounting for real estate such as the fair value method cannot be construed to be any more accurate or relevant than the comparable methodologies of real estate valuation found in GAAP. Nevertheless, we believe that the use of FFO, which excludes the impact of real estate-related depreciation and amortization and impairments, provides a further understanding of our operating performance to investors, industry analysts and to our management, and when compared year over year, reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses and interest costs, which may not be immediately apparent from net income (loss).

~~However,~~We define normalized FFO ~~and modified funds from operations~~ attributable to controlling interest, or ~~MFFO,~~NFFO, as described below, should not be construed to be more relevant or accurate than the current GAAP methodology in calculating net income (loss) or in its applicability in evaluating our operating performance. The method utilized to evaluate the value and performance of real estate under GAAP should be construed as a more relevant measure of operational performance and considered more prominently than the non-GAAP FFO ~~and MFFO measures and the adjustments to GAAP in calculating FFO and MFFO.~~

The IPA, an industry trade group, has standardized a measure known as modified funds from operations, which the IPA has recommended as a supplemental performance measure for publicly registered, non-listed REITs and which we believe to be another appropriate supplemental performance measure to reflect the operating performance of a publicly registered, non-listed REIT having the characteristics described above. MFFO is not equivalent to our net income (loss) as determined under GAAP, and MFFO may not be a useful measure of the impact of long-term operating performance on value if we do not continue to operate with a limited life and targeted exit strategy, as currently intended. We believe that, because MFFO excludes expensed acquisition fees and expenses that affect our operations only in periods in which properties are acquired and that we consider more reflective of investing activities, as well as other non-operating items included in FFO, MFFO can provide, on a going forward basis, an indication of the sustainability (that is, the capacity to continue to be maintained) of our operating performance after the period in which we are acquiring our properties and once our portfolio is in place. By providing MFFO, we believe we are presenting useful information that assists investors and analysts to better assess the sustainability of our operating performance after the initial offering stage has been completed and our properties have been acquired. We also believe that MFFO is a recognized measure of sustainable operating performance by the publicly registered, non-listed REIT

~~Table of Contents~~

industry. Further, we believe MFFO is useful in comparing the sustainability of our operating performance after our offering stage and acquisitions are completed with the sustainability of the operating performance of other real estate companies that are not as involved in acquisition activities. Investors are cautioned that MFFO should only be used to assess the sustainability of our operating performance after the initial offering stage has been completed and properties have been acquired, as it excludes expensed acquisition fees and expenses that have a negative effect on our initial operating performance during the periods in which properties are acquired.

~~We define MFFO, a non-GAAP measure, consistent with the Practice Guideline 2010-01,~~ ~~Supplemental Performance Measure for Publicly Registered, Non-Listed REITs: Modified Funds from Operations, or the Practice Guideline, issued by the IPA in November 2010. The Practice Guideline defines modified funds from operations as funds from operations~~ further adjusted for the following items included in the determination of GAAP net income (loss): expensed acquisition fees and ~~costs;~~costs, which we refer to as business acquisition expenses; amounts relating to changes in deferred rent and amortization of above- and below-market leases ~~and liabilities~~ (which

Table of Contents

are adjusted in order to reflect such payments from a GAAP accrual ~~basis~~basis); the non-cash impact of changes to ~~closer to an expected to be received cash basis~~our equity instruments; non-cash or non-recurring income or expense; the non-cash effect of ~~disclosing the rent and lease payments); accretion~~income tax benefits or expenses; capitalized interest; impairment of ~~discounts and~~goodwill; amortization of ~~premiums~~closing costs on debt investments; mark-to-market adjustments included in net income (loss); gains or losses included in net income (loss) from the extinguishment or sale of debt, hedges, foreign exchange, derivatives or securities holdings where trading of such holdings is not a fundamental attribute of the business plan; ~~unrealized gains or losses resulting from consolidation from, or deconsolidation to, equity accounting;~~ and after adjustments for consolidated and unconsolidated partnerships and joint ventures, with such adjustments calculated to reflect ~~modified funds from operations~~NFFO on the same basis. ~~Our MFFO calculation complies with~~

However, FFO and NFFO should not be construed to be more relevant or accurate than the ~~IPA’s Practice Guideline described above.~~

~~Our management uses MFFO~~current GAAP methodology in calculating net income (loss) as an indicator of our operating performance or GAAP cash flows from operations as an indicator of our liquidity. The method utilized to evaluate the value and performance of real estate under GAAP should be construed as a more relevant measure of operational performance and considered more prominently than the non-GAAP FFO and NFFO measures and the adjustments ~~used~~ to ~~calculate it~~GAAP in ~~order to evaluate our performance against other publicly registered, non-listed REITs which intend to have limited lives with short~~calculating FFO and defined acquisition periods and targeted exit strategies shortly thereafter. As noted above, MFFO may not be a useful measure of the impact of long-term operating performance if we do not continue to operate in this manner. We believe that our use of MFFO and the adjustments used to calculate it allow us to present our performance in a manner that reflects certain characteristics that are unique to publicly registered, non-listed REITs, such as their limited life, limited and defined acquisition period and targeted exit strategy, and hence, that the use of such measures may be useful to investors.

NFFO. Presentation of this information is intended to provide useful information to management, investors and industry analysts as they compare the operating performance ~~of different REITs,~~used by the REIT industry, although it should be noted that not all REITs calculate funds from operations and ~~modified~~normalized funds from operations the same way, so comparisons with other REITs may not be meaningful. ~~Furthermore, FFO and MFFO are not necessarily indicative~~None of cash flow available to fund cash needs and should not be considered as an alternative to net income (loss) as an indication of our performance, as an alternative to cash flows from operations, which is an indication of our liquidity, or indicative of funds available to fund our cash needs including our ability to make distributions to our stockholders. FFO and MFFO should be reviewed in conjunction with other measurements as an indication of our performance. MFFO may be useful in assisting management and investors in assessing the sustainability of operating performance in future operating periods, and in particular, after the offering and acquisition stages are complete. FFO and MFFO are not useful measures in evaluating net asset value because impairments are taken into account in determining net asset value but not in determining FFO and MFFO.

~~Neither~~ the SEC, NAREIT, ~~nor~~or any other regulatory body has passed judgment on the acceptability of the adjustments that we use to calculate FFO or ~~MFFO.~~NFFO. In the future, the SEC, NAREIT, or another regulatory body may decide to standardize the allowable adjustments across the ~~publicly registered, non-listed~~ REIT industry and we would have to adjust our calculation and characterization of ~~FFO or MFFO.~~FFO.

For the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recognized government grants as grant income or as a reduction of property operating expenses, as applicable, and within income or loss from unconsolidated entities. Such amounts were granted through federal and state government programs, such as through the CARES Act, and which were established for eligible healthcare providers to preserve liquidity in response to the COVID-19 pandemic. See the “Results of Operations” section above for a further discussion. The government grants helped mitigate some of the negative impact that the COVID-19 pandemic had on our financial condition and results of operations. Without such relief funds, the COVID-19 pandemic would have had a material adverse impact to our FFO and ~~MFFO.~~NFFO. For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ FFO would have been approximately ~~$24,638,000~~$11,548,000 and ~~$17,168,000, respectively, excluding government grants recognized. For the six months ended June 30, 2022 and 2021, FFO would have been approximately $52,882,000 and $21,626,000,~~$28,244,000, respectively, excluding government grants recognized. For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021, MFFO~~NFFO would have been approximately ~~$28,752,000~~$20,086,000 and ~~$17,974,000, respectively, excluding government grants recognized. For the six months ended June 30, 2022 and 2021, MFFO would have been approximately $61,474,000 and $22,681,000,~~$33,419,000, respectively, excluding government grants recognized.

5746

Table of Contents

The following is a reconciliation of net income or loss, which is the most directly comparable GAAP financial measure, to FFO and ~~MFFO~~NFFO for the periods presented below:

Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
Net loss $ (15,542,000) $ (7,961,000) $ (16,439,000) $ (24,234,000)
Add:
Depreciation and amortization related to real estate — consolidated properties 39,939,000 26,357,000 82,250,000 52,080,000
Depreciation and amortization related to real estate — unconsolidated entities 420,000 762,000 846,000 1,568,000
Impairment of real estate investments — consolidated properties 17,340,000 3,335,000 17,340,000 3,335,000
Loss (gain) on dispositions of real estate investments — consolidated properties 73,000 42,000 (683,000) 377,000
Less:
Net (income) loss attributable to noncontrolling interests (1,768,000) 283,000 (3,827,000) 4,709,000
Depreciation, amortization, impairments and gain/loss on dispositions — noncontrolling interests (7,744,000) (4,891,000) (14,153,000) (9,656,000)
FFO attributable to controlling interest $ 32,718,000 $ 17,927,000 $ 65,334,000 $ 28,179,000
Business acquisition expenses(1) $ 1,757,000 $ 2,750,000 $ 1,930,000 $ 3,998,000
Amortization of above- and below-market leases(2) 699,000 212,000 1,204,000 248,000
Amortization of closing costs(3) 58,000 49,000 114,000 96,000
Change in deferred rent(4) (1,278,000) (148,000) (2,304,000) (482,000)
(Gain) loss on debt extinguishments(5) (181,000) 5,000 4,410,000 2,293,000
Gain in fair value of derivative financial instruments(6) — (1,775,000) (500,000) (3,596,000)
Foreign currency loss (gain)(7) 3,607,000 (238,000) 4,994,000 (653,000)
Adjustments for unconsolidated entities(8) 85,000 148,000 190,000 319,000
Adjustments for noncontrolling interests(8) (633,000) (197,000) (1,446,000) (1,168,000)
MFFO attributable to controlling interest $ 36,832,000 $ 18,733,000 $ 73,926,000 $ 29,234,000
Weighted average Class T and Class I common shares outstanding — basic and diluted 263,017,692 179,628,847 262,768,637 179,628,315
Net loss per Class T and Class I common share — basic and diluted $ (0.06) $ (0.04) $ (0.06) $ (0.13)
FFO attributable to controlling interest per Class T and Class I common share — basic and diluted $ 0.12 $ 0.10 $ 0.25 $ 0.16
MFFO attributable to controlling interest per Class T and Class I common share — basic and diluted $ 0.14 $ 0.10 $ 0.28 $ 0.16

~~___________~~

~~(1)~~In evaluating investments in real estate, we differentiate the costs to acquire the investment from the operations derived from the investment. Such information would be comparable only for publicly registered, non-listed REITs that have completed their acquisition activity and have other similar operating characteristics. By excluding business acquisition expenses that have been deducted as expenses in the determination of GAAP net income or loss, we believe MFFO provides useful supplemental information that is comparable for each type of real estate investment and is consistent with management’s analysis of the investing and operating performance of our properties. Business acquisition expenses include payments to our former advisor or its affiliates and third parties.

~~(2)~~Under GAAP, above- and below-market leases are assumed to diminish predictably in value over time and amortized, similar to depreciation and amortization of other real estate related assets that are excluded from FFO. However, because real estate values and market lease rates historically rise or fall with market conditions, including inflation, interest rates, the business cycle, unemployment and consumer spending, we believe that by excluding charges relating to the amortization of above- and below-market leases, MFFO may provide useful supplemental information on the performance of the real estate.

~~Table of Contents~~

~~(3)~~Under GAAP, closing costs are amortized over the term of our debt security investment as an adjustment to the yield on our debt security investment. This may result in income recognition that is different than the contractual cash flows under our debt security investment. By adjusting for the amortization of the closing costs, MFFO may provide useful supplemental information on the realized economic impact of our debt security investment, providing insight on the expected contractual cash flows of such investment, and aligns results with management’s analysis of operating performance.

~~(4)~~Under GAAP, as a lessor, rental revenue is recognized on a straight-line basis over the terms of the related lease (including rent holidays). As a lessee, we record amortization of right-of-use assets and accretion of lease liabilities for our operating leases. This may result in income or expense recognition that is significantly different than the underlying contract terms. By adjusting such amounts, MFFO may provide useful supplemental information on the realized economic impact of lease terms, providing insight on the expected contractual cash flows of such lease terms, and aligns results with management’s analysis of operating performance.

~~(5)~~The loss associated with the early extinguishment of debt primarily relates to the write-off of unamortized deferred financing fees, write-off of unamortized debt discount or premium, penalties, or other fees incurred. We believe that adjusting for such non-recurring losses provides useful supplemental information because such charges (or losses) may not be reflective of on-going business transactions and operations and is consistent with management’s analysis of our operating performance.

~~(6)~~Under GAAP, we are required to include changes in fair value of our derivative financial instruments in the determination of net income or loss. We believe that adjusting for the change in fair value of our derivative financial instruments to arrive at MFFO is appropriate because such adjustments may not be reflective of on-going operations and reflect unrealized impacts on value based only on then current market conditions, although they may be based upon general market conditions. The need to reflect the change in fair value of our derivative financial instruments is a continuous process and is analyzed on a quarterly basis in accordance with GAAP.

~~(7)We believe that adjusting for the change in foreign currency exchange rates provides useful information because such adjustments may not be reflective of on-going operations.~~

~~(8)~~Includes all adjustments to eliminate the unconsolidated entities’ share or noncontrolling interests’ share, as applicable, of the adjustments described in notes (1) – (7) above to convert our FFO to MFFO.


	Three Months Ended March 31,
		2023		2022
Net loss		$	(27,615,000)	$	(897,000)

Depreciation and amortization related to real estate — consolidated properties		44,632,000		42,311,000
Depreciation and amortization related to real estate — unconsolidated entities		63,000		426,000


Loss (gain) on dispositions of real estate investments — consolidated properties		132,000		(756,000)
Net loss (income) attributable to noncontrolling interests		1,743,000		(2,059,000)
Gain on re-measurement of previously held equity interest		(726,000)		—
Depreciation, amortization, gain/loss on dispositions and gain on re-measurement — noncontrolling interests		(6,538,000)		(6,409,000)
FFO attributable to controlling interest		$	11,691,000	$	32,616,000

Business acquisition expenses		$	332,000	$	173,000
Amortization of above- and below-market leases		8,675,000		505,000
Amortization of closing costs		65,000		56,000
Change in deferred rent		(60,000)		(1,026,000)

Non-cash impact of changes to equity instruments		1,072,000		778,000
Capitalized interest		(26,000)		(64,000)

Loss on debt extinguishments		—		4,591,000
Loss (gain) in fair value of derivative financial instruments		195,000		(500,000)
Foreign currency (gain) loss		(1,008,000)		1,387,000
Adjustments for unconsolidated entities		(74,000)		98,000
Adjustments for noncontrolling interests		(633,000)		(823,000)
NFFO attributable to controlling interest		$	20,229,000	$	37,791,000
Weighted average Class T and Class I common shares outstanding — basic and diluted		66,026,173		65,629,204
Net loss per Class T and Class I common share — basic and diluted		$	(0.42)	$	(0.01)
FFO attributable to controlling interest per Class T and Class I common share — basic and diluted		$	0.18	$	0.50
NFFO attributable to controlling interest per Class T and Class I common share — basic and diluted		$	0.31	$	0.58

Net Operating Income

Net operating income, or NOI, is a non-GAAP financial measure that is defined as net income (loss), computed in accordance with GAAP, generated from properties before general and administrative expenses, business acquisition expenses, depreciation and amortization, interest expense, gain or loss on dispositions, ~~impairment of real estate investments,~~ income or loss from unconsolidated entities, gain on re-measurement of previously held equity interest, foreign currency gain or loss, other income and income tax benefit or expense.

NOI is not equivalent to our net income (loss) as determined under GAAP and may not be a useful measure in measuring operational income or cash flows. Furthermore, NOI should not be considered as an alternative to net income (loss) as an indication of our operating performance or as an alternative to cash flows from operations as an indication of our ~~liquidity, or indicative of cash flow available to fund our cash needs including our ability to make distributions to our stockholders.~~liquidity. NOI should not be construed to be more relevant or accurate than the current GAAP methodology in calculating net income (loss) or in its applicability in evaluating our operating performance. Investors are also cautioned that NOI should only be used to assess our operational performance in periods in which we have not incurred or accrued any business acquisition expenses.

We believe that NOI is an appropriate supplemental performance measure to reflect the performance of our operating assets because NOI excludes certain items that are not associated with the operations of the properties. We believe that NOI is a widely accepted measure of comparative operating performance in the real estate community. However, our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

Table of Contents

For the three ~~and six~~ months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ we recognized government grants as grant income or as a reduction of property operating expenses, as applicable. The government grants helped mitigate some of the negative impact that the COVID-19 pandemic had on our financial condition and results of operations. Without such relief funds, the COVID-19 pandemic would have had a material adverse impact to our NOI. For the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021,~~ NOI would have been approximately ~~$66,608,000~~$66,742,000 and ~~$48,449,000,~~$68,470,000, respectively, excluding government grants recognized. ~~For the six months ended June 30, 2022 and 2021, NOI would have been approximately $135,078,000 and $78,301,000, respectively, excluding government grants recognized.~~

~~Table of Contents~~

To facilitate understanding of this financial measure, the following is a reconciliation of net income or loss, which is the most directly comparable GAAP financial measure, to NOI for the periods presented below:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended March 31,
		2022		2021		2022		2021				2023		2022
Net loss	Net loss	$	(15,542,000)	$	(7,961,000)	$	(16,439,000)	$	(24,234,000)	Net loss		$	(27,615,000)	$	(897,000)
General and administrative	General and administrative	10,928,000		7,343,000		22,047,000		14,600,000		General and administrative		13,053,000		11,119,000
Business acquisition expenses	Business acquisition expenses	1,757,000		2,750,000		1,930,000		3,998,000		Business acquisition expenses		332,000		173,000
Depreciation and amortization	Depreciation and amortization	39,971,000		26,357,000		82,282,000		52,080,000		Depreciation and amortization		44,670,000		42,311,000
Interest expense	Interest expense	20,345,000		16,715,000		43,170,000		35,259,000		Interest expense		39,206,000		22,825,000
Loss (gain) on dispositions of real estate investments	Loss (gain) on dispositions of real estate investments	73,000		42,000		(683,000)		377,000		Loss (gain) on dispositions of real estate investments		132,000		(756,000)
Impairment of real estate investments		17,340,000		3,335,000		17,340,000		3,335,000
(Income) loss from unconsolidated entities		(638,000)		901,000		(2,024,000)		2,672,000
Foreign currency loss (gain)		3,607,000		(238,000)		4,994,000		(653,000)

Loss (income) from unconsolidated entities										Loss (income) from unconsolidated entities		306,000		(1,386,000)
Gain on re-measurement of previously held equity interest										Gain on re-measurement of previously held equity interest		(726,000)		—
Foreign currency (gain) loss										Foreign currency (gain) loss		(1,008,000)		1,387,000
Other income	Other income	(469,000)		(191,000)		(1,729,000)		(463,000)		Other income		(1,608,000)		(1,260,000)
Income tax expense	Income tax expense	205,000		495,000		373,000		658,000		Income tax expense		143,000		168,000
Net operating income	Net operating income	$	77,577,000	$	49,548,000	$	151,261,000	$	87,629,000	Net operating income		$	66,885,000	$	73,684,000

Subsequent Event

For a discussion of a subsequent event, see Note 20, Subsequent Event, to our accompanying condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business plan, we expect that the primary market risk to which we will be exposed is interest rate risk. There were no material changes in our market risk exposures, or in the methods we use to manage market risk, from those that were provided for in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022.~~17, 2023.

Interest Rate Risk

We are exposed to the effects of interest rate changes primarily as a result of long-term debt used to acquire and develop properties and other ~~permitted~~ investments. Our interest rate risk is monitored using a variety of techniques. Our interest rate risk management objectives are to limit the impact of interest rate increases on earnings, prepayment penalties and cash flows and to lower overall borrowing costs while taking into account variable interest rate risk. To achieve our objectives, we may borrow or lend at fixed or variable rates.

We have entered into, and may continue to enter into, derivative financial instruments such as interest rate swaps and interest rate caps in order to mitigate our interest rate risk on a related financial instrument, and for which we have not and may not elect hedge accounting treatment. We did not elect to apply hedge accounting treatment to these derivatives; therefore, changes in the fair value of interest rate derivative financial instruments were recorded as a component of interest expense in gain or loss in fair value of derivative financial instruments in our accompanying condensed consolidated statements of operations and comprehensive loss. As of ~~June 30, 2022, we did not have any derivative financial instruments.~~March 31, 2023, our interest rate swap is recorded in security deposits, prepaid rent and other liabilities in our accompanying condensed consolidated balance sheet at its fair value of $195,000. We do not enter into derivative transactions for speculative purposes.

~~In July 2017, the~~The Financial Conduct Authority, or FCA, that regulates LIBOR announced its intention to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified SOFR as its preferred alternative to United States dollar LIBOR in derivatives and other financial contracts. The FCA, ceased publishing one-week and two-month LIBOR after December 31, 2021 and intends to cease publishing all remaining LIBOR after June 30, 2023. ~~On January 19, 2022, we entered into the~~ ~~2022 Credit Agreement that~~ bears interest at varying rates based upon SOFR. Please see Note 9, Lines of Credit and Term Loans — 2022 Credit Facility, to our accompanying condensed consolidated financial statements for a further discussion.

~~Table of Contents~~

We have two variable rate ~~debt~~mortgage loans outstanding for an aggregate principal balance of $98,743,000, which are maturing in 2024 and ~~maturing on various dates from 2023 to~~ 2031 ~~that~~and are indexed to LIBOR. As such, we are monitoring and evaluating the related risks of the discontinuation of ~~LIBOR, which include possible changes to the interest on loans or amounts received and paid on derivative instruments we may enter into in the future.~~LIBOR. These risks arise in connection with transitioning contracts to a new alternative rate, including any resulting value transfer that may occur. The

Table of Contents

value of mortgage loans ~~or derivative instruments~~payable tied to LIBOR could also be impacted ~~by the discontinuation of LIBOR.~~when LIBOR is discontinued. For some instruments, the method of transitioning to an alternative rate may be challenging, as they may require negotiation with the respective counterparty. If a contract is not transitioned to an alternative rate ~~upon LIBOR’s discontinuation~~when LIBOR is discontinued, the impact on our contracts is likely to vary. ~~Currently we cannot~~When LIBOR is discontinued, interest rates on our current indebtedness may be adversely affected. We estimate the overall impact of the phase-out of LIBOR on our current debt agreements ~~although~~to be minimal, but it is possible that an alternative variable rate could raise our borrowing costs. It is not possible to predict whether LIBOR will continue to be viewed as an acceptable market “benchmark” prior to June 30, 2023, and it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and magnified.

As of ~~June 30, 2022,~~March 31, 2023, the table below presents the principal amounts and weighted average interest rates by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate ~~changes.~~changes, excluding the effect of our interest rate swap. For information on our interest rate swap, see Note 9, Derivative Financial Instruments, to our accompanying condensed consolidated financial statements.


		Expected Maturity Date																								Expected Maturity Date
		2022			2023			2024			2025			2026			Thereafter			Total			Fair Value			2023			2024			2025			2026			2027			Thereafter			Total			Fair Value
Assets	Assets																								Assets
Debt security held-to-maturity	Debt security held-to-maturity	$	—		$	—		$	—		$	93,433,000		$	—		$	—		$	93,433,000		$	93,470,000	Debt security held-to-maturity	$	—		$	—		$	93,433,000		$	—		$	—		$	—		$	93,433,000		$	93,248,000
Weighted average interest rate on maturing fixed-rate debt security	Weighted average interest rate on maturing fixed-rate debt security	—		%	—		%	—		%	4.24		%	—		%	—		%	4.24		%	—		Weighted average interest rate on maturing fixed-rate debt security	—		%	—		%	4.24		%	—		%	—		%	—		%	4.24		%	—
Liabilities	Liabilities																								Liabilities
Fixed-rate debt — principal payments	Fixed-rate debt — principal payments	$	25,507,000		$	34,521,000		$	71,636,000		$	29,107,000		$	154,927,000		$	510,768,000		$	826,466,000		$	690,787,000	Fixed-rate debt — principal payments	$	14,270,000		$	73,554,000		$	135,365,000		$	154,966,000		$	34,207,000		$	468,408,000		$	880,770,000		$	716,622,000
Weighted average interest rate on maturing fixed-rate debt	Weighted average interest rate on maturing fixed-rate debt	3.92		%	3.78		%	3.53		%	3.35		%	2.98		%	3.01		%	3.12		%	—		Weighted average interest rate on maturing fixed-rate debt	3.18		%	3.55		%	4.28		%	2.98		%	3.29		%	2.97		%	3.24		%	—
Variable-rate debt — principal payments	Variable-rate debt — principal payments	$	221,000		$	452,891,000		$	158,085,000		$	356,000		$	413,270,000		$	569,345,000		$	1,594,168,000		$	1,600,195,000	Variable-rate debt — principal payments	$	450,203,000		$	204,502,000		$	30,179,000		$	428,092,000		$	550,206,000		$	27,239,000		$	1,690,421,000		$	1,697,118,000
Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of June 30, 2022)		5.00		%	4.17		%	3.82		%	3.81		%	3.25		%	3.22		%	3.59		%	—
Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of March 31, 2023)																									Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of March 31, 2023)	7.60		%	7.24		%	7.06		%	6.60		%	6.55		%	6.90		%	6.94		%	—

Debt Security Investment, Net

As of ~~June 30, 2022,~~March 31, 2023, the net carrying value of our debt security investment was ~~$81,167,000.~~$83,955,000. As we expect to hold our debt security investment to maturity and the amounts due under such debt security investment would be limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that fluctuations in interest rates, and the resulting change in fair value of our debt security investment, would have a significant impact on our operations. See Note ~~16,~~14, Fair Value Measurements, to our accompanying condensed consolidated financial statements, for a discussion of the fair value of our investment in a held-to-maturity debt security. The effective interest rate on our debt security investment was 4.24% per annum as of ~~June 30, 2022.~~March 31, 2023.

Mortgage Loans Payable, Net and Lines of Credit and Term ~~Loans~~Loan

Mortgage loans payable were ~~$1,152,998,000~~$1,257,057,000 ($1,233,745,000, net of discount/premium and deferred financing costs) as of ~~June 30, 2022.~~March 31, 2023. As of ~~June 30, 2022,~~March 31, 2023, we had 6668 fixed-rate mortgage loans payable and 12 variable-rate mortgage loans payable with effective interest rates ranging from 2.21% to ~~5.25%~~7.76% per annum and a weighted average effective interest rate of ~~3.35%~~4.46%. In addition, as of ~~June 30, 2022,~~March 31, 2023, we had ~~$1,267,634,000~~$1,314,134,000 ($1,313,222,000, net of deferred financing fees) outstanding under our lines of credit and term ~~loans,~~loan, at a weighted average interest rate of ~~3.50%~~6.84% per annum.

As of ~~June 30, 2022,~~March 31, 2023, the weighted average effective interest rate on our outstanding debt, factoring in our fixed-rate interest rate swap, was ~~3.43%~~5.56% per annum. An increase in the variable interest rate on our variable-rate mortgage loans payable and lines of credit and term ~~loans~~loan constitutes a market risk. As of ~~June 30, 2022,~~March 31, 2023, a 0.50% increase in the market rates of interest would have increased our overall annualized interest expense on all of our other variable-rate mortgage loans payable and lines of credit and unhedged term ~~loans~~loan by ~~$8,082,000,~~$7,176,000, or ~~11.6%~~5.0% of total annualized interest expense on our mortgage loans payable and lines of credit and term ~~loans.~~loan. See Note 8,7, Mortgage Loans Payable, Net and Note 9,8, Lines of Credit and Term ~~Loans,~~Loan, to our accompanying condensed consolidated financial statements.

~~Table of Contents~~

Other Market Risk

In addition to changes in interest rates and foreign currency exchange rates, the value of our future investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

Table of Contents

Item 4. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under ~~the Securities Exchange Act of 1934, as amended, or~~ the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms, and that such information is accumulated and communicated to us, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and we necessarily are required to apply our judgment in evaluating whether the benefits of the controls and procedures that we adopt outweigh their costs.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, an evaluation as of ~~June 30, 2022~~March 31, 2023 was conducted under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of ~~June 30, 2022,~~March 31, 2023, were effective at the reasonable assurance level.

(b) Changes in internal control over financial reporting. There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended ~~June 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

6250

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

For a discussion of our legal proceedings, see Note ~~12,~~11, Commitments and Contingencies — Litigation, to our accompanying condensed consolidated financial statements.

Item 1A. Risk Factors.

There were no material changes from the risk factors previously disclosed in our ~~2021~~2022 Annual Report on Form 10-K, as filed with the SEC on March ~~25, 2022.~~17, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

On ~~April 1, 2022,~~January 10, 2023, we granted an aggregate of 76,800 time-based restricted stock units to one of our executive officers and certain of our key employees pursuant to our 2015 Incentive Plan, representing the right to receive shares of our Class T common stock upon vesting. Such restricted stock units were issued in transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act and vest in three equal annual installments beginning on the first anniversary following the date of grant and ending on the third anniversary of the date of grant.

~~On June 15, 2022, we granted an aggregate of 54,900~~1,956 shares of our restricted Class T common stock to two of our independent directors pursuant to ~~our 2015~~the AHR Incentive Plan ~~as compensation for services~~ in connection with their ~~re-election~~initial election as independent directors to our ~~board at our annual meeting of stockholders.~~board. Such shares of restricted stock were issued in transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act and vest on June 15, 2023.

Purchase of Equity Securities by the Issuer and Affiliated Purchasers

Share Repurchase Plan

Our share repurchase plan ~~allows~~allowed for repurchases of shares of our common stock by us when certain criteria ~~are~~were met. Share repurchases ~~will be~~were made at the sole discretion of our board. Funds for the repurchase of shares of our common stock ~~will come~~originated exclusively from the cumulative proceeds we ~~receive~~received from the sale of shares of our common stock pursuant to ~~the AHR DRIP.~~

our DRIP offerings. On ~~October 4, 2021,~~November 14, 2022, our board approved our amended and restated share repurchase plan that included a change in the repurchase price with respect to repurchases resulting from the death or qualifying disability (as such term is defined in our share repurchase plan) of stockholders, to the most recently published estimated per share NAV. In addition, on October 4, 2021, our board authorized the partial reinstatement ofsuspended our share repurchase plan with respect to all repurchase requests, ~~to repurchase shares~~including repurchases resulting from the death or qualifying disability of stockholders, ~~effective~~beginning with ~~respect to qualifying~~share repurchases for the ~~fiscal~~ quarter ending December 31, ~~2021. All share repurchase requests other than those requests resulting from the death or qualifying disability of stockholders were and shall be rejected.~~2022. See Note 13, Equity — Share Repurchase Plan, to our accompanying condensed consolidated financial statements.

During the three months ended ~~June 30, 2022,~~March 31, 2023, we repurchased shares of our common stock pursuant to our share repurchase plan, as follows:

Period
Total Number of
Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased As Part of
Publicly Announced
Plan or Program Maximum Approximate
Dollar Value
of Shares that May
Yet Be Purchased
Under the
Plans or Programs
April 1, 2022 to April 30, 2022 699,460 $ 9.22 699,460 (1)
May 1, 2022 to May 31, 2022 — $ — — (1)
June 1, 2022 to June 30, 2022 — $ — — (1)
Total 699,460 $ 9.22 699,460


Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased As Part of Publicly Announced Plan or Program	Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 1, 2023 to January 31, 2023	—	$	—	—	(1)
February 1, 2023 to February 28, 2023	—	$	—	—	(1)
March 1, 2023 to March 31, 2023(2)	1,681	$	37.16	1,681	(1)
Total	1,681	$	37.16	1,681

___________

(1)A description of the maximum number of shares that may be purchased under our share repurchase plan is included in Note ~~14,~~13, Equity — Share Repurchase Plan, to our accompanying condensed consolidated financial statements.

(2)Due to an administrative delay, certain repurchase requests that were submitted in good order prior to the suspension of our share repurchase plan were processed after the suspension of our share repurchase plan.

AHR Incentive Plan

In January 2023, we repurchased 429 shares of our common stock, for $16,000, at a repurchase price of $37.16 per share in order to satisfy minimum statutory withholding tax obligations associated with the vesting of restricted stock awards issued pursuant to the AHR Incentive Plan.

Item 3. Defaults Upon Senior Securities.

None.

6351

Table of Contents

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the period ended ~~June 30, 2022~~March 31, 2023 (and are numbered in accordance with Item 601 of Regulation S-K).


3.1			Fourth Articles of Amendment and Restatement of Griffin-American Healthcare REIT IV, Inc., dated October 1, 2021 (included as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-55775) filed October 1, 2021 and incorporated herein by reference)

3.2			Amended and Restated Bylaws of American Healthcare REIT, Inc. (included as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-55775) filed ~~October 5, 2021~~February 17, 2023 and incorporated herein by reference)

~~4.1~~10.1			First Amendment to Amended and Restated ~~Distribution Reinvestment Plan~~Credit Agreement dated as of ~~Griffin-American~~March 1, 2023, among American Healthcare REIT ~~IV,~~Holdings, L.P., American Healthcare REIT, Inc. and certain subsidiaries and Bank of America, N.A., KeyBank, National Association, Citizens Bank, National Association and certain lenders named therein (included as Exhibit ~~4.6~~10.1 to our ~~Registration Statement~~Current Report on Form ~~S-3~~8-K (File No. ~~333-229301)~~000-55775) filed ~~January 18, 2019~~March 7, 2023 and incorporated herein by reference)

10.2*			Fourth Amendment to the First Amended and Restated Senior Secured Credit Agreement, dated as of March 30, 2023, among Trilogy RER, LLC and certain subsidiaries of Trilogy RER, LLC, Trilogy Investors, LLC, Trilogy Healthcare Holdings, Inc., Trilogy OpCo, LLC and Trilogy Pro Services, LLC, KeyBank National Association and the other lenders which are parties thereto from time to time

31.1*			Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*			Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**			Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002

32.2**			Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*			Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document

101.SCH*			Inline XBRL Taxonomy Extension Schema Document

101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*			Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

___________


*			Filed herewith.
**			Furnished herewith. In accordance with Item 601(b)(32) of Regulation S-K, this Exhibit is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

6452

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

American Healthcare REIT, Inc.

(Registrant)

~~August~~May 15, ~~2022~~2023

By:

/s/ DANNY PROSKY

Date

Danny Prosky

Chief Executive Officer, President and Director

(Principal Executive Officer)

~~August~~May 15, ~~2022~~2023

By:

/s/ BRIAN S. PEAY

Date

Brian S. Peay

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

6553


	Three Months Ended June 30, 2022
	Stockholders’ Equity
	Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — March 31, 2022	263,809,729	$	2,629,000	$	2,536,811,000	$	(980,613,000)	$	(2,160,000)	$	1,556,667,000	$	174,154,000	$	1,730,821,000

Offering costs — common stock	—	—		1,000		—		—		1,000		—		1,000
Issuance of common stock under the DRIP	1,199,427	12,000		11,131,000		—		—		11,143,000		—		11,143,000
Issuance of nonvested restricted common stock	54,900	1,000		(1,000)		—		—		—		—		—
Amortization of nonvested restricted common stock and stock units	—	—		980,000		—		—		980,000		—		980,000


Stock based compensation	—	—		—		—		—		—		21,000		21,000
Repurchase of common stock	(699,460)	(7,000)		(6,442,000)		—		—		(6,449,000)		—		(6,449,000)

Distributions to noncontrolling interests	—	—		—		—		—		—		(3,537,000)		(3,537,000)

Reclassification of noncontrolling interests to mezzanine equity	—	—		—		—		—		—		(21,000)		(21,000)
Adjustment to value of redeemable noncontrolling interests	—	—		(976,000)		—		—		(976,000)		(1,000)		(977,000)
Distributions declared ($0.10 per share)	—	—		—		(26,405,000)		—		(26,405,000)		—		(26,405,000)
Net (loss) income	—	—		—		(17,310,000)		—		(17,310,000)		1,986,000		(15,324,000)		(1)
Other comprehensive loss	—	—		—		—		(493,000)		(493,000)		—		(493,000)
BALANCE — June 30, 2022	264,364,596	$	2,635,000	$	2,541,504,000	$	(1,024,328,000)	$	(2,653,000)	$	1,517,158,000	$	172,602,000	$	1,689,760,000


	Three Months Ended June 30, 2021
	Stockholders’ Equity
	Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — March 31, 2021	179,658,367	$	1,798,000	$	1,730,237,000	$	(876,118,000)	$	(1,939,000)	$	853,978,000	$	164,095,000	$	1,018,073,000




Amortization of nonvested restricted common stock	—	—		26,000		—		—		26,000		—		26,000





Distributions to noncontrolling interests	—	—		—		—		—		—		(179,000)		(179,000)


Adjustment to value of redeemable noncontrolling interests	—	—		(261,000)		—		—		(261,000)		(112,000)		(373,000)
Distributions declared ($0.02 per share)	—	—		—		(3,187,000)		—		(3,187,000)		—		(3,187,000)
Net loss	—	—		—		(7,678,000)		—		(7,678,000)		(253,000)		(7,931,000)		(1)
Other comprehensive income	—	—		—		—		42,000		42,000		—		42,000
BALANCE — June 30, 2021	179,658,367	$	1,798,000	$	1,730,002,000	$	(886,983,000)	$	(1,897,000)	$	842,920,000	$	163,551,000	$	1,006,471,000


	Six Months Ended June 30, 2022
	Stockholders’ Equity
	Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — December 31, 2021	263,032,031	$	2,622,000	$	2,531,940,000	$	(951,303,000)	$	(1,966,000)	$	1,581,293,000	$	175,553,000	$	1,756,846,000

Offering costs — common stock	—	—		(2,000)		—		—		(2,000)		—		(2,000)
Issuance of common stock under the DRIP	2,425,500	24,000		22,423,000		—		—		22,447,000		—		22,447,000
Issuance of nonvested restricted common stock	54,900	1,000		(1,000)		—		—		—		—		—
Amortization of nonvested restricted common stock and stock units	—	—		1,791,000		—		—		1,791,000		—		1,791,000


Stock based compensation	—	—		—		—		—		—		42,000		42,000
Repurchase of common stock	(1,147,835)	(12,000)		(10,571,000)		—		—		(10,583,000)		—		(10,583,000)

Distributions to noncontrolling interests	—	—		—		—		—		—		(7,052,000)		(7,052,000)

Adjustment to noncontrolling interest in connection with the Merger	—	—		(1,173,000)		—		—		(1,173,000)		1,173,000		—
Reclassification of noncontrolling interests to mezzanine equity	—	—		—		—		—		—		(42,000)		(42,000)
Adjustment to value of redeemable noncontrolling interests	—	—		(2,903,000)		—		—		(2,903,000)		(930,000)		(3,833,000)
Distributions declared ($0.20 per share)	—	—		—		(52,759,000)		—		(52,759,000)		—		(52,759,000)
Net (loss) income	—	—		—		(20,266,000)		—		(20,266,000)		3,858,000		(16,408,000)		(1)
Other comprehensive loss	—	—		—		—		(687,000)		(687,000)		—		(687,000)
BALANCE — June 30, 2022	264,364,596	$	2,635,000	$	2,541,504,000	$	(1,024,328,000)	$	(2,653,000)	$	1,517,158,000	$	172,602,000	$	1,689,760,000


	Six Months Ended June 30, 2021
	Stockholders’ Equity
	Common Stock
	Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders’ Equity		Noncontrolling Interests		Total Equity
BALANCE — December 31, 2020	179,658,367	$	1,798,000	$	1,730,589,000	$	(864,271,000)	$	(2,008,000)	$	866,108,000	$	168,375,000	$	1,034,483,000

Offering costs — common stock	—	—		(1,000)		—		—		(1,000)		—		(1,000)


Amortization of nonvested restricted common stock	—	—		53,000		—		—		53,000		—		53,000
Stock based compensation	—	—		—		—		—		—		(14,000)		(14,000)




Distributions to noncontrolling interests	—	—		—		—		—		—		(355,000)		(355,000)


Adjustment to value of redeemable noncontrolling interests	—	—		(639,000)		—		—		(639,000)		(260,000)		(899,000)
Distributions declared ($0.02 per share)	—	—		—		(3,187,000)		—		(3,187,000)		—		(3,187,000)
Net loss	—	—		—		(19,525,000)		—		(19,525,000)		(4,195,000)		(23,720,000)		(1)
Other comprehensive income	—	—		—		—		111,000		111,000		—		111,000
BALANCE — June 30, 2021	179,658,367	$	1,798,000	$	1,730,002,000	$	(886,983,000)	$	(1,897,000)	$	842,920,000	$	163,551,000	$	1,006,471,000


	June 30, 2022		December 31, 2021
Intangible assets subject to amortization:
In-place leases, net of accumulated amortization of $31,132,000 and $28,120,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 8.1 years and 8.2 years as of June 30, 2022 and December 31, 2021, respectively)	$	72,431,000	$	81,538,000
Above-market leases, net of accumulated amortization of $4,306,000 and $2,082,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 9.4 years and 9.7 years as of June 30, 2022 and December 31, 2021, respectively)	32,849,000		35,106,000
Customer relationships, net of accumulated amortization of $710,000 and $635,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 14.2 years and 14.7 years as of June 30, 2022 and December 31, 2021, respectively)	2,130,000		2,205,000
Internally developed technology and software, net of accumulated amortization of $446,000 and $399,000 as of June 30, 2022 and December 31, 2021, respectively (with a weighted average remaining life of 0.2 years and 0.7 years as of June 30, 2022 and December 31, 2021, respectively)	24,000		70,000
Intangible assets not subject to amortization:
Certificates of need	96,693,000		99,165,000
Trade names	30,787,000		30,787,000
	$	234,914,000	$	248,871,000


	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Asset management fees(1)	$	5,401,000	$	10,763,000
Property management fees(2)	681,000		1,335,000
Development fees(3)	357,000		640,000
Lease fees(4)	120,000		385,000
Construction management fees(5)	68,000		80,000
Operating expenses(6)	53,000		116,000
Acquisition fees(7)	10,000		1,344,000
	$	6,690,000	$	14,663,000